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Abstract 
Introduction and aim 
Increases in the bioavailability of nitric oxide have been shown to reduce the 
oxygen (O2) cost of exercise, improve exercise performance, alter gastric blood 
flow and mediate glucose uptake in healthy individuals. Aim; does dietary nitrate 
reduce the O2 cost of exercise, improve walking performance in individuals with 
type 2 diabetes mellitus (T2DM) and chronic obstructive pulmonary disease 
(COPD) or alter hepatic diffusion and positively affect glucose homeostasis in 
healthy adults?    
Methods 
Experimental chapters utilised a double-blind, placebo-controlled, randomised, 
experimental design. Breath by breath pulmonary gas analysis was utilised to 
assess the O2 cost of exercise in 48 individuals with T2DM and 13 with COPD. 
Walking performance was assessed via the six minute walk test (6MWT) in 
cohorts 1 and 2. Magnetic resonance imaging was used to assess portal vein 
flux, velocity and the apparent diffusion coefficient, in order to assess hepatic 
microvascular diffusion (apparent diffusion coefficient (ADC)). Blood pressure 
(BP) was measured in all trials.          
Results   
Relative to placebo, beetroot juice resulted in a significant increase in plasma 
nitrate and nitrite. There were no differences between placebo vs. beetroot juice 
for the O2 cost of walking (T2DM: placebo; 946 ± 221 vs. beetroot juice; 939 ± 
223 ml.min-1; P=0.59) or cycling (COPD: placebo; 933 ± 323 vs. beetroot juice; 
939 ± 302 ml: min-1; P=0.88), distance covered in the 6MWT (T2DM: placebo; 
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550 ± 83 vs. beetroot juice; 554 ± 90m; P=0.17 or COPD: placebo; 456 ± 86 vs. 
beetroot juice; 449 ± 79 m; P=0.37) or BP (T2DM: systolic: placebo; 134 ± 10 
vs. beetroot juice; 132 ± 12 mmHg, P=0.17; diastolic: placebo; 77 ± 7: vs. 
beetroot juice; 76 ± 11 mmHg, P=0.27. COPD: systolic: placebo; 123 ± 14 vs. 
beetroot juice; 123 ± 14 mmHg; P=0.91; diastolic: placebo; 77 ± 9 vs. beetroot 
juice; 79 ± 9 mmHg; P=0.27). No differences were seen between placebo and 
beetroot juice for ADC (young adults: F(3, 45) = 0.25, P = 0.74; older adults; F(3, 42) 
= 1.3, P = 0.28), portal vein flux (young adults: F(3, 45) = 0.339, P = 0.79; older 
adults; F(3, 42) = 1.65, P = 0.19) however, there was an interaction effect in the 
young adults: (F(3, 45) = 2.9, P = 0.04) but not in the older adults; F(3, 42) = 1.8, P 
= 0.16) between visits for portal vein velocity.  
Nitrate supplementation did not reduce plasma glucose concentrations (young 
adults: F(3, 45) = 0.96, P = 0.42; older adults; F(3, 42) = 0.04, P = 0.99). Nitrate 
supplementation did not reduce systolic blood pressure (young adults: F(3, 45) = 
0.20, P = 0.89; older adults; F(3, 42) = 1.7, P = 0.18) or diastolic blood pressure 
(young adults: F(3, 45) = 0.25, P = 0.86; older adults; F(3, 42) = 0.45, P = 0.72).     
Conclusion 
Dietary nitrate supplementation does not alter the O2 cost of exercise, improve 
walking performance or reduce BP in individuals with T2DM or COPD. Nitrate 
supplementation does not alter hepatic diffusion, glucose homeostasis or BP.     
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Chapter 1: Introduction  
Nitric oxide (NO∙) was first found to be an endothelium derived relaxation factor 
in 1987 by Ignarro et al. (1987). The research questions surrounding its 
functions and biochemical pathways have expanded vastly since the 
identification of a stepwise reduction on nitrate (NO3
-) to nitrite (NO2
-) via 
facultative anaerobic bacteria and subsequently a conversion to NO∙ within the 
stomach (Lundberg et al., 1994, Benjamin et al., 1994).  
More recently, trials investigating the impact of supplementation of inorganic 
NO3
- have shown some remarkable findings, predominantly in young healthy 
individuals. These include: improvements in mitochondrial efficiency (Larsen et 
al., 2011); reduction in the metabolic rate (Larsen et al., 2014), increases in 
blood flow (matching to skeletal muscle requirements and delivery to the brain) 
(Presley et al., 2011); reductions in systolic and diastolic blood pressure (Webb 
et al., 2008a, Vanhatalo et al., 2010, Vanhatalo et al., 2011, Lansley et al., 
2010, Lansley et al., 2011a, Engan et al., 2012, Wylie et al., 2013b, Thompson 
et al., 2014, Muggeridge et al., 2014, Keen et al., 2014, Levitt et al., 2015, 
Treichler et al., 2015, Kocoloski and Crecelius, 2015, Bond Jr et al., 2013, Bond 
et al., 2014) and increase glucose uptake (Merry et al., 2010). In this 
introduction the biochemical pathways of NO∙ synthesis will be reviewed along 
with exploration of what is known surrounding NO3
- supplementation and the 
potential clinical applications of these beneficial effects.  
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1.1: Inorganic nitrate (NO3
-), nitrite (NO2
-) & NO∙ 
1.1.1: NO∙ synthesis in man: 
NO∙ is a gaseous signalling molecule involved in many physiological processes 
such as vasodilation (Ignarro et al., 1987), neuronal signalling (Garthwaite, 
2008) calcium handling (Hart and Dulhunty, 2000) and protection against 
bacterial pathogens (Chakravortty and Hensel, 2003). There are two major 
pathways in which NO∙ is produced in humans, firstly; the nitric oxide synthase 
(NOS) pathway, which is oxygen (O2) dependent and creates endogenously 
derived NO∙. There are three NOS isoforms which are bi-domain in structure 
including; (i) neuronal NOS (nNOS), (ii) inducible NOS (iNOS) and (iii) 
endothelial NOS (eNOS), all of which produce NO∙ in different locations of the 
body (see figure 1). The families of NOS’s catalyse a five stage oxidation of L-
arginine to produce the biologically active molecule NO∙ and also L-citrulline 
(Stamler and Meissner, 2001). This reaction relies on a constant substrate 
availability of six key compounds in order to maintain NO∙ production via the 
NOS pathway (Crabtree et al., 2009), these are: nicotinamide adenine 
dinucleotide phosphate hydrogen (NADPH), flavin adenine dinucleotide (FAD), 
flavin mononucleotide (FMN), haem, calmodulin (CaM) and tetrahydrobiopterin 
(BH4) (Alderton et al., 2001). If any of these substrates are not present the 
production of NO∙ via NOS enzymes is diminished. For eNOS activation to 
occur, the release of its inhibition is required by two CaM attachments which 
transfer electrons from the reductase domain of the NOS to the oxygenase 
domian (Andrew and Mayer, 1999).  
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The second is the entero-salivary pathway (NO3
-, NO2
- & NO∙ conversion); this 
pathway can act as a pool to provide additional NO∙. This pathway functions 
with the body absorbing inorganic NO3
- from food and from NO3
- produced 
endogenously within the body. 60-80% of a western dietary intake of NO3
- is 
derived from vegetables (Ysart et al., 1999), with beetroot, leafy greens and 
cruciferous vegetables containing the highest concentrations of dietary NO3
-. 
The conditions in which plants is grown can have an impact on where the NO3
- 
is stored within the plant (Gilchrist et al., 2010). If the plant is grown in 
conditions with small amounts of light it will store the NO3
- as it cannot be 
converted to amino acids during photosynthesis. Beetroot store copious 
amounts of NO3
- in their roots as its main anion (Gilchrist et al., 2010).     
NO3
- consumption through normal habitual dietary means has been described 
as part of a healthy balanced diet (Bryan and Hord, 2010). The average 
consumption of NO3
- per day is ~1-2 mmols in a typical western diet (ECETOC., 
1988), of which the majority of the available NO3
- is quickly absorbed in the 
upper gastrointestinal tract (Florin et al., 1990, van Velzen et al., 2008). 
Approximately 60% of the NO3
- from our diets is excreted in our urine (Lundberg 
and Govoni, 2004) within 48 hours (Wagner et al., 1983). Of the available NO3
- 
Figure 1: NO∙ production via NOS.  
This graphical representation shows the movement of electrons through the NOS enzyme 
with its key co-factors. The net outcome produces NO∙.   
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either produced endogenously or taken in from the diet, 25% passes into the 
entero-salivary circulation where it is concentrated by a magnitude of 10 fold in 
salivary glands (Lundberg and Weitzberg, 2010).  
The entero-salivary pathway is reliant on a number of factors, principally the 
symbiotic relationship that humans share with facultative anaerobic bacteria that 
live on the surface of the tongue (Duncan et al., 1995). The salivary glands 
secrete high concentrations of NO3
- in our oral cavity. NO3- acts as an
 
alternative electron acceptor (Duncan et al., 1995) where bacteria on the tongue 
reduces the NO3
- to NO2
- . The NO2
- is swallowed and some of the NO2
- is 
further reduced to NO∙ in the acid environment of the stomach (Benjamin et al., 
1994). Not all of the NO2
- is reduced to NO∙ in the stomach, some is absorbed 
into the circulating plasma where it can act as a storage pool for later reduction 
to NO∙ (Lundberg and Govoni, 2004).  
This NO2
- to NO∙ reduction can also be catalysed by deoxyhaemoglobin, 
deoxymyoglobin, xanthine oxide, NOS, aldehyde oxidase, cytochrome P-450 
and the mitochondrial electron transfer complexes (Cosby et al., 2003, Shiva et 
al., 2007, Zhang et al., 1998, Vanin et al., 2007, Li et al., 2008b, Kozlov et al., 
2003, 1999). Other specific conditions can also expedite the conversion of NO2
- 
to NO∙ such as hypoxia (Castello et al., 2006) and acidic environments (Modin 
et al., 2001), which can occur during exercise (Bailey et al., 2009). This may be 
important for clinical populations, such as those with T2DM, who find day to day 
activities difficult, and have a reduced NOS derived NO∙ (Wu and Meininger, 
2009). Lauer et al. (2008) used plasma NO2
- concentration change as a marker 
of NO∙ production. Lauer et al. (2008) suggest that a reduced concentration of 
NO2
- is associated with a reduced exercise tolerance.  
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1.1.2: The beneficial effects of NO3
-, NO2
- and NO∙: 
Consuming a diet that is high in fruits and vegetables has been shown to lower 
blood pressure (Appel et al., 1997, Rouse et al., 1983).  These diets have the 
ability to lower the risk of morbidity and mortality from cardiovascular disease 
(Bazzano et al., 2001, Joshipura et al., 1999, Joshipura et al., 2001). Due to 
large variation in the diet between individuals, it is difficult to elucidate which 
components decrease the risk of mortality and have cardio protective effects. 
Individuals who consume greater quantities of vegetables, such as those 
following the DASH diet (Appel et al., 1997), may take in up to 20 mmol of NO3
- 
per day (Hord et al., 2009). Individuals who consume the greatest amounts of 
green leafy and cruciferous vegetables, which typically have high NO3
- 
contents, have the largest protective effect from cardiovascular disease 
(Joshipura et al., 1999, Joshipura et al., 2001). More recently it has been shown 
that diets rich in green leafy vegetables may also protect against the risk of 
developing type 2 diabetes (T2DM) (Carter et al., 2010) and COPD (Hirayama 
et al., 2009, Watson et al., 2002).  
1.1.3: Exercise efficiency & performance: 
A basic premise of exercise physiology was that an individual’s O2 requirement 
for an exercise bout could be accurately predicted if the work load was known 
(Jones and Poole, 2005).  
The O2 cost of moderate intensity exercise is unaffected by having a disease 
such as T2DM, ageing, having a sedentary lifestyle and poor health status 
(Jones and Poole, 2005). Exercise training (in the short term) will not modulate 
the O2 cost of moderate intensity exercise (see Jones and Poole, 2005 for 
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review). It is, therefore, surprising that dietary supplementation with inorganic 
NO3
- can elicit a reduction in the O2 cost of exercise.  
A 3-5% reduction in the O2 cost of exercise has been shown following NO3
- 
supplementation with beetroot juice (Bailey et al., 2009, Larsen et al., 2007b) 
and pharmacological sodium NO3
- (Larsen et al., 2010). Subsequent to these 
studies, a reduction in the O2 cost of exercise following submaximal exercise 
and/or improvements in exercise performance following supplementation of 
beetroot juice or sodium NO3
- in recreationally active individuals have been 
shown in multiple studies (Bailey et al., 2009, Lansley et al., 2010, Larsen et al., 
2011, Larsen et al., 2007b, Larsen et al., 2010, Vanhatalo et al., 2010, Bescos 
et al., 2011, Cermak et al., 2012b, Wylie et al., 2013a, Wylie et al., 2013b, 
Breese et al., 2013). It should be noted that some studies have not reported 
such positive effects (Christensen et al., 2013, Murphy et al., 2014, Martin et al., 
2014, Fulford et al., 2013) (for more examples see review table 1 and 13 a,b 
and c).   
The question that remains in the clinical context is: can this reduction in the O2 
cost of exercise be seen in populations that may benefit from improved exercise 
efficiency and elicit improvements in quality of life and activities of daily living? 
NO3
- supplementation in clinical populations is a novel concept and there is 
limited research published. At the commencement of this body of work only one 
study has been conducted with NO3
- supplementation in a clinical population. It 
demonstrated an increase in walking time, time to onset of claudication pain 
and improved muscle oxygenation in individuals with peripheral arterial disease 
(Kenjale et al., 2011). However, this study is very small (n=8) and was not 
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double blinded. Thus the robustness of the conclusions should be interpreted 
with care.  
A recent review (Bailey et al., 2012) suggests that as athletes have elevated 
plasma NO3
- and NO2
- (Jungersten et al., 1997, Cuzzolin et al., 2002) 
concentrations compared to non-athletic controls, well-trained athletes may not 
gain the same benefits as recreationally active individuals following NO3
- 
supplementation. This perhaps indicates the existence of a ceiling limit, 
whereby further increases in the bioavailability of NO2
- may not have an additive 
effect on exercise performance. Other evidence exists to suggest that it is not a 
ceiling limit per se but it is more likely to have diminishing effects as the aerobic 
capacity of the individual increases. A recent study demonstrated that a cohort 
of well-trained cyclists over a 50 mile time trial did not cover the distance in a 
shorter time (Wilkerson et al., 2012). Interestingly, there was a significant 
correlation between a rise in plasma NO2
- concentration and time trial 
performance. Elite athletes tend to have a higher plasma NO2
- concentration 
(Wilkerson et al., 2012). This may diminish the ability of athletes to gain 
ergogenic effects from NO3
- supplementation. If this hypothesis is correct then 
individuals with reduced plasma NO3
- and NO2
- concentration such as 
individuals with T2DM (Vanhoutte, 2009) may stand to get the greatest benefits 
from NO3
- supplementation. Although Vanhoutte presents data suggesting 
individuals with T2DM have a reduced plasma NO3
- and NO2
- concentration the 
method used to assess this was the greiss method and is less sensitive at lower 
concentrations.        
NO∙ increases following exercise have been positively correlated to increases in 
cardiovascular health (Jungersten et al., 1997). There is an association 
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between the increase of endogenously produced NO2
- and an improvement in 
exercise tolerance (Dreißigacker et al., 2010) whilst an increase in plasma NO2
- 
concentration following beetroot juice has been correlated with improvements in 
time trial performance (Wilkerson et al., 2012). If an individual’s tolerance to 
exercise improves then they have the potential to perform the same amount of 
exercise whilst feeling less physiological stress or do more work while feeling 
the same physiological stress as incurred previously at a lower level of exercise.   
Enabling people with chronic disease to exercise more, via reducing early onset 
fatigue, may lead to significant health and quality of life benefits. Exercise 
performance could improve in individuals with reduced plasma NO3
- and NO2
- 
by doing regular exercise via increases in endogenously produced NO·. Whilst 
this is unlikely to have a large effect it could occur due to increases in vascular 
production of NO∙ due to shear stress (Cooke et al., 1991, Miller and Burnett, 
1992). As the individual exercises the subsequent increase in cardiac output will 
create shear stress producing more NO∙ (van Citters and Franklin, 1969). Given 
that individuals with reduced NO∙ bioavailability such as people with T2DM,  and 
they have a lower ?̇?O2 max (Regensteiner et al., 1995b, Regensteiner et al., 
2009), NO3
- supplementation could enable individuals with disease to begin 
exercising at a lower ?̇?O2, thus exercise feels relatively easier and have the 
potentially to yield more endogenously derived NO∙. Another potential means of 
improving exercise tolerance would be to improve efficiency in a non-
haemodynamic process such as an improved mitochondrial efficiency or 
calcium handling.  
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1.1.4: NO∙ mechanisms for the reductions in the O2 cost of exercise: 
Multiple potential mechanisms for the reduction in O2 cost of exercise following 
supplementation with inorganic NO3
- have been hypothesised. These include a 
reduced O2 cost of mitochondrial ATP re-synthesis (Clerc et al., 2007, Basu et 
al., 2008) and or a reduction in the ATP turnover (Bailey et al., 2010b). A 
vasodilatory effect has also been postulated, allowing for a better coupling of 
blood flow to metabolic demand and finally an increase in the anaerobic energy 
production (Larsen et al., 2007b, Bailey et al., 2009). These mechanisms will be 
discussed below.  
The reduction in the O2 cost of exercise has been shown in numerous studies 
with athletes, recreationally active individuals and groups of individuals with 
disease (See table 1 and 13). The reduction in the O2 cost of mitochondrial ATP 
synthesis may be brought about via two different mechanisms (Larsen et al., 
2011). The first is that NO2
- could act as an alternative electron acceptor via the 
inhibition of cytochrome-c (Basu et al., 2008). Cytochrome-c is the last enzyme 
in the electron transport chain. NO∙ could become a surrogate for O2 at 
cytochrome-c’s binding site, replacing the need for O2 during ATP production 
(Brown and Cooper, 1994). This, in vitro study appears to show a near linear 
relationship between increasing NO∙ concentration (via light releasing 
nitroprusside) and decreasing O2 consumption of brain synaptosomes. At 60nM 
NO∙ concentration and 30µM O2 concentration half of the cytochrome-c binding 
sites were inhibited (Brown and Cooper, 1994). This is of great importance 
given the difficulties of O2 delivery in many clinical populations.  
The second proposed mechanism involves an increase in the phosphate - O2 
(P/O) ratio. The term P/O ratio was coined by Hinkle (2005). The P/O ratio is 
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used as a measure of mitochondrial oxidative phosphorylation efficiency. The 
P/O ratio is the term given for the number of ATP molecules that can be 
produced for an molecule of O2. If the ratio is relatively higher, then more ATP 
can be produced for the same amount of O2. The reduction in the O2 cost is 
thought to have been brought about via a reduced slippage of protons across 
the mitochondrial proton pumps essentially reducing energy waste and 
increasing oxidative phosphorylation. This is thought to occur due to one of two 
reasons; firstly there is an increase in the efficiency of the electron transport 
chain and secondly a decrease in the proton gradient consuming process (Clerc 
et al., 2007). P-magnetic resonance spectrometry has been used to access the 
turnover rate of ATP. Bailey et al., measured phosphocreatine, ADP and 
inorganic phosphate in addition to pH. Bailey et al., showed that with NO3
- 
supplementation you can significantly reduce the estimated turnover rate of 
ATP (essentially reduce the O2 cost of exercise) (Bailey et al., 2010b).   
NO∙ is a potent vasodilator. The potential for NO∙ to vasodilate hypoxic and 
anoxic areas to improve oxygenation is a theory often referred to in NO∙ related 
blood pressure lowering effects (Webb et al., 2008b, Gautier et al., 2006). NO∙ 
production via eNOS is important for maintaining vascular tone. If the 
microvasculature has a greater flux of oxygenated blood, it is possible that a 
greater matching of O2 delivery to O2 demand within the working muscles may 
occur. However, this may be impaired in individuals with O2 delivery 
deficiencies such as individuals with T2DM and chronic obstructive pulmonary 
disease (COPD). Moreover, if there is a greater matching of O2 to the working 
muscles then uptake and utilisation may increase. Therefore, O2 delivery is an 
unlikely source of reduction in steady state O2 consumption but may mediate 
increased performance.      
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Given the reduced O2 cost of exercise another potential mechanism for this 
improvement in efficiency could be an increase, proportionally, by the anaerobic 
contribution. This is unlikely based on two studies showing no increase in blood 
lactate levels measured via capillary blood sampling (Larsen et al., 2007b, 
Bailey et al., 2009) post NO3
- supplementation. Bailey et al., (2012) showed via 
p-magnetic resonance spectrometry that the pH was unchanged during 
moderate and severe exercise, further suggesting that the reduction in the O2 
cost of exercise is not due to an increase in anaerobic contribution to ATP 
production.   
With regards to the reduction in the O2 cost of exercise, the evidence suggests 
that NO∙ acts as a surrogate for O2 in the electron transport chain (Basu et al., 
2008, Brown and Cooper, 1994) in conjunction with an increase in the P/O ratio 
via mitochondrial protein changes (Larsen et al., 2011, Clerc et al., 2007). 
Larsen’s 2011 protocol utilised muscle biopsies harvested from healthy young 
individuals. The primary skeletal muscle cell cultures were conducted in 
ambient conditions. This would place the cells in an artificially elevated O2 rich 
environment which would cause oxidative stress. In order to assess the O2 
consumption relative to the muscle the O2 concentration could be lowered to 
~3% which would match the pO2 at the muscle. This makes the findings within 
this study questionable as the utilisation of NO∙ in different redox balances is 
likely to be vastly different. The limitations of these data supporting a reduction 
of proton slippage at the proton pumps and improvements of efficiency via the 
P/O must be borne in mind when seeking to understand the mechanism behind 
the reduction in O2 cost of exercise. However, the data shows the potential for 
improvements in efficiency and more research is warranted in this area.     
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1.1.5: NO∙, cGMP and sGC in vascular function:  
NO∙ is a small size molecule that carries no charge. Due to this, it can diffuse 
easily across membranes without the need for a transport system, removing a 
rate limiting step (Lancaster, 1996, Lancaster, 1994, Denicola et al., 1996). NO∙ 
is relatively ‘unreactive’ and moves freely from the cell in which it was created to 
a target cell prior to being utilised (Denninger and Marletta, 1999). Within 
plasma the half-life of NO∙ is thought to be very short ~ 3 seconds (Yoshizumi et 
al., 1993, Lundberg and Govoni, 2004); NO2
- is ~ 110 seconds (Kelm, 1999) 
and NO3
- is ~ 5 hours (McKnight et al., 1997). 
The bioavailability of NO∙ is paramount for normal cellular function and in 
particular, smooth muscle relaxation and signalling transduction. Many actions 
of NO∙ mediated vascular function are produced via cyclic guanosine 
monophosphate (cGMP) (Alzawahra et al., 2008). cGMP is created by the 
reduction of guanosine triphosphate (GTP) which is catalysed by guanylate 
cyclase (GC) (Denninger and Marletta, 1999). GC can be soluble (sGC) or 
attached to a receptor on the cell membrane. NO∙ increases GC activity 
(Schultz et al., 1977, Arnold et al., 1977) and subsequently cGMP 
concentrations (Denninger and Marletta, 1999). The elevations in cGMP lead to 
the phosphorylation of protein kinase C activity which phosphorylates proteins 
and decreases intracellular levels of Ca2+ via compartmentalisation or inhibits its 
release (Lohmann et al., 1997). This reduction leads to relaxation of vascular 
smooth muscle which ultimately lowers blood pressure (Lohmann et al., 1997).  
1.1.6: Entero-salivary pathway and its role in blood pressure regulation:  
The importance of reduction of NO3
- to NO2
- in the entero-salivary pathway was 
initially tested by having participants refrain from swallowing their own saliva 
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(Webb et al., 2008a) or by spitting post NO3
- supplementation (Lundberg and 
Govoni, 2004). These studies suggest that by preventing the swallowing of  
NO2
-, the beneficial effects of NO3
- supplementation are removed due to 
interruption of the pathway. Recently, it has been shown by limiting the amount 
of microflora in the oral cavity (via the use of antibacterial mouthwash) the 
circulating plasma NO2
- concentration is reduced without any decrease in the 
plasma NO3
- concentration (Kapil et al., 2012; Petersson et al., 2009) again 
providing evidence that oral microflora are a key step in the entero-salivary 
pathway (Spiegelhalder et al., 1976, Lundberg et al., 2004, Duncan et al., 
1995). Consequently, the use of antibacterial mouthwash has also been shown 
to increase the blood pressure of the participants involved (Kapil et al., 2012, 
Petersson et al., 2009) (shown in human and animal models), therefore, 
suggesting that antibacterial mouthwash may attenuate the NO∙ stimulated 
blood pressure reducing effects. Individuals with elevated blood pressure could 
potentially have raised systolic and diastolic pressures due to a depletion in NO∙ 
(either due to increased scavenging, reduced NOS production, poor diet and or 
other failures in the entero-salivary pathway), as opposed to earlier hypotheses 
that a high blood pressure causes a reduced NO∙ level (Rockey and Chung, 
1998).  
The role of NO3
- and its subsequent conversion to NO∙ has many beneficial 
effects. Previously, Lundberg et al., (2006) hypothesised that NO3
- rich 
vegetables may play a key role in blood pressure reduction. Subsequently, 
there have been numerous reports of a reduction in blood pressure, either with 
sodium NO3
- (Larsen et al., 2006) or beetroot juice (Bailey et al., 2010b, Lansley 
et al., 2010).  
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At the start of this project the only study to examine a clinical population with 
NO3
- supplementation was in individuals with peripheral artery disease which 
found a statistically significant reduction in diastolic blood pressure (BP) (7 
mmHg) but no change in systolic BP (Kenjale et al., 2011). For more details on 
blood pressure changes in NO3
- supplementation studies see table 1 and 13.  
Much of the early literature (and a number of more recent studies) used a 
placebo that is not a ‘true’ placebo, i.e. blackcurrant juice or prune/orange juice. 
Whilst the increase in exercise time or reductions in the O2 cost of exercise in 
these studies are of interest, there are significant limitations. By utilising fruit 
juice they are likely to  have a substantially different antioxidant content which 
could alter NO∙ bioavailability (Bondonno et al., 2012). This could therefore 
explain some of the variability in these studies. Moreover, related to the lack of 
a ‘true’ placebo where the participant did not know whether active or placebo 
juice was being taken, the widely reported beneficial effects of beetroot juice [in 
the lay press] on exercise performance/tolerance may have given rise to a 
“placebo” effect in those informed volunteers taking beetroot juice. For example 
the Daily Mail online published an article stating beetroot juice ‘helps lower 
blood pressure by 7%’. On the 29th of June 2010 the Daily Mail stated that 
beetroot juice ‘could save your life’ (DailyMail, 2013).  
Beetroot is known to contain a number of antioxidants within the juice and it was 
an important stage in NO3
- research to determine if antioxidants could reduce 
the O2 cost of exercise. Bailey (2011) found that supplementing with N-
acetylcysteine (an antioxidant) had no changes in the O2 cost of sub maximal 
exercise. There is, however, some evidence to suggest that antioxidants and 
polyphenols can reduce NO2
- to NO∙ (Gago et al., 2007, Carlsson et al., 2001) 
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albeit in the stomach and urine. Beetroot juice has a variety of antioxidants (see 
experimental chapter 1 for antioxidant content of beetroot juice). Lansley et al. 
(2010) removed the NO3
- content from the beetroot juice to act as a placebo. 
This was performed via an ion exchange resin. They subsequently 
supplemented their participants with the active and placebo juices. These 
results provided evidence to suggest that in young healthy individuals it is NO3
- 
that is the active ingredient as there was no reduction in the O2 cost of exercise 
with the NO3
- depleted juice. 
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Table 1. A summary of dietary NO3
- supplementation and its effects on plasma NO3
-/ NO2
- concentrations, BP and exercise (2007 - 
2012). 
Author Participants & Protocol  NO3
- supplement Plasma NO3
- & NO2
- 
concentration (BR 
vs. PL respectively)   
BP changes Exercise efficiency or 
performance and/or 
clinical relevance 
Primary 
outcome 
successful? 
Larsen et 
al. 
(2007b) 
9 healthy well-trained 
males. Min 10 day 
washout. 5 mins cycling at 
45, 60, 70, 80, 85 and 
100%  of V̇O2 max 
3 days 
supplementation of 
NaNO3
- (0.1 mmol 
Kg-1 day-1) 
NO3
- = 182 ± 55 and 
27 ± 6.9 μM 
NO2
- = 226 ± 87 
and124 ± 28 nM.  
↓SBP 
↓DBP 
 
↓V̇O2 over 4 lowest WR 
↑ average GE over 4 
lowest WR 
↑ average DE over 4 
lowest WR 
Yes 
Webb et 
al. 
(2008a) 
14 healthy subjects (10 in 
phase two), min 7 day 
washout period. 3BP 
measurements taken every 
15mins for 1 hour. 
500ml BR juice (NO3
- = 
45 mmol/L) or water  
16 fold ↑ in plasma 
NO3
- 
2 fold ↑ in plasma 
NO2
-  
(Values not given) 
2.5h peak 
↓SBP 
3h peak  
↓ DBP and 
MAP 
IR of the forearm slowed 
the FMD and protected 
against IR injury (phase 
two). 
Yes 
Bailey et 
al. (2009) 
8 healthy males. With a 
min of a 10 day washout 
period. 3BP measurements 
taken at the 6th 
supplementation point. 4 
MI and 2 SI bouts on days 
4, 5& 6.  
500ml/day of BR juice 
(NO3
- =5.5mmol/day) 
or black current cordial 
for 6 days 
NO2
- = 273 ± 44 and 
140 ± 50 nM 
↓ SBP ↓ V̇O2 amplitude in MI 
↓ V̇O2 slow component in 
SI 
↑ time to exhaustion in SI 
↓ deoxyhaemoglobin 
↑ haemoglobin  
↑ total haemoglobin  
Yes 
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Bailey et 
al. 
(2010b) 
7 healthy makes. With a 
min of a 10 day washout 
period. 3BP measurements 
taken at the 6th 
supplementation point.  
Metabolic milieu measured 
via P-MRS.  
500ml/day of BR juice 
(NO3
- =5.1mmol/day) 
or black current cordial 
for 6 days 
NO2
- = 643 ± 110  
and 206 ± 93nM 
 
↓SBP 
↓DBP 
↓MAP 
 
↓ V̇O2 amplitude in LI 
↓ V̇O2 slow component in 
HI  
↑ time to exhaustion in SI 
↓ muscle ATP turnover 
rate 
↓ muscle ADP 
accumulation  
↓ muscle Pi accumulation 
↓ muscle PCr depletion 
 
Yes 
Vanhatalo 
et al. 
(2010) 
8 healthy physically active 
subjects. With a min of a 
10 day washout period. 
4BP measurements were 
taken on each visit. 
Protocol consisted of a 
ramp and MI exercise. 
500ml/day of BR juice 
(NO3
- =5.2mmol) or 
juice cordial for an 
acute dose (2.5h) and 
chronic exposure (5 
and 15 days) 
NO2
- = 454 ± 81 nM 
at baseline and 
increased by 39% 
(post 2.5h), 25% 
(after 5 days) and 
46% after 15days.  
↓SBP 
↓MAP 
For all 
conditions 
For acute and chronic 
supplementations.  
↓ V̇O2 amplitude in MI  
After 15 days only: 
↑V̇O2max 
↑peak work rate during 
the ramp test 
↑GET & WR 
 
Yes 
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Larsen et 
al. (2010) 
Nine (7 male) healthy 
subjects. With a min of a 7 
day washout period. 2 BP 
measurements were taken 
on the final visit.  
Acute (1h prior to 
exercise) & Chronic 
exposure; 2 days 
NaNO3
- 
supplementation (0.1 
mmol Kg-1 day-1) or 
placebo which was 
equally dosed NaCl.  
NO2
- = 142 ± 35  
and 61 ± 11 nM 
NO3
- = 230 ± 31 and 
17.3 ± 3 μM 
 
No change 
in resting 
SBP & DBP. 
↓DBP post 
ex.  
Acute ingestion; 
V̇O2 during LI cycle 
exercise 
Chronic ingestion; 
↑ cGMP  
↑V̇O2max  
 
 
Yes 
Vanhatalo 
et al. 
(2011) 
9 healthy (7 male) 
physically active 
participants. BP was 
measured prior to exercise 
commencement after 
breathing normoxic or 
hypoxic air for 15 minutes.   
750ml/day of BR juice 
(NO3
- =9.3mmol) or PL 
(NO3
- =0.006mmol). 
Juice was consumed 
24, 12 and 2.5h prior 
to exercise.  
NO2
- = 194 ± 51 and 
129 ± 23 nM 
 
↓SBP 
↓DBP 
↓MAP 
 
 
↑PCr recovery  
↓SaO2 in BR and PL 
compared to control.  
↓ Tlim PL compared to 
control 
↔ Tlim BR to control 
 
No 
Larsen et 
al. (2011) 
Mitochondria harvested 
from healthy volunteers 
post supplementation.  
3 days NaNO3
- 
supplementation (0.1 
mmol Kg-1 day-1) 
NO2
- = 163 ± 29 and 
35 ± 7nM 
NO3
- = 169 ± 18 and 
27 ± 2.6μM 
N/A ↑ Mitochondrial P/O ratio 
by 19%, suggesting a 
higher max ATP turnover 
which increased by 23% 
↓V̇O2 in LI exercise 
 
Yes 
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Lansley et 
al. 
(2011b) 
9 healthy active males. 
With a min of a 10 day 
washout period. 4 BP 
measurements were taken 
on each visit to the lab (10 
occasions)  
500ml/day of BR juice 
(NO3
- =6.2mmol/day) 
or PL(NO3
- 
=0.003mmol/day) for 6 
days 
 
NO2
- =  373 ± 211 
and  183 ± 119 nM 
 
↓SBP 
 
↓ V̇O2 whilst walking 
↓ V̇O2 amplitude in MI 
↓ end exercise V̇O2 in SI 
↑ time to exhaustion in SI 
Yes 
Lansley et 
al. 
(2011a) 
9 healthy male club level 
cyclists. With a min of a 
48h washout period. 
Exercise involved a 4 & 
16.1km TT.  
500ml/day of BR juice 
(NO3
- =6.2mmol) or 
PL(NO3
- 
=0.005mmol/day) 2.5h 
prior to exercise 
NO2
- = 575 ± 199 
and 241 ± 125 nM    
 
↓SBP ↑  TT performance 
(time=↓) 
↑PO in TT 
Yes 
Kenjale et 
al. (2011) 
8 (4 males) PAD patients. 
With a 7 – 14 day washout 
period. 1 BP measurement 
was taken prior to the 
intervention and 2h post 
juice. ABI and endothelium 
function were assessed.  
500ml/day of BR juice 
(NO3
- =18,181 umol/l) 
or PL (orange juice) 3h 
prior to exercise.  
NO2
- =  943 ± 826 
and 152 ± 72 nM    
↓DBP 
 
↓ time to onset of 
claudication  
↑ walking distance  
↓ deoxyhaemoglobin 
↑ haemoglobin  
↑ total haemoglobin  
 
Yes 
Bescós et 
al. (2011) 
11 healthy participants. 
With a 7 day washout 
period.  
NaNO3
- 
supplementation (10 
mg.kg-1) or equivalent 
dosed PL (NaCl).  
NO2
- = 2.3 μM ± 157 
nM and 2 μM ± 206 
nM 
NO3
- =  250 ± 80 
and 29 ± 8 μM 
N/A 
 
↓V̇O2peak without 
affected TTE or max 
power.  
 
Yes 
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Cermak et 
al. 
(2012a) 
12 active male cyclists. 
With a 14 day washout 
period. Exercise involved a 
60min sub max cycling 
followed by a10-km TT. 
500ml/day of BR juice 
(NO3
- =8mmol/day) or 
PL (NO3
- depleted 
juice) for 6 days.   
Abstract only, 
figures not 
presented. 
N/A ↓ TT time 
↑Power output 
↓ MI V̇O2 
 
 
Yes 
Cermak et 
al. 
(2012b) 
20 well-trained males. 
Exercise included a ~1h 
TT. 
140ml BR 2.5h prior to 
exercise (NO3
- =8.7 
mmol).  
NO2
- =   532 ± 32 
and 271 ± 13 nM    
 
N/A ↔ TT time 
↔ Power output 
No 
 
 
↑ = statistical significant increase; ↔ = no statistical reduction; ↓ = statistical significant reduction; V̇O2 = oxygen uptake; V̇O2peak = peak oxygen uptake; WR = 
work rate; GE = gross efficiency; DE = delta efficiency; SBP = systolic blood pressure, DBP = diastolic blood pressure; MAP = mean arterial blood pressure; IR = ischemic 
reperfusion, FMD =  flow-mediated dilation; MI = moderate intensity; RPE = rating of perceived exertion ; SI = severe intensity; V̇O2max = maximal oxygen uptake; LI = low 
intensity; HI = high intensity; PCr = phosphocreatine; Pi = inorganic phosphate; ADP = adenosine diphosphate; ATP = adenosine triphosphate; GET = gas exchange 
threshold; PAD = peripheral arterial disease; cGMP = cyclic guanosine monophosphate; SaO2 = arterial O2 saturation; Tlim = limit of tolerance; P/O ratio = phosphorylation 
efficiency; PO = power output; TT = time trial;  TTE = time to exhaustion; LNF = low nitrate food; HNF = high nitrate food; PO2 = partial pressure of oxygen; DMBA = 
dimethoxybenzaldehyde (a powerful organ-specific laboratory carcinogen); NIRS = near infrared spectrometry and sGC = Soluble guanylate cyclase; RQ = respiratory 
quotation; MVC = maximal voluntary contraction. Where NO3
- & NO2
- values are given it is from the final supplementation period if multiple doses given. 
 
 
 
 
 
.    
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From 2008 until the start of this body of work, 20 papers were published in the field 
of NO3
- supplementation (regardless of the primary outcome). Variability of NO3
- 
dose between studies must be considered when comparing results from different 
trials. Webb et al., (2008a) administered ~22.5 mmol of NO3
- in a single 500ml bolus. 
Many studies have supplementation regimens between ~4.5 and 6.5 mmol (see 
table 1 above for published values). These differences are also seen in plasma NO3
- 
concentration values, which can range from 17.3 to 27μM (23.8 ± 5.6 μM) after 
placebo juice supplementation compared with the active juice ranging from 169 to 
230μM (194 ± 32 μM). Plasma NO2
- concentrations have greater variability between 
studies with concentrations following placebo juice supplementation from 29nM to 
2μM (326 ± 524 nM) and concentrations following active juice supplementation 
ranging from 142nM to 2.3μM (543 ± 575 nM). A minority of published papers have 
reported plasma NO2
- concentration in the μM range with a minimal increase post 
supplementation (Bescos et al., 2011). The majority of the inorganic NO3
- 
supplementation studies have used chemiluminescence to determine NO3
- and NO2
- 
concentrations. Unsupplemented or placebo plasma NO2
- concentrations are 
predominantly in the nM range. The measurement of NO2
- poses significant 
challenges with substantial environmental contamination and plasma values that are 
often approaching the limits of detection of most assays. Furthermore there are a 
range of assay techniques available, with varying sensitivities. When this study is 
removed (Bescos et al., 2011) from the NO2
- and NO3
- data there is still a ~10 fold 
difference between the largest and the smallest baseline plasma NO2
- values which 
some researchers would argue is due to training status. It is unlikely that the 
variation in reported plasma NO2
- values is entirely due to genuine biological 
variation and dietary intake. Dietary intake accounts for ~1 - 2 mmol of NO3
- per day 
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(ECETOC., 1988) and would therefore not elicit these variations with much less than 
this being derived from the L-arginine pathway. Assay variation remains a likely 
contributor to these large variations. A consensus within and between groups would 
help to establish norms within populations.    
Variation in length of supplementation of NO3
- ranges from 2.5 hours to 15 days with 
variation in washout periods for acute and chronic supplementation ranging from 2.5 
days to 28 days. For supplementation periods that do not have time to elicit protein 
expression within the mitochondria (i.e. < 3 days) (Larsen et al., 2011) the washout 
period is less important. Conversely, longer washout periods are needed for longer 
supplementation periods. Research examining the length of RNA expression 
changes following supplementation withdrawal would elucidate how long it would 
take to lose these mitochondrial adaptations.     
1.1.7: Endothelial dysfunction and red blood cells:  
Endothelial function and the blood pressure lowering effects of NO∙ have been 
closely linked in previous research studies. It has been hypothesised that eNOS 
could act as another NO2
- reductase in areas where it may be needed, such as 
hypoxia (Webb et al., 2008b) and anoxia (Gautier et al., 2006). Plasma NO2
- 
concentrations have been shown to mirror endothelial dysfunction in humans 
(Kleinbongard et al., 2006), with dysfunction in endothelial function and reduced 
bioavailability of NO∙ being closely linked to cardiovascular disease (Forte et al., 
1997, Vanhoutte, 2009). This potentially could be the reason for poor control of 
vascular tone (Forte et al., 1997).  
Endothelial dysfunction is a systemic disease of the vascular endothelium which is 
brought about via a disparity between vasodilation and vasoconstricting substances. 
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This endothelial dysfunction is associated with T2DM and has been strongly linked to 
a reduced bioavailability of NO∙ (Calver et al., 1992, Cohen, 1993, Cockcroft et al., 
2000). This is likely to be underpinned by multiple factors; firstly, an impairment of 
NOS (Ito et al., 2002, Huynh and Tayek, 2002) to create NO∙ and secondly, 
increased inactivation of NO∙ by oxidants or reactive O2 species (Vallejo et al., 2000, 
Angulo et al., 1996). A third possibility includes scavenging of NO∙ in the vascular 
lumen which can be expedited by four key proteins such as, oxyhaemoglobin (to 
form methemoglobin and NO3
-), deoxyhaemoglobin (to create nitrosyl haemoglobin), 
O2 and thiols (creating S-nitrosohaemoglobin) (Kharitonov et al., 1995, Gow et al., 
1999, Gow and Stamler, 1998, Lancaster, 1996).  
Nitrosyl-haemoglobin levels are higher in individuals with type 1 diabetes compared 
to healthy controls. It would appear that higher concentrations of glycated 
haemoglobin will reduce the bioavailability of NO∙ (Milsom et al., 2002). S-
nitrosohaemoglobin related dilation is inversely related to oxygenation status (James 
et al., 2004). However, the deoxygenation of haemoglobin has been proposed as a 
mechanism of NO∙ delivery (Jia et al., 1996). NO∙ delivered via red blood cells (RBC) 
has been suggested to play a role in vasodilation in healthy participants under 
hypoxic conditions and contributes to a role in healthy physiology (McMahon and 
Stamler, 1999). If these metabolites do act as a NO∙ storage pool then they could be 
key for NO∙ mediated vasodilation in conditions such as acidosis or hypoxia (James 
et al., 2004) which are particularly prevalent conditions in skeletal muscle of 
individuals with T2DM and the respiratory muscles of individuals with chronic 
obstructive pulmonary disease (COPD). However, more NO∙ is bound to glycated 
haemoglobin (HbA1c) which appears to reduce the vasodilatory functions of red 
blood cells (James et al., 2004) and thus individuals with T2DM will retain more NO∙ 
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than non-diabetic controls. This RBC derived NO∙ delivery appears to be expedited 
under pathological conditions such as ischemia reperfusion injury (Duranski et al., 
2005), pulmonary hypertension (Hsu et al., 2007), atherosclerosis (Kim-Shapiro et 
al., 2006) and cerebral vasospasm (Pluta et al., 2005).  
Blood vessel relaxation can be induced by insulin and is mediated at least in part via 
nitric oxide (Scherrer et al., 1994). Vascular function is impaired in T2DM (Steinberg 
et al., 1996). However, the perturbations in nitric oxide production and metabolism in 
T2DM and consequent modulation of vascular health are currently not clear. Some 
investigators suggest basal nitric oxide production is reduced in individuals with 
T2DM compared with healthy controls (Woodman et al., 2006, Scherrer and Sartori, 
2000, Tessari et al., 2010). This could be a result of the increased expression of the 
intracellular inhibitor of endothelial nitric oxide synthase (Garcı́a-Cardeña et al., 
1997), caveolin-1 in the adipose tissue of individuals with T2DM (Catalán et al., 
2008), elevated levels of NOS inhibitors such as asymmetric dimethylarginine 
(ADMA) (Abbasi et al., 2001) or BH4 oxidation. Other groups report elevated levels of 
oxidised products of nitric oxide (Maejima et al., 2001, Chien et al., 2005, Ghasemi 
et al., 2010) with associations with specific genetic polymorphisms of eNOS noted 
(Monti et al., 2003). Together these reports would suggest T2DM is accompanied by 
either impaired production of NO∙, rapid scavenging of nitric oxide before it can 
cause downstream changes or a failure of activation of secondary messengers such 
as cGMP which are known to mediate NO∙’s vascular effects (Young and Leighton, 
1998).  
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1.1.8: NO∙ hepatic glucose uptake and T2DM: 
Following a meal, glucose along with other carbohydrates and dietary constituents 
gets absorbed from the gastrointestinal tract. These nutrients are taken directly to 
the liver by the portal blood vessels allowing the liver to control the levels of nutrients 
like glucose in the blood. Glucose is the predominant energy source for mammalian 
cells and these cells require a steady supply of glucose to maintain normal function. 
Blood glucose regulation is maintained by numerous actions including: the rate of 
glucose consumption, carbohydrate uptake from the intestine, skeletal muscle 
glucose uptake and utilisation, and the rate of uptake/release via the kidney (Nordlie 
and Arion, 1964) and via the generation of endogenous glucose when required. 
Under normal physiological conditions glucose does not accumulate in the plasma. 
The surplus glucose gets metabolised, stored as glycogen (glycogenesis) 
predominantly in the liver) or converted to fat. Following ingestion of food, portal vein 
diameter widens increasing blood flow to the liver (Pazahr et al., 2014). This process 
may expedite glucose disposal. 
Incretins, such as glucagon like peptide (GLP-1) and Glucose dependent 
insulinotropic peptide (GIP), are a group of gastrointestinal hormones that are 
released into the blood stream from cells in the small intestine in response to 
ingestion of food (Holst, 2007). They are predominantly involved in the regulation of 
blood glucose levels via their ability to have an insulinotropic (i.e. they promote 
insulin secretion) effect essentially augmenting the glucose-induced insulin secretion 
(known as the incretin effect). Other functions of incretins include regulation of gut 
motility, gall bladder constriction, nutrient absorption and secretion of gastric acids 
and pancreatic enzymes (Drucker, 2006). Glucagon-like peptide receptors (GLP-
1Rs) have been found in many cardiovascular tissues including vascular and 
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coronary endothelium smooth muscle, cardiomyocytes and endocardium (Wei and 
Mojsov, 1995, Bullock et al., 1996). A diverse range of beneficial cardiovascular 
effects have been shown by multiple groups which include: regulation of blood 
pressure and heart rate, vascular tone and myocardial contractility (Barragán et al., 
1996, Vila Petroff et al., 2001, Yamamoto et al., 2002, Green et al., 2008). 
Importantly these beneficial effects have been shown in healthy adults and also 
individuals with T2DM (Nikolaidis et al., 2004a, Nystrom et al., 2004, Özyazgan et 
al., 2005, Sokos et al., 2007).  
L-cells present in the intestines secrete the biologically active GLP-1 (7-37), GLP-1 
(7-36 amide) and GLP-2 (Baggio and Drucker, 2007) into the microcirculation to 
which the cells are closely associated. GLP-1 is known to slow gastric emptying 
(Meier et al., 2006) which reduces feelings of hunger (Zander et al., 2002) and in 
combination with receptors within the brain, GLP-1 creates a feeling of satiety (Goke 
et al., 1995) which have been shown to improve weight loss in individuals with 
T2DM. Other beneficial effects have been shown such as increased myocardial and 
endothelial function (note, in cardiac disease patients) (Basu et al., 2007, Nikolaidis 
et al., 2004a, Nikolaidis et al., 2004b).  
A consensus within the literature has emerged that individuals with T2DM have an 
impaired incretin response compared to healthy controls (Nauck et al., 2011). This 
appears to be due to both reduced GLP-1 secretion and a resistance to GIP. The 
impaired incretin response increases as T2DM  progresses (Nauck et al., 2011). 
GLP-1 has been shown to elicit myocardial glucose uptake (Bhashyam et al., 2010) 
and increases skeletal muscle microvascular blood flow, glucose uptake, nitric oxide 
production and insulin clearance mediated via nitric oxide-dependant mechanisms 
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(Chai et al., 2012). Specifically, GLP-1 analogues in animal models (dog) have also 
been shown to up-regulate the production of the vasodilator NO∙ (Post et al., 2010) 
whilst GIP has been shown to stimulate NO∙ production from eNOS in the portal vein 
but not in the hepatic artery (Ding et al., 2004). The portal vein is of paramount 
importance for glucose disposal; it collates tributaries from the stomach, proximal 
small intestines and the spleen and directs nutrient rich blood towards the hepatic 
vasculature / parenchyma for processing.  
NO∙ mediated vasodilation facilitates insulin stimulated glucose uptake into skeletal 
muscle (measured via an L-NAME NO∙ blockade) (Roy et al., 1998).  In endothelial 
cells insulin promotes nitric oxide synthesis (via eNOS) leading to activation of 
GLUT4 translocation and increased glucose uptake into the cell (Jiang et al., 2014). 
Therefore, increasing NO∙ concentration may increase glucose uptake into cells via 
both activation of GLUT’s translocation and/or via vasodilation. As described above 
dietary NO3
- is converted to NO2
- which is rapidly absorbed in the stomach and 
proximal small intestine. NO2
-, absorbed by the stomach and the proximal small 
intestine will be delivered via the portal vein along with other micro and 
macronutrients to the stomach. Therefore the highest plasma concentrations of NO2
- 
in the body will occur in the portal circulation. Nitrite may play a vital role in glucose 
homeostasis following a meal either by direct signalling as a vasodilator or following 
conversion to NO∙ (Petersson et al., 2007). The portal vein is partially deoxygenated. 
Deoxyhaemoglobin is a NO2
- reductase (Cosby et al., 2003) and thus there may be 
an increase in the bioavailability of NO∙. As the elevated plasma NO2
- concentrations 
reach the liver, many more NO2
- reductases are present such as neuroglobin, 
cytoglobin, xanthine oxide and aldehyde oxidase  which may increase the 
bioavailability of NO∙(Martin et al., 2004, Li et al., 2008b).  
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Over recent years experimental evidence has shown that NO∙ may be key for 
glucose uptake (particularly in animal models) with skeletal muscle and in the 
intestines. In 2002 Kingwell et al, used a NOS inhibitor to assess the role of glucose 
uptake with skeletal muscle of an individuals with T2DM. They present a 13% drop in 
glucose uptake (Kingwell et al., 2002). One year later Guan et al., infused GLP-2 into 
neonatal piglets with an without a NOS inhibitor and found a marked reduction in 
glucose uptake with L-NAME (Guan et al., 2003). L-NMMA has also be shown to 
reduce glucose uptake in skeletal muscle in a mouse model (Merry et al., 2010). 
Another animal model used eNOS deficient mice, supplemented half the mice with 
nitrate rich water for 10 weeks. Carlstrom et al., demonstrate reduction in HbA1c, 
baseline plasma glucose concentrations and post prandial glucose concentrations 
and reduction in weight and circulating triglycerides (Carlström et al., 2010). 
Together these animal models suggest that NO∙ may be a mediator of glucose 
uptake. Potentially via an increase in GLUT-4 translocation (Bedard et al., 1997) or 
increased perfusion with the parenchyma. One study has also shown that nitrate 
supplementation in healthy young individuals increases glucose uptake compared to 
placebo during exercise (Wylie et al., 2013b).  
An intervention that can increase the bioavailability of NO∙ within the liver (a major 
site for glucose disposal) may help expedite reductions in postprandial plasma 
glucose concentrations.        
1.1.9: eNOS coupling 
Uncoupling is a term used to describe the physiological process where eNOS no 
longer produces NO∙ but creates O2
- (Li and Forstermann, 2013). Coupled and 
uncoupled NOS are commonly present in the same cell (Li and Forstermann, 2013). 
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As the coupled NOS produces NO∙ and the uncoupled NOS produces O2
-, the 
potential for an increase in peroxynitrite concentration and subsequently a change in 
redox balance increases (Zou et al., 2004).  
eNOS is mainly found in the endothelium but also in the cardiomyocytes (Wei et al., 
1996), airway endothelium (Giaid and Saleh, 1995), and the tubular cells of the 
kidneys (Tracey et al., 1994). The eNOS N-terminus (i.e. the start of a polypeptide) 
contains the oxygenase aspect of the NOS, BH4, heam and also the L-arginine 
binding sites.  
L-arginine and BH4 stabilise the eNOS protein when in its dimeric form (non-covalent 
bonded macromolecule of two similar sub-units (Reif et al., 1999, Venema et al., 
1997)). Zinc thiolate is key in maintaining the BH4 binding site and maintains its 
structure in a dimeric form (Raman et al., 1998). Therefore maintaining BH4 and zinc 
thiolate is key to prevent uncoupling and an increase in oxidative stress. Guanosine 
triphosphate (GTP) is converted to BH4 via GTP cyclohydrolase (GTPCH1). Under 
elevated conditions of oxidative stress BH4 is converted to dihydropterin (BH2) which 
ultimately leads to a perpetual increase in NOS uncoupling. O2
- and NO∙ combine to 
produce peroxynitrite (OONO-), which is a powerful free radical. This is a reversible 
reaction which can be catalysed by dihydrofolate reductase (DHFR) (Crabtree et al., 
2011). Individuals with T2DM are in a pro-oxidant state, which is likely to lead to 
uncoupled NOS and in particular eNOS (Siasos et al., 2007) which will generate O2
-. 
NO∙ can react with O2
- which will create OONO2
-. This will reduce the bioavailability 
of NO∙ (Beckman and Koppenol, 1996).    
Methylation of L-arginine naturally occurs in the cytoplasm of any normal functioning 
cell. Methylation of L-arginine can create one of three distinct derivatives of this 
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amino acid (i), Asymmetric dimethylarginine (ADMA), (ii) symmetrical 
dimethylarginine (SDMA) and (iii) monomethyl-L-arginine (L-NMMA). Two distinct 
enzymes are required to produce ADMA and SDMA: they are type 1 (forms ADMA) 
and type 2 (forms SDMA) protein-arginine methyltransferases (PMRTs). ADMA can 
inhibit all three NOS isoforms and has a greater affinity for eNOS (Tousoulis et al., 
2007). ADMA is elevated in individuals with T2DM (Abbasi et al., 2001, Lu et al., 
2011, Schulze et al., 2006), and hypertension (Surdacki et al., 1999). Elevated 
ADMA has been shown to predict cardiovascular disease (Ravani et al., 2005, Lajer 
et al., 2008, Lu et al., 2011, Schnabel et al., 2005). Moreover, plasma ADMA 
concentrations have been shown to independently predict not only non-fatal 
myocardial infarctions but also death from cardiovascular causes (Schnabel et al., 
2005, Meinitzer et al., 2007) in patients with coronary artery disease. Similar findings 
have been shown in haemodialysis patients (Zoccali et al., 2001) and angina (Lu et 
al., 2003a). Hyperglycaemia impairs dimethylargininase in the endothelium and 
smooth muscles which results in raised ADMA levels in individuals with T2DM (Lin et 
al., 2002). ADMA causes atherosclerosis lesions and renal damage which impairs 
NO∙ output in eNOS deficient mice (Suda et al., 2004).  These deleterious effects are 
caused by upregulation of angiotensin-converting enzyme and elevated levels of O2
- 
(Suda et al., 2004).    
1.1.10: Preventing eNOS uncoupling via pharmaceutical methods: 
Uncoupling of eNOS decreases O2 dependent NO∙ production and elevates 
oxidative stress (Li and Forstermann, 2013). Strategies that increase NO∙ 
bioavailability either through pharmacological methods or through dietary sources 
could alter the redox balance to prevent NO∙ and BH4 oxidation. This may lead to 
reduced superoxide production from uncoupled NOS (Förstermann and Sessa, 
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2012). Below is a summary of supplements/drugs that can help prevent the 
uncoupling of eNOS and therefore elevate NO∙ bioavailability.  
BH4  
BH4 supplementation has been shown to vasodilate blood vessels after arterial-
infusion in patients with coronary heart disease (Cunnington et al., 2012). Its 
effectiveness as an anti-hypertensive is limited by its rapid oxidation. When BH4 is 
administered as an oral treatment it has no effect on endothelial function 
(Cunnington et al., 2012). There is some evidence that BH4 elevates iNOS activity 
(McNeill and Channon, 2012). Sepiapterin is a molecule that is converted to BH4 via 
Sepiapterin-reductase and DHFR. These reductases have been shown to be down-
regulated in hypertension (Youn et al., 2012). Therefore, given the rapid oxidation of 
BH4 as an oral agent (Cunnington et al., 2012), its use as a supplement is unlikely to 
be beneficial. Maintaining redox balance however, will prevent the uncoupling of 
NOS (Zou et al., 2004).   
Antioxidants 
There are data to suggest that beetroot juice will not only increase the bioavailability 
of NO∙ by the entero-salivary pathway involving inorganic NO3
- but also via its 
antioxidant content (see experimental chapter 1 for table of antioxidant content) 
(Kanner et al., 2001). Antioxidant supplementation per se has the potential to 
alleviate oxidative stress via reductions in cell damage (de Boer et al., 2005), anti-
inflammatory effects (Kelley et al., 2006) an inhibition of uric acid production (Jacob 
et al., 2003) and potentially prevent NOS uncoupling.   
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Statins  
Statins are a group of drugs that are utilised to lower plasma cholesterol levels via 
the inhibition of 3-hydroxy-3-methyl-glutaryl-CoA reductase. Statins enhance the 
availability of superoxide dismutase (SOD) and GPx isoforms (Carrepeiro et al., 
2011, Landmesser et al., 2005). Statins also have an anti-atherosclerotic effect 
which is may in part be due to their impact on NO∙ bioavailability (Antonopoulos et 
al., 2012). In vivo, statins have been shown to increase the expression of BH4 and 
also GTPCH1 in humans (Antoniades et al., 2011). This increase in GTPCH1 is 
likely to be responsible for the increase in BH4 and ultimately reducing eNOS 
uncoupling (Hattori et al., 2003, Antoniades et al., 2011).  
Organic nitrates 
Organic NO3
- act as NO∙ donors (such as isosorbide mononitrate). Pentaerithrityl 
tetranitrate has been shown to prevent eNOS uncoupling (again via elevated BH4 
concentrations (Schuhmacher et al., 2011)), induce SOD isoforms (Oppermann et 
al., 2009), HO-1, reduce NADPH oxidase and xanthine oxidase activity.  
ARB, ACEi and Beta Blockers 
Angiotensin-converting enzyme inhibitor (ACEi) and angiotensin receptor blockers 
(ARBs) impact upon the renin-angiotensin-aldosterone system. ACEi have been 
shown to increase NO∙ production via reductions in NAPDH oxidase, O2
- and OONO- 
whilst elevating BH4 concentrations in an the wantanabe heritable hyperlipidemic 
rabbits (Imanishi et al., 2008). ARBs have antioxidant properties (Warnholtz et al., 
1999) and long term exposure leads to re-coupling of eNOS (Warnholtz et al., 1999). 
This appears to be via the prevention of BH4 oxidation (Wenzel et al., 2008). 
GTPCH1 mediates BH4 synthesis (Wenzel et al., 2008, Satoh et al., 2008) and by 
up-regulation of dihydrofolate reductase mediates reduction of BH2 to BH4 (Oak and 
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Cai, 2007). Nebivol, a beta blocker, not only stimulates eNOS to produce NO∙ 
(Münzel and Gori, 2009) but has the ability to reverse its uncoupling (Mollnau et al., 
2003) by inhibiting NADPH oxidase.   
eNOS transcriptional enhancers (AVE3085) 
AVE3085 is an eNOS transcription factor which is involved in the regulation of eNOS 
protein expression (Wohlfart et al., 2008). AVE3085 has been shown to elevate 
vascular BH4 concentrations and thus reduce eNOS uncoupling (Wohlfart et al., 
2008). AVE3085 also appears to have antioxidant effects and reduces the 
expression of NADPH oxidase (Westermann et al., 2009) which may contribute to 
elevated NO∙ bioavailability.     
1.1.11 Ageing and NO∙  
 
Two key co-factors in the production of NO∙ are reduced in concentration as we age. 
These are BH4 and L-arginine (Delp et al., 2008). This may mean that as we age we 
get a greater increase in uncoupled NOS, creating more superoxide and 
subsequently peroxynitrite (Kang et al., 2009). Moreover, plasma nitrite 
concentrations have also been shown to be reduced in older adults (Sindler et al., 
2011). Given the putative benefits of NO∙ in healthy young adults, using a dietary 
source of nitrate may increase NO bioavailability in healthy older adults and enable 
them to benefit from the positive association that has been shown between NO∙ and 
vascular health (Ignarro et al., 1999).  
1.1.12: Toxicology: 
Methemoglobinemia occurs when the heme group in a haemoglobin is oxidised to its 
ferric state (Fe3+) and is therefore incapable of transporting O2 (Avery, 1999). As far 
back as 1868 the combination of NO3
- and blood has been shown to produce 
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methemoglobinemia (Eusterman and Keith, 1929, Gamgee, 1868, Reichert, 1880). 
This was later corroborated in animal models as large doses of NO3
- caused the 
formation of methemoglobinemia (Binz and Geringer, 1901). In 1945 concerns about 
nitrates’ potential toxicity emerged again as fears over methemoglobinemia or blue 
baby syndrome arose. Blue baby syndrome was first reported by Comly (1945) with 
the observation that the well-water had large contamination of NO3
-. Occurrences of 
methemoglobinemia were shown in (Walton) 1951 to be rare in water that contained 
< 44mg/l of NO3
-. Given this knowledge, the level at which the US (44 mg/l) and the 
European union (50 mg/l) set the NO3
- levels in drinking water was addressed. The 
notion that NO3
- by itself can cause methemoglobinemia has been strongly argued 
against by Avery (1999). Avery proposed a more likely scenario that NO3
- in the well 
water contributed to methemoglobinemia. Bacterial contamination within the well was 
converting NO3
- to NO2
-. Furthermore, given the beneficial effects of NO3
- that are 
described later in this chapter, the removal of NO3
- from water supplies could be 
detrimental to human health by reducing the daily intake of NO3
-.  
N-nitrosamines were shown to cause hepatic tumours in rats (Magee and Barnes, 
1956). In 1976 two independent groups from Germany and the USA introduced the 
concept that NO3
- could be transformed into N-nitrosamines under acidic 
environments (Tannenbaum et al., 1976, Spiegelhalder et al., 1976). Given that NO3
- 
and NO2
- have been used as a preservative in food for centuries and that NO3
- is 
abundant in many foods which epidemiological evidence has suggested to have 
cardio protective effects such as vegetables (Joshipura et al., 1999, Joshipura et al., 
2001), the publication by (Newberne, 1979) stating that NO2
- caused lymphomas in 
rats was surprising. The food and agriculture organisation and the world health 
organisation expert committee on food additives jointly released a statement which 
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stated “Overall, the epidemiological studies showed no consistently increased risk for 
cancer with increasing consumption of NO3
-. These data, combined with the results 
of the epidemiological studies considered by the Committee at its forty-fourth 
meeting, do not provide evidence that NO3
- is carcinogenic to humans” (Speijers and 
Brandt, 2003).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
50 
 
1.2: Introduction to Type 2 Diabetes Mellitus: 
T2DM is a chronic disease and progressive in nature. The aetiology of the disease is 
chronic hyperglycaemia caused via insulin resistance and diminishing pancreatic 
beta cell insulin production (Stumvoll et al., 2007). These characteristics cause micro 
and macrovascular complications (such as cardiovascular disease) which ultimately 
result in elevated morbidity and mortality (Jaffe et al., 1984, Sprafka et al., 1991). 
T2DM is emerging as an epidemic in both the developed world as well as the 
developing world. Life expectancy has risen sharply over recent years (Oeppen and 
Vaupel, 2002) whilst obesity is rising due to a sedentary lifestyle and excessive 
intake of calories. This review will aim to explore the demographics of T2DM, insulin 
resistance and the development of T2DM, measurement of T2DM, genetics, 
response to exercise, macrovascula,r microvascular disease and metabolic 
complications and NO∙.   
1.2.1: T2DM demographics and costs: 
T2DM accounts for 90 - 95% of all cases of diabetes worldwide  (Harris, 1998, Hariri 
et al., 2006). Physical inactivity and obesity increases the prevalence of this 
metabolic disease (Wild et al., 2004). As we age (on a population level) we do less 
and less activity (Sallis, 2000) which may explain some of the increased risk with 
aging. As the global population expands the number of people with T2DM is 
increasing (Wild et al., 2004). The chances of developing diabetes increases from 
0.3 - 0.5 % per year for 50-60 year olds to 0.5 - 1% for 60-70 year olds and greater 
than 1% a year for over 70 year olds (Berger et al., 1999). Wild et al., (2004) 
projected that by 2030 this figure of 171 million will have doubled to over 340 million 
worldwide. However, this may be conservative given these calculations were based 
on obesity levels remaining stable and the observation that obesity levels are in fact 
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increasing. More recent estimates of 439 million by 2030 have been suggested after 
extrapolation from the 2010 figure of 285 million individuals (Shaw et al., 2010). In 
the UK 3.1 million people (diagnosed and undiagnosed) have T2DM, which equates 
to 7.4% of the population (PHO, 2010). With increasing numbers of individuals 
developing T2DM the associated costs increase (Caro et al., 2002). T2DM is 
responsible for 8% of the NHS annual budget equating to £8.8 billion per annum. 
The total cost of direct and indirect care  comes to a total of £20.5 billion (Hex et al., 
2012).   
1.2.2: Insulin resistance, beta cell dysfunction, and type 2 diabetes mellitus:  
Reduction in sensitivity to the hormone insulin causes three major abnormalities to 
occur in the body: firstly, a reduced insulin mediated uptake of glucose by skeletal 
muscle, secondly, an increase in free fatty acid metabolism via adipose tissues and 
finally over production/secretion of glucose by the liver (Kabir et al., 2005). As insulin 
resistance progresses hyperglycaemia will begin to manifest itself in the fasted state 
(Lebovitz, 1999). Insulin resistance is a precursor to the development of T2DM in 
which the cells within the bodies fail to respond to the hormone correctly. The body 
produces adequate concentrations of insulin, however, changes in the cell surface 
receptors, (Kolterman et al., 1980), mitochondrial dysfunction (Holloszy, 2009), 
endoplasmic reticulum stress (Cnop et al., 2012), fat in skeletal muscle and glucose 
modification (Hart et al., 2011) (via the hexosamine biosynthesis pathway) prevent 
the correct response (i.e. the uptake of glucose into the cell). As peripheral insulin 
resistance progresses in skeletal muscle, liver, and fat tissues circulating plasma 
glucose concentrations will rise. Rising plasma glucose concentrations stimulate the 
pancreatic ß-cells to secrete more insulin (hyperinsulinanemia) in an attempt to 
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maintain metabolic homeostasis. This will continue until total ß-cells’ death (Stumvoll 
et al., 2005) (See figure 2 below).  
The aetiology of T2DM and the subsequent insulin resistance and beta cell 
dysfunction is multifactorial. Of primary importance are the following: relative 
excessive calorie intake (Bloomgarden, 2000), aging (Harris et al., 1998), and a lack 
of exercise (Morgan et al., 2002, Shaw et al., 2010). This means that insulin resistant 
individuals are in a chronically elevated energy balance (Stumvoll et al., 2005, 
Eriksson, 2007, Kahn et al., 2006). If an individual has a persistent positive energy 
balance (i.e. over and above the requirements for daily living) adipocytes will uptake 
triglycerides until they become saturated, creating adiposopathy (Bays, 2011). This 
mainly occurs in the visceral adipocytes. If adipocytes are at maximum capacity the 
ability to reduce circulating fats is diminished (Tushuizen et al., 2007). 
Hyperglycaemic mediated insulin production has been shown to be stunted by 
exposure of the ß-cells to fatty acid deposits, which are present in higher 
concentrations due to reduced clearance (Lee et al., 1994, Tushuizen et al., 2007). 
Furthermore, persistent chronically elevated fatty acid and triglyceride levels lead to 
abnormal amounts of these fats being stored in skeletal muscle (Boden, 1997, 
Boden and Chen, 1995) and the liver (Kabir et al., 2005). Storage of fats in skeletal 
muscle and the liver expedites the insulin resistance as skeletal muscle is the 
predominate source of glucose uptake (Berg et al., 2001, Kelley et al., 1993).  
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1.2.3: Measurement of insulin resistance and T2DM 
HbA1c is haemoglobin that has been glycated. HbA1c is created via an Amadori 
reaction which causes an irreversible binding of glucose molecules to the β -N-
terminal valine residues on the globin chains. During the reaction the haemoglobin is 
rearranged to 1-deoxy-1-N-valyl-fructose (Bookchin and Gallop, 1968, Dixon, 1972, 
Bunn et al., 1975). Although exposure of haemoglobin to glucose during the 120 day 
life time is stable in individuals with controlled diabetes, the HbA1c concentration is 
higher in older erythrocytes (Huisman and Dozy, 1962, Fitzgibbons et al., 1976). 
When circulating glucose concentrations rise the proportion of HbA1c rises as well, 
therefore the higher the plasma glucose the higher the HbA1c (Rohlfing et al., 2002). 
HbA1c is used as a measure of glycaemic control over a prolonged period as it is 
stable over time, typically accurate over a 3 month period due to the replacement of 
new red blood cells. The WHO have published a report on the use of HbA1c as a 
diagnostic tool for diabetes (WHO, 2011).  
Figure 2: Change in insulin resistance, insulin production and fasting blood glucose as diabetes severity 
increases. 
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1.2.4: Genetics  
T2DM appears to have a heritable component with heritability of T2DM being 
suggested to be greater than 50% in studies of monozygotic twins (Herder and 
Roden, 2011, Poulsen et al., 2009), and first degree relatives of individuals with 
T2DM. (Hemminki et al., 2010, Poulsen et al., 2009, Tattersall and Fajans, 1975, 
Saxena et al., 2007). Genetic mapping over recent years has shown more than 40 
loci that are thought to be partly responsible for the development of T2DM (Herder 
and Roden, 2011, Voight et al., 2010, Dupuis et al., 2010, Zeggini et al., 2008, 
Saxena et al., 2010). Most of these loci are associated with the dysfunction of 
pancreatic β-cells with the most common named ‘TCF7L2’ (Dupuis et al., 2010). The 
identified loci can only explain 10% of the heritability in T2DM (Herder and Roden, 
2011). The remaining cause of heritability is unknown. However, Nolan and 
colleagues (2011) suggest that variants in allele frequency maybe involved. Genetics 
also have a role to play in the development of microvascular disease, there appears 
to be an abnormality in the loci within chromosomes 7 and 20 which increases 
susceptibility to nephropathy (Imperatore et al., 1998).  
Ethnicity and environment can affect the risk of developing T2DM and it can also 
affect the likelihood of complications. Fasting plasma glucose levels were measured 
in Pima Indians (Pettitt et al., 1980, McCance et al., 1994), Egyptians (Engelgau et 
al., 1997), sections of the US population (Alberti and Zimmet, 1998) and Caucasians 
(Jarrett et al., 1984) independently. Measurements of the associated risk diabetes 
related complications and fasting plasma glucose concentrations were correlated 
with the mg/dL ranging from 108-140. African American and Mexican Americans 
have been shown to be at greater risk of diabetes related retinopathy compared to 
Caucasian Americans. In African American individuals this could be explained by a 
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larger % of the population having high blood pressure and a higher HbA1c. However, 
in Mexican Americans this is unexplained (Harris et al., 1998).  
1.2.5: T2DM and response to exercise:  
Fatigue: 
During exercise T2DM can lead to increased discomfort and early fatigue 
(Regensteiner et al., 1995a, Regensteiner et al., 1998) which may impair people with 
T2DM’s ability to achieve the recommended amounts of exercise that are a key part 
of the management of T2DM (NICE, 2008). This premature fatigue has been 
attributed to abnormalities occurring at multiple points during the transport of O2 from 
the lungs to the muscles where it is utilised during exercise (Scognamiglio et al., 
1998). Possible explanations for this impairment include compromised cardiac 
function which can manifest with reduced stroke volume (Gusso et al., 2008), 
reduced cardiac innervation (Scognamiglio et al., 1998) reduced left ventricular 
diastolic function (Poirier et al., 2000) and impaired cardiac autonomic function 
(Gerritsen et al., 2001). Other explanations of exercise impairment include 
diminished skeletal muscle O2 diffusion and a reduced mitochondrial O2 utilisation 
(Regensteiner et al., 1995a, Regensteiner et al., 1998, Baldi et al., 2002). These 
effects are likely underpinned by reductions in mitochondrial density (MÅrin et al., 
1994, Mathieu-Costello et al., 2005, Ritov et al., 2005) and amplified levels of 
mitochondrial dysfunction (Padilla et al., 2007). This dysfunction is characterised by 
an impaired bioenergetic capacity (specifically diminished NADH and citrate 
synthase (Kelley et al., 2002) and a reduced ability to uptake glucose (Mathieu-
Costello et al., 2003).  
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Maximal O2 uptake: 
Individuals with T2DM have an elevated resting O2 consumption coupled with a 
profound reduction in maximal O2 uptake (Baldi et al., 2002, Regensteiner et al., 
1998, Regensteiner et al., 1995a, Wilkerson et al., 2011, O'Connor et al., 2015). 
Maximal O2 uptake is an important predictor of all-cause mortality (Myers et al., 
2002, Galant et al., 2012). Therefore, individuals with T2DM are likely to be closer to 
their maximum exercise capacity than individuals without diabetes for any given 
intensity of exercise (Regensteiner et al., 1998). The consequence of being closer to 
the maximal exercise capacity is that a greater physiological stress and thus greater 
discomfort will be experienced by the individual (Regensteiner et al., 1998), resulting 
in a reduction in exercise tolerance. If two individuals exercise at the same work 
load, the one with higher O2 consumption will typically find the exercise more difficult. 
This may translate with individuals with T2DM having greater perceived exertion at 
the same workload. Difficulties completing submaximal exercise tasks may manifest 
as a barrier to attain the recommended amounts of exercise recommended by the 
WHO (Huebschmann et al., 2009). The reduction in maximal O2 uptake is ultimately 
caused by an irregularity in  O2 delivery (Regensteiner et al., 1995a, Regensteiner et 
al., 1998, Baldi et al., 2002, Wilkerson et al., 2011).  
O2 delivery:  
Many of the abnormalities that are related to premature fatigue in individuals with 
T2DM are likely caused via O2 delivery perturbations. These include O2 
transportation form the lungs to the muscle during exercise (Scognamiglio et al., 
1998), along with reduced stroke volume (Gusso et al., 2008), cardiac innervation 
(Scognamiglio et al., 1998), cardiac autonomic function (Gerritsen et al., 2001) and 
left ventricular diastolic function (Poirier et al., 2000). O2 delivery may also be limited 
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by a reduced total and fractional O2 extraction into the mitochondria which is caused 
via reduction in mitochondria density, size and function (Regensteiner et al., 1995a, 
Regensteiner et al., 1998, Baldi et al., 2002, Padilla et al., 2007, Shore et al., 1994, 
MÅrin et al., 1994, Mathieu-Costello et al., 2005). Individuals with T2DM also have 
elevated plasma endothelin-1 (endothelin-1 are a group of peptides that modulate 
vascular tone) (Schneider et al., 2002), reduced capillary density (MÅrin et al., 1994, 
Mathieu-Costello et al., 2003), impaired haemodynamics (Padilla et al., 2007, Shore 
et al., 1994) and mitochondrial function (Kelley et al., 2002) in the skeletal muscle.   
?̇?O2 kinetics and exercise tolerance:  
The rate at which V̇O2 projects towards the steady state is a major determinant in the 
ability of an individual to tolerate exercise. The quicker an individual can attain a 
steady state following the onset of exercise, the greater the contribution of oxidative 
compared to non-oxidative metabolism (Jones and Poole, 2005). By increasing the 
speed of the O2 uptake response, individuals can reduce the intracellular changes in 
metabolic milieu that have been linked to the fatigue process. By using a larger 
proportion of oxidative metabolism, the speed at which lactic acid concentrations 
build up are slowed. Lactic acid disassociates into lactate and H+ , the H+ causes 
acidosis and thus is an important determinant of fatigue (Bruton et al., 1998, Pate et 
al., 1995, Westerblad et al., 1997, Wiseman et al., 1996). Similarly, in anaerobic 
respiration, phosphocreatine is broken down into creatine and inorganic phosphate 
(Pi). Pi concentrations appear to have a larger contribution to fatigue than reduced 
pH levels (at least at physiological temperatures) (Dahlstedt et al., 2001, Dahlstedt et 
al., 2000, Dahlstedt and Westerblad, 2001, Fryer et al., 1995, Kabbara and Allen, 
1999, Kabbara and Allen, 2001). Fatigue may however be expedited in low pH levels 
by inhibition of key enzymes involved in glycolysis and glycogenolysis. This may 
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slow the adenosine diphosphate to adenosine triphosphate turnover rate 
(Westerblad, Allen, & Lännergren, 2002).   
The V̇O2 kinetics of individuals with T2DM have been shown to be slowed (Bauer et 
al., 2007, Regensteiner et al., 1998, Regensteiner et al., 1995a, Brandenburg et al., 
1999). Conversely, Wilkerson et al. (2011) showed no difference in the V̇O2 kinetics 
of older individuals with T2DM compared to healthy age matched controls. More 
recently, the putative slowed V̇O2 kinetics shown by some studies in older individuals 
with T2DM has been revisited by O'Connor et al. (2015) to assess whether the lack 
of effect shown in some studies in the kinetics of older individuals with T2DM was 
due to disease duration or age. Disease duration was matched between a younger 
group and an older group of individuals with T2DM. Their findings indicate that 
middle aged men have impaired V̇O2 kinetics (i.e. a longer time constant) compared 
to healthy matched controls. However, older (65 years old) individuals with T2DM 
were similar to their healthy matched controls, replicating Wilkerson et al’s findings in 
2011. This suggests that aging is the predominant cause for slowed V̇O2 kinetics.  
Medication and exercise performance:  
T2DM is a disease that affects multiple systems. Many of the medications that are 
used to treat one aspect of their condition can also have many other beneficial 
effects. Drug treatment used to reduce hyperglycaemia such as sulfonylureas, 
insulin and metformin have all been shown to help reduce microvascular 
complications (Turner et al., 1998, UKPDS, 1998, Ohkubo et al., 1995, Patel et al., 
2008) and improve exercise performance. For instance insulin when used to treat 
patients with T2DM and heart failure as a comorbidity have been shown to improve 
ventilatory efficiency and V̇O2 (Guazzi et al., 2003). Moreover, ramipril has been 
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shown to increase treadmill walking time compared with a placebo in individuals with 
peripheral artery disease (Ahimastos et al., 2013).  
1.2.6: Micro & macrovascular Complications: 
Between 1950 and 1995 the absolute risk of myocardial infarction, strokes and 
intermittent claudication has fallen by ~50% in individuals with diabetes (Fox et al., 
2004). However, individuals who have T2DM still have a two to four fold increased 
chance of developing coronary heart disease compared to individuals without T2DM 
(Stamler et al., 1993, Hanefeld et al., 1991, Wei et al., 1998, Wilson et al., 1991). 
Although the overall risk of CVD has fallen in individuals with T2DM over resent 
decades, more of the risk is attributable to T2DM (Fox et al., 2007) (the Framingham 
heart study). Having diabetes and CVD increases the risk of mortality compared to 
non-diabetic controls following a myocardial infarct by 50% (Sprafka et al., 1991). 
Jaffe et al., also showed an increased mortality in individuals with T2DM compared 
with controls. However when both groups were stratified for congestive heart failure 
the survival rates were similar (Jaffe et al., 1984).  
Cholesterol is one of the major components involved in the pathogenesis of CVD (Lu 
et al., 2003b). Superficially, individuals with T2DM appear to have a similar lipid 
profile to age matched controls, for instance they have total cholesterol and LDL-
cholesterol that are very similar (Laakso et al., 1985). Individuals with T2DM have a 
lower HDL-cholesterol and higher triglycerides (Wilson et al., 1985, Taskinen, 2003) 
which in turn are known risk factors for the development of CVD (Fontbonne et al., 
1989, Assmann and Schulte, 1991).  
Poor glycaemic control is detrimental to microvascular function and has been 
strongly associated with elevated microvascular dysfunction (Stratton et al., 2000). 
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The risk for microvascular disease is thought to be determined by the level of 
glycaemia, with extremely high glucose concentrations creating the greatest risk 
(Krolewski et al., 1995). Every percentage point decrease in HbA1c  (and thus 
improving control) results in a 35% reduction in microvascular complications 
(UKPDS, 1998). This group also suggested that by improving glycaemic control via 
diet and metformin as opposed to insulin therapy, microvascular complications can 
be reduced by 32%. Some of these findings have since been replicated in a 
Japanese cohort (Shichiri et al., 2000) when comparing 3 or more insulin injections 
compared with 1-2 injections. When more injections were used a greater level of 
glycaemic control was delivered which correlated with a reduced risk of 
microvascular complications. Not all of the experimental and epidemiological 
evidence supports this notion. In 2009 evidence was published to suggested that 
intensive glycaemic control in individuals with T2DM had no effect in controlling for 
microvascular complications or even major cardiovascular events (ADVANCE trial 
2009) (Duckworth et al., 2009). Another study in 2008 showed no effect where 
aggressive treatment of HbA1c with intensive therapy (increased medications with 
monthly visits to assess glycaemic control) compared with conventional therapy (as 
prescribed by their clinician) actually increases mortality (ACCORD (Hertzel C. 
Gerstein et al., 2008)).  
1.2.7: NO∙ and related microvascular diseases: 
The availability of NO∙ is important in the pathophysiology of diabetes related 
vascular disease, with reduced availability leading to reduced endothelial relaxation 
(Creager et al., 2003). This impairment ultimately contributes to diabetes related 
microvascular angiopathy. This microvascular disease is a hallmark of diabetes 
related retinopathy and nephropathy (Santilli et al., 2004). Polymorphisms of  eNOS 
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have been shown to increase the severity of retinopathy and nephropathy in 
individuals with T2DM (Awata et al., 2004). By contrast a recent study has shown 
that an eNOS genotype is not associated with the development of diabetes related 
retinopathy (de Syllos et al., 2006, Neugebauer et al., 2000). However, eNOS 
polymorphisms are associated with nephropathy progression (Neugebauer et al., 
2000). de Syllos and Awata et al’s cohorts have ~50 participants with similar 
methodologies. The differences in these trials may be explained by differences in the 
cohorts. de Syllos et al’s cohort had diabetic retinopathy for ~4 years more than 
Awata cohort. Awata et al’s cohort also appear to have an abnormally low BMI for 
individuals with T2DM, at ~ 24 kg/m2.  
1.2.8: Retinopathy: 
Awata et al., suggest that the down-regulation of basal eNOS expression resulted in 
the macular oedema (caused via protein deposits and fluid build-up under the 
macula) which leads to a degradation of the blood-retina barrier. Larger cohorts are 
required to definitively explore the effects of eNOS genetic variation on retinal status. 
If the retardation of eNOS is limiting NO∙ availability through the traditional NOS 
pathway, this may reduce its vasodilatory effect in the microvasculature. Habitual 
supplementation of NO3
- could alleviate the damage by providing a pool of NO2
- for 
later conversion to NO∙ in the microvasculature of the retina along with other micro 
vessels. Retinopathy is the changes in the microvasculature of the retina. Initially the 
changes are characterised by increased vascular permeability which can progress to 
proliferative diabetic retinopathy (PDR) and eventually blindness. PDR is 
characterised by growth of new blood vessels on the retina and vitreous with an 
increase in blood flow (Patel et al., 1992). Macular oedema caused by retinal 
thickening is a common development with this disease (Fong et al., 2004). Within the 
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first two decades of diagnosis > 60% of individuals with T2DM have retinopathy 
(Fong et al., 2004). The greatest predictor for diabetes related retinopathy and 
progression is the duration of diabetes. As the years of disease increase so does the 
incidence of retinopathy, after 3 years there is a 8% prevalence which increased to 
25% after 5 years and 60% at 10 years (Klein et al., 1984).  
1.2.9: Nephropathy:  
Diabetes related nephropathy (DRN) is a progressive disease that affects the 
kidneys. It is caused by angiopathy of the capillaries within and surrounding the 
glomerulus (Christensen, 1971). DRN affects approximately 40% of all individuals 
with T2DM (Parving et al., 2001) with 5-10% of individuals with T2DM newly 
diagnosed with microalbuminuria each year (Ravid et al., 1993, Nelson et al., 1996, 
Gæde et al., 1999, HOPE, 2000). Approximately 40% of all end stage renal failure 
occurs due to diabetes related nephropathy (USRDS, 2012). Patients that have 
microalbuminuria have a 10-20 fold increased risk of developing nephropathy 
(Parving, 1996). Glomerular filtration rates may be elevated at diagnosis with T2DM 
due to hyperfiltration with or without microalbuminuria. Once macroalbuminuria 
develops the glomerular filtration rate progressively declines (Nelson et al., 1996). 
Ethnicity has a large impact upon nephropathy rates. However, age doesn’t appear 
to have an impact. African American individuals have the highest risk followed by 
Asian and Hispanic with Caucasian individuals having the lowest risk factor (USRDS, 
2012) with costs rising sharply to treat nephropathy with estimates ranging from 
$68,000 to $88,000 (USRDS, 2012, Foley and Collins, 2007).   
1.2.10: Neuropathy:  
Neuropathy is a microvascular complication thought to be brought about by damage 
to blood vessels that supply blood to nerves. Approximately 10% of individuals with 
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T2DM have neuropathy (Said, 2007). The prevalence of neuropathy is believed to 
increase with poor glycaemic control and the individual’s duration of T2DM (Pirart, 
1978, TDCCTRG, 1993, Martin et al., 2006). Neuropathy is usually a distal 
symmetric disease accounting for approximately 80% of all cases (Palumbo et al., 
1978, Freitas et al., 1992). Progression of polyneuropathy can also be triggered by 
amyloid polyneuropathies (Said, 1981). Competitive inhibition of the breakdown of 
amyloid-β in individuals with T2DM, by insulin degrading enzyme, occurs 
predominantly due to hyperinsulinanemia. In individuals with an impaired insulin 
response (Qiu and Folstein, 2006), this process may lead to increases in amyloid 
related polyneuropathies that are diagnosed as diabetic neuropathy in individuals 
with T2DM.  
1.2.11: Conclusion: 
T2DM metabolic disease with a rising prevalence that affects hundreds of millions of 
people worldwide. Attenuating sedentary time in individuals with T2DM appears to 
improve markers of metabolic health (Falconer et al., 2015). Therefore, strategies 
aimed at making exercise easier (thus removing barriers to exercise and fatigue) or 
reducing hyperglycaemia are needed to help combat the economic burden and 
improve quality of life in individuals with T2DM.  
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1.3: Introduction to chronic obstructive pulmonary disease  
1.3.1: Background: 
Chronic obstructive pulmonary disease (COPD) is an umbrella term given to group of 
diseases; emphysema, chronic bronchitis and chronic obstructive airways disease 
(Sin and Vestbo, 2009). Chronic obstructive pulmonary disease (COPD) is 
characterised by constricted airflow that is treatable but not entirely reversible, with a 
gradual decline in function (Kirkham and Rahman, 2006). Individuals with COPD 
typically report: exertional breathlessness, a chronic cough, regular sputum 
production, bronchitis and wheezing (GOLD., 2011). Multiple factors lead to relative 
hypoxemia in individuals with COPD such as reduced cardiac function (Jardin et al., 
1984), muscle deconditioning (Maltais et al., 2014), irregular pulmonary blood flow 
distribution leading to incomplete gas exchange (Marshall et al., 1994) and cor 
pulmonale. These manifestations often lead to a significant reduction in quality of life 
(DiBonaventura et al., 2012) and feelings of breathlessness and fatigue (Nici et al., 
2006). This review will consist of a brief introduction, demographics and economic 
burden, causes of the disease, COPD and exercise, pulmonary hypertension, 
dynamic hyperinflation and treatments.  
1.3.2: Demographics and economic burden: 
It is projected that by 2020 COPD will be the third most common cause of death 
worldwide (GOLD., 2011), due to an ageing population which have more exposure to 
COPD risk factors (Mathers and Loncar, 2006). There are approximately 3 million 
people living in the UK with COPD. However, 2 million of these remain undiagnosed 
(Healthcare-Commission, 2006). COPD accounts for 30,000 deaths a year in the UK 
with ~90% of these deaths occurring in those over 65 year olds (DoH, 2009). COPD 
accounts for 23% of all respiratory deaths in the UK (Society, 2006). There is a 
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substantial economic burden to society as a result of COPD. The Chief Medical 
Officer for England and the United Kingdom’s governmental Chief Medical Advisor 
reported that COPD accounts for ~£800 million in direct health care costs (DoH, 
2005), with other reports estimating the cost to be as high as £930 million (Society, 
2006). The healthcare commission also states that more than 50% of these costs are 
related to direct provision of care, and as such it is the single most costly provision of 
care within hospitals (Healthcare-Commission, 2006). The total economic cost of 
COPD is much larger given that it accounts for the loss of 24 million working days in 
the UK each year (Healthcare-Commission, 2006).        
1.3.3: Chronic bronchitis & emphysema:  
Chronic bronchitis is a disease defined by bronchial hypersecretion and a cough 
which is present for a minimum of 3 months at a time in at least two consecutive 
years (MRC, 1965). However, not all patients with chronic bronchitis will develop 
airflow limitations (Vestbo and Lange, 2002). Chronic bronchitis is associated with a 
chronic secretion of mucus combined with a progressive decline in lung function. 
Chronic bronchitis increases incidences of hospitalisation and mortality (Vestbo et 
al., 1996). Chronic bronchitis is predominantly caused by smoking. Evidence 
following on from the clean air act of 1956 which improved urban air quality 
dramatically has shown an associated reduction in the incidence of COPD and its 
associated diseases.  
As the disease progresses the alveoli are broken down which leads to large voids 
within the lungs, drastically reducing surface area for gas exchange (Snider, 1985). 
The pathology of emphysema involves the infiltration of alveoli by neutrophils, 
macrophages and lymphocytes (Taraseviciene-Stewart and Voelkel, 2008). 
Emphysema is also known to create a loss of elastic recoil within the lungs which is 
66 
 
caused by activated macrophages which release MMP-12 and neutrophil elastase 
which breaks down the elastin matrix between the alveoli (Mercer et al., 2004). Other 
cells such as epithelial and endothelial cells can also produce and secrete proteases 
(Mercer et al., 2004, Taraseviciene-Stewart et al., 2005). Subsequent scaring to lung 
tissue and a reduction in elastic recoil causes hyperinflation which causes major 
limitation to gas exchange (O'Donnell and Laveneziana, 2007). As the physiological 
drive to expire CO2 rises and demand for O2 increases, ventilation will increase 
(Fishman et al., 1955). The air enters the lung as the rib cage expands and pulls the 
scarred connective tissues. When the individual breathes out the air becomes 
trapped as the proximal and distal airways collapse. When the air becomes trapped 
the ability to breathe off CO2 decreases which in turn will increase ventilation and 
create a vicious cycle of air trapping (Fishman et al., 1955).  
1.3.4: COPD assessment:  
Severity or grade of COPD is accessed via the measurement of the forced expiratory 
volume in the first second (FEV1 (GOLD., 2011)). The speed at which FEV1 declines 
is a good indicator of survival (Anthonisen et al., 1986). The authors also showed 
that those individuals with a lower FEV1 at the beginning of the trial had the smallest 
reduction in FEV1   relative to baseline. Moreover, with individuals with relatively 
preserved FEV1 their speed of reduction correlated well with their response to a 
bronchodilator (Anthonisen et al., 1986). This landmark study also demonstrated an 
average reduction in FEV1 of 44 ml/year over three years (n = 985). The severity of 
dyspnoea correlated significantly with Quality of Life (QoL) as measured via a health 
related questionnaire (SF-36) but not significantly with FEV1 (Mahler and Mackowiak, 
1995). This suggests that as FEV1 does not correlate well with the QoL of an 
individual (Mahler and Mackowiak, 1995), a qualitative approach should be 
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considered when assessing QoL in individuals with COPD. This may be due to 
COPD being a multisystem disease.  
1.3.5: Smoking and oxidative stress:  
The recent report (GOLD., 2011) looking at the effects and causes of COPD has 
emphasised the impact of ‘noxious particles and gases’ and recently defined COPD 
as “a disease state characterized by airflow limitation that is not fully reversible. The 
airflow limitation is usually both progressive and associated with an abnormal 
inflammatory response of the lungs to noxious particles or gases” (GOLD., 2011). 
COPD has been linked to elevations in oxidative stress within the lungs (Roy et al., 
2007, Langen et al., 2003). Experimental research provides evidence that oxidants 
play a critical role in the pathogenesis of COPD. The principal contributory factor to 
the increase in oxidants is widely accepted to be cigarette smoke (Ciencewicki et al., 
2008). Of all COPD related mortality, 85% is attributed to smoking (Healthcare-
Commission, 2006). Cigarette smoke and smoke in general is known to have high 
concentrations of reactive oxygen species (ROS) (Chen et al., 2015). These ROS 
are thought to upregulate a transcription factor, NF-κB, known to be involved in 
inflammation (Li et al., 2009). Increases in ROS will therefore increase the 
inflammatory response and lead to alveoli breakdown. However, cigarette smoke is 
not the only cause of COPD. COPD can be caused via exposure to occupational air 
pollution for example, from burning wood or other biofuels (Salvi and Barnes, 2009). 
This is important because there is a delicate balance within the body between ROS 
and antioxidants termed as a redox balance. When this balance is shifted past the 
antioxidant capacity, ROS cause damage to proteins, lipids and DNA (Ciencewicki et 
al., 2008). ROS are also endogenously produced in epithelial and inflammatory cells 
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in response to cellular damage/injury and metabolism of O2 (Ciencewicki et al., 2008, 
Thannickal and Fanburg, 2000).  
1.3.6: Smoking and exercise:  
Reduced exercise tolerance is often found in individuals with COPD. The reduction 
in exercise tolerance is not a linear relationship dependent upon the number of 
cigarettes smoked (Wüst et al., 2008). This suggests that it is either an acute effect 
or, that after a certain number of cigarettes, the amount of intolerance to exercise 
that an individual experiences will reach a plateau (Wüst et al., 2008). This reduction 
in tolerance to exercise could simply be due to a sedentary lifestyle which is often 
linked to smoking (Larsson et al., 1998). Approximately 80% of individuals diagnosed 
with COPD are current or were former smokers. The only known way to slow the 
decline in pulmonary function is smoking cessation. Aggressive smoking 
interventions can significantly slow the decline in FEV1 (Anthonisen et al., 1994). The 
majority of the reduction in FEV1 decline was shown within the first year and the 
individuals who stopped smoking for the longest periods (within the year) 
experienced the greatest pulmonary function protective effects. Other medications 
which are usually utilised for asthmatic relief are used to ease the symptoms of the 
disease such as mucolytic agents, corticosteroids or bronchodilators (GOLD., 2011).   
1.3.7: Impact of pulmonary hypertension, and dynamic hyperinflation on exercise:  
The formation of abnormal pulmonary blood vessels in individuals with COPD 
creates hypoxia via reduced gas exchange (O'Donnell and Laveneziana, 2007). 
Subsequent to these deleterious effects a diminished O2 saturation occurs which 
contributes to pulmonary hypertension via pulmonary vasoconstriction (Hopkins & 
McLoughlin, 2002. Pulmonary hypertension is defined by a resting mean pulmonary 
artery pressure (mPAP) of 20-25 mmHg. The mPAP can be used as a prognostic 
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tool. For mPAP > 25, the 5 year survival rate is 36% compared to < 25 mmHg is 62% 
(Oswald-Mammosser et al., 1995). The mPAP has been treated effectively via O2 
therapy (Zieliński et al., 1998) and NO∙ inhalation (in rats) (Kouyoumdjian et al., 
1994). Over time pulmonary hypertension leads to increasing vascular damage and 
further decreasing lung function (Hopkins and McLoughlin, 2002). Pulmonary 
hypertension is strongly associated with COPD, especially in the advanced stages of 
the disease (Barberà and Blanco, 2009, Barberà et al., 2003). Pulmonary 
hypertension is also a key predictor of mortality in COPD (Burrows et al., 1972), and 
can have significant implications for morbidity (Chaouat et al., 2005). There are 
conflicting views as to the prevalence of pulmonary hypertension depending on 
which of these values are used. The occurrence of pulmonary hypertension can 
range from 20% to 91% of the COPD cohort (Oswald-Mammosser et al., 1991, 
Weitzenblum et al., 1984, Scharf et al., 2002, Thabut et al., 2005).  
Tibetans appear to be able to utilise NO∙ to control hypoxia (due to altitude) via an 
elevated blood flow without the negative effects of pulmonary hypertension or 
vascular resistance (Erzurum et al., 2007). Non-indigenous people who go to high 
altitude have higher mPAP which impedes NO∙ bioavailability (Bailey et al., 2010a). 
Other research groups have suggested that high endogenous NO∙ levels are 
correlated with less severe injury within the lungs and may have a protective effect 
for pulmonary and systemic endothelium and may act as a protective function for 
acute lung injury (McClintock et al., 2007).  
The significance of pulmonary hypertension to individuals with COPD can be stark. 
Pulmonary hypertension is usually stable when patients are assessed at rest. 
However, pulmonary hypertension is exacerbated during exercise (Thabut et al., 
2005). Blood pressure rises during exercise which can increase the pressure of 
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blood moving through the lungs. The severity of pulmonary hypertension has a direct 
effect on exercise performance in the 6 minute walk test (6MWT) (Cuttica et al., 
2010, Sims et al., 2009). Individuals with COPD, with or without pulmonary 
hypertension, may have a significant overlap within measures of lung function such 
as: SpO2, peak O2 uptake, ventilatory efficiency, maximal ventilation and spirometry 
levels has been previously demonstrated (Holverda et al., 2008). Reduction in SpO2 
at rest which exacerbate when exercising have a clear correlation with pulmonary 
hypertension (Holverda et al., 2008).  
When individuals with COPD exercise they can have a further hyperinflation known 
as dynamic hyperinflation. End-expiratory lung volume increases due to a 
superimposed increase above the hyperinflation at rest (Marin et al., 2001, O'Donnell 
et al., 1998, Gallagher, 1994).  
1.3.8: COPD, exercise and medicines:   
COPD is not only a pulmonary disease, but also a systemic disease. Impairments in 
FEV1 do not account for all of the limitations associated with COPD (Roy et al., 
2009). Diminished functional capacity is brought about via a higher resting O2 
requirement and lower peak V̇O2 (Gosker et al., 2003). The elevated energy 
requirement at rest represents a much higher fraction of their maximal exercise 
capacity (Gosker et al., 2003) and thus patients experience greater physiological 
stress during exercise. Other reasons for a reduced exercise tolerance are muscular 
atrophy, fibre type plasticity (changes from slow to fast) (Wüst and Degens, 2007), 
changes in pulmonary blood flow distribution (Marshall et al., 1994) and cardiac de-
conditioning (Maltais et al., 2014).  
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Some improvements in exercise capacity have been shown following structured 
exercise programs (Griffiths et al., 2000, Cockcroft et al., 1981). To date, three 
processes have been shown to aid in this improvement: physical reconditioning 
(Casaburi et al., 1991), improved ventilatory efficiency (Casaburi et al., 1997) and 
desensitisation to dyspnoea (Cooper, 2009). Some researchers have also suggested 
that improvements in ventilatory muscle function could also aid these improvements 
(Cooper, 2009).  
Individuals with COPD can have numerous exercise limiting cardiovascular defects. 
These consist of:-  
(i) An impaired left ventricular function as a direct result of hypoxemia. Hypoxemia 
creates a reduced pulmonary blood flow (Cooper, 1995) which exacerbates the 
pulmonary hypertension causing a negative feedback loop.  
(ii) There is an increasing amount of experimental evidence that suggests that 
deconditioning due to a sedentary lifestyle in individuals with COPD brings about 
markers of fatigue such as elevated blood lactate levels (Cooper, 1995).  
(iii) A shift from aerobic to anaerobic metabolism due to a reduced delivery of O2 to 
the muscle causes lactate production (Cooper, 1995). This process stimulates 
increased ventilation which in turn further reduces the time available for exhalations, 
creating a vicious cycle of air trapping (Cooper, 2001).  
Reductions in exercise tolerance are also brought about via feelings of dyspnoea 
and early onset fatigue. Cooper et al., (2009) showed that a general physical training 
program elicited an improved feeling of dyspnoea as determined via a visual 
analogue scale following a 6MWT, whereas inspiratory muscle training had no effect. 
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However, participants with COPD can become ‘acclimatised’ to exercise after being 
deconditioned for a prolonged period which leads to an alleviation of the fear 
dyspnoea  (Agle et al., 1973).  
1.3.9: Nitric oxide (NO∙) and its effects as a bronchodilator: 
NO∙ is an endothelium derived relaxant factor in the vasculature. NO∙ and the ROS 
that develop from this molecule play a critical role in COPD pathophysiology (Bove 
and van der Vliet, 2006). NO∙ acts as a bronchodilator (Dupuy et al., 1992) via 
mediation of the actions of nitrovasodilator drugs such as glyceryl trinitrate and 
nitroprusside. These vasodilators relax smooth muscle in the airways which 
subsequently increases production of soluble guanylyl cyclase (sGC) and cyclic 
guanosine 3’ 5’ monophosphate (cGMP) (Dupuy et al., 1992, Gruetter et al., 1989). 
In animal models, inhaled NO∙ diffuses across the alveolar membrane into the 
vascular smooth muscle due to its highly lipophilic properties (Shaw and Vosper, 
1977) and induces vasodilation, which reduces hypoxia induced pulmonary 
vasoconstriction (Frostell et al., 1991, Fratacci et al., 1991). However, when NO∙ 
comes into contact with haemoglobin a rapid oxidation (Gruetter et al., 1981) occurs 
which essentially makes the NO∙ inert due to its oxidation to NO2
-, diminishing its 
potent vasodilatory effects in the systemic circulation. COPD can cause an increase 
in expired NO∙ (Clini et al., 2001) compared to healthy controls.  
1.3.10: COPD therapies and treatments:  
There are numerous therapies used in the treatment of individuals with COPD and 
its associated co-morbidities, some of which are briefly reviewed below.   
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Smoking cessation  
Smoking cessation is the only known intervention that has been shown to slow the 
progression of the disease (Barnes, 2003) and therefore is the most important 
intervention (Pauwels, 2000). An aggressive smoking cessation program can 
significantly reduce the progressive decline of FEV1 shown in smokers (Anthonisen 
et al., 1994), in addition to improving long term prognosis in individuals with mild-
moderate COPD (Scanlon et al., 2000).     
Broncodilators  
COPD is characterised by airway obstruction caused via airway narrowing in 
combination with cholinergic vagal bronchoconstriction (GOLD., 2011). The ability to 
use a drug in order to vasodilate the airways is key for day to day activities of 
individuals with COPD but also to reduce symptoms during exacerbations. There are 
currently 3 classes of broncodilators in clinical use: anticholinergics, ß2-
sympathomimetic agonists and methylxanthines. All these classes of drugs when 
administered work via smooth vessel relaxation. The mechanism of action however, 
is different. Anticholinergics cause antagonism of acetylcholine within the airway 
smooth muscle (Barnes, 1995) and ß2-sympathomimetic agonists stimulate ß2-
recptors inducing elevations in cAMP (Lulich et al., 1988), methylxanthines work by 
inhibiting phosphodiesterase which breaks down cAMP. 
Simvastatin & Beta-blockers 
Simvastatin, a drug usually used to lower cholesterol, has been shown to reduce 
pulmonary arterial hypertension (PAH (Sun and Ku, 2008, Girgis et al., 2003)) in 
animal models (male adult Sprague-Dawley rats) perhaps due to their anti-
inflammatory, antioxidant and antithrombotic effects (Wang et al., 2008a). However, 
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Wilkins et al. (2010) provide evidence that simvastatin does also enhance exercise 
tolerance, as measured via the 6MWT (n = 42 in a parallel group design).   
Beta-blockers are often prescribed for COPD patients with cardiovascular 
comorbidity. Approximately 27% of individuals with COPD have coronary heart 
disease (Karoli and Rebrov, 2005). Beta-blockers have been shown to decrease 
mortality in individuals with severe COPD (Chen et al., 2001) and improve outcomes 
following a myocardial infarction (Quint et al., 2013). Their use in some patients is 
limited by bronchoconstriction (Albouaini et al., 2007).  
Sildenafil 
Sildenafil is used to treat/reduce pulmonary hypertension and secondly it is used to 
treat erectile dysfunction. Both of these effects are mediated by an inhibition of 
phosphodiesterase type 5 (PDE-5) enzyme which lowers the activity of PDE-5 via 
competitive inhibition of cGMP (Corbin, 2004). Therefore, cGMP concentrations rise. 
Intracellular cGMP levels are key as they play a critical role in the activation of 
protein kinases, protein phosphorylation and subsequent smooth muscle cell (SMC) 
relaxation via calcium modulation (Lucas et al., 2000, Wang et al., 2008b). There are 
a total of 11 known PDE isoenzymes which are all thought to act on specific tissue 
targets and substrates (Ramani and Park, 2010). Critically, PDE-5 has been a focus 
for PAH therapeutics due to its high expression with lung tissues, vascular beds and 
systemic circulation (Francis and Corbin, 2005). Sildenafil inhibits PDE-5 which 
extends the half-life of cGMP (the intracellular mediator for NO∙ vasodilatory 
pathways) and enhances SMC relaxation creating an increase in pulmonary 
vasodilation (Steiner et al., 2005).         
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Nitric Oxide gas 
NO∙ inhalation has been shown to have both positive and negative effects in 
individuals with COPD. In individuals with COPD and CVD, it can reduce peripheral 
vascular resistance (Kieler-Jensen et al., 1994) and it has been shown to increase 
the exercise capacity of heart failure patients with pulmonary hypertension (Koelling 
et al., 1998). However, there is evidence to suggest that in some individuals the NO∙ 
gas can lead to increased venous return to the lungs which can cause elevated 
pulmonary capillary pressure and exacerbate pulmonary hypertension in heart failure 
patients (Ichinose et al., 2004). Furthermore, to gain the greatest beneficial effects, 
the NO∙ needs to be administered with a small amount of O2 (Yoshida et al., 1997). 
This has been shown to enable a greater PaO2 in comparison to breathing O2 alone 
or when mixed with air (Barberà et al., 1996). O2 and NO∙ inhalation has 
subsequently been shown to work over a 3 month period with decreases in 
pulmonary arterial pressure and pulmonary vascular resistance with increases in 
cardiac output (Vonbank et al., 2003).  
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1.4: Aims, objective and hypothesis  
Dietary NO3
- supplementation appears to offer a low cost therapeutic supplement 
that may alter the O2 cost of exercise, improve exercise performance, lower blood 
pressure (in individuals with T2DM and COPD) alter hepatic diffusion and improve 
glucose homeostasis in healthy young and older adults.   
The global aim of this thesis is to assess the therapeutic effects of inorganic dietary 
NO3
- supplementation in individuals with type 2 diabetes (T2DM), chronic obstructive 
pulmonary disease (COPD) and healthy adults.  
Specifically, in individuals with T2DM and COPD, will dietary NO3
-: 
1. Lower the O2 cost of exercise? 
2. Improve walking performance? 
Additionally, in healthy young and older adults, can an acute NO3
- rich meal alter: 
1. Hepatic diffusion?  
2. Affect glucose homeostasis?  
Secondary objectives; 
1. To assess the effects of dietary NO3
- on blood pressure in all the above 
cohorts. 
Hypothesis  
1. Dietary nitrate supplementation will reduce the oxygen cost of exercise in 
individuals with T2DM and COPD.2. Dietary nitrate supplementation will improve 
walking performance in individuals with T2DM and COPD. 
3. Dietary nitrate supplementation will reduce blood pressure in individuals with 
T2DM and COPD. 
4. Dietary nitrate supplementation will increase portal vein velocity, flux and 
microvascular diffusion in healthy young and older adults.  
5, Dietary nitrate supplementation will reduce postprandial plasma glucose 
concentrations in healthy young and older adults. 
6. Dietary nitrate supplementation will reduce blood pressure in healthy young and 
older adults. 
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2.0: Methods 
2.1: Chemiluminescence  
2.1.1: Blood collection and sampling  
Blood sampling and processing were identical for all three experimental chapters. 
Free flowing blood samples for NO3
- and NO2
- analysis were drawn into room 
temperature lithium heparin tubes (Sarstedt S-Monovette, Nümbrecht, Germany). 
Samples were immediately centrifuged at 3600 rpm for 10 minutes at 4°C. The 
plasma was then aliquoted into (barcoded eppendorf’s for experimental chapter 1) 
eppendorf’s and flash frozen in liquid nitrogen prior to storing in -80°C freezers. 
Plasma samples were stored with minimal headspace between the sample and lid to 
minimise NO∙ / NO2
- contamination. Eppendorf’s were triple washed and left to dry 
overnight to remove NO2
- contamination. Determination of plasma NO3
- and NO2
- 
concentrations were performed on a nitric oxide analyser via ozone 
chemiluminescence (Sievers NOA 280; Analytix Ltd, Durham, UK).   
2.12: Deproteinisation  
Samples were thawed in batches at room temperature on the laboratory bench. 
Samples were only used for a single freeze thaw cycle. Samples were completely 
defrosted prior to analysis (~1 hour) and deproteinised as soon as thawing had 
occurred. 200 μl of sample was added to the triple washed eppendorf’s. 400 μl of 1M 
sodium hydroxide (NaOH) was added to the eppendorf, vortexed for 1 minute and 
incubated for 10 minutes (at room temperature). 400μl of zinc sulphate (ZnSO4 (10% 
w/v)) was added and vortexed once more and left to stand for a further 10 minutes. 
Samples were centrifuged for 5 minutes and decanted into triple washed eppendorfs. 
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Fresh reagents used in the deproteinisation process were created each day to 
prevent the accumulation of NO∙ from the ambient air (Pelletier et al., 2006).   
2.1.3: NO3
- analysis  
For both NO3
- and NO2
- assays, following their respective reduction of NOx content 
to NO∙, the NO∙ reacted with ozone and created nitrogen dioxide, which on creation 
emits light (via the release of a photon). This luminescence is detected by a 
thermoelectrically cooled, red-sensitive photomultiplier tube. This tube is held within 
the chemiluminescence nitric oxide analyser (Sievers NOA 280i, Analytix Ltd, 
Durham, UK) (see figure 3).  
 
 
NO∙ + O3 → NO2
-  + O2 
 
     NO2
-  → NO2 + λν 
Λν = poton 
O3 = Ozone 
The analysis of NO3
- was performed with an injection of 100µl of deproteinised 
plasma and performed in duplicate. To analyse plasma NO3
- concentration it was 
reduced in a stepwise order to NO∙ via a 5ml solution of vanadium (III) chloride (VCl) 
in 1M hydrochloric acid (0.8% w/v) at 95°C. To quantify NO∙ concentration within the 
plasma samples it was bubbled through the purge vessel (where the VCl reduced 
NO3
- to NO∙), condenser and NaOH trap with an inert gas (nitrogen). The NaOH trap 
was required in order to neutralise any corrosive gases that had bubbled through 
with the NO∙ and nitrogen prior to reacting the analyser.  
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The effectiveness of the reagents diminished over the course of the assay. For NO3
- 
analysis the VCl remained stable for ~12 injections. The reagents reduced NO3
- at a 
slower speed. This manifested as an area under the curve that was stable but the 
peak had lowered. In order to account for this a biological standard was used at the 
start and end of each assay and the known concentration checked. The assay was 
accepted if the biological standard was within 10% of the previously determined inter 
assay mean. Reagents were changed in a timely manner, usually for each assay.  
Equation 1: Plasma NO3
- reduction 
    
2NO3
- + 3V3
+ + 2H2O → 2NO + 3V̇O2
+ + 4H+ 
 
 
 
 
 
 
 
 
 
 
Figure 3. NOA analyser and associated equipment for nitrate reduction. 
Depicts the NOA analyser and associated equipment for nitrate reduction to NO∙. 100μl of 
deproteinised plasma was injected in the injection port. The VCl reduced the nitrate and nitrite to 
NO∙, where nitrogen bubbles the NO∙ through the purge vessel, condenser, NaOH trap and into the 
analyser. 
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2.1.4: NO3
- assay validation 
To ensure that NO3
- was being accurately measured NO3
- spiked samples were 
used. A plasma standard was created by following the blood collection procedures 
above and subsequently pooling 300 ml of plasma from 3 individuals in a NO3
- and 
NO2
- free sterile beaker prior to aliquoting. Post deproteinisation spiked recovery was 
used to quantify the concentration of the NO3
- and NO2
- concentration in the plasma 
samples. Two separate, known concentrations of (100µl) standards (typically 1µM 
and 5µM) were added to separately to different eppendorf’s with 100µl of biological 
standard prior to deproteinisation. These were vortexed for ~1 minute and 
deproteinised. 4x 200µl of plasma was also deproteinised and analysed to compared 
with the spike recovery concentration and repeated on numerous days. An average 
of the 4x 200µl of plasma was taken for the equation.  
 (Average + standard concentration / 2) / (concentration of the spiked plasma x 100)  
Equation 2: A working example (spike recovery):   
 
 
((44.7 µM + 20 µM) / 2 = 32.35µM) / (34.55 µM x 100 = 93.6%)  
 
Initial attempts to perform a spike recovery revealed that the method was either not 
being reliably executed or that there was contamination. The initial spike recoveries 
ranged between 140 – 210% of predicted concentration. Standard operating 
procedure was being strictly followed and therefore it was more likely to be explained 
by contamination. To get a reliable spike recovery (SR) for the plasma NO3
- 
concentration distinct methodological changes were required. Numerous 
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amendments to the protocol were required in order to establish where the poor 
repeatability was emanating from. Firstly, the vortex was used for a longer period to 
ensure the plasma was mixed well with the ZnSO4 and NaoH. This was done for ~60 
seconds and the mixing was confirmed by eye. A visible swirl of the mixture can be 
seen moving down the Eppendorf. When it reached the bottom of the Eppendorf it 
was mixed. This maximised the removal of as much protein in the precipitate.  
Another key aspect was to use VCl as the purge vessel was warming up. Previously, 
the vessel was washed with deionised water. The high temperature and the VCl 
cleaned the vessel of all detergent and debris. Prior to the analysis fresh reagent 
was added to the reaction chamber. This step allowed for a repeatable standard 
curve. When these errors were corrected the spike recovery was much more 
reliable. The final five plasma samples averaged 45.68 ± 2.91 µM, the spike recovery 
with 10µM sodium NO3
- concentration averaged 95.45 ± 4.1 µM % and the 20µM 
sodium NO3
- concentration averaged 97.23 ± 4.6 µM %.     
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Table 2. Nitrate plasma standards and spike recovery reproducibility.  
This table depicts the raw values, means, SD and CV for plasma standards, and two 
different spike recovery concentrations (10 and 20 μM).    
 
 
 
 
 
  
 
 
 
 
 
 
 
 
Figure 4. NO3
-
, representative standard curves.  
This figure depicts the average ± SD of 10 representative NO3
-
 standard curves 
Nitrate 
Plasma standard 
μM SR10 SR20 
  48.4 97.3 93 
  47.7 95.7 100 
  41.9 99.8 102.3 
  44.7 89 93.6 
  46.7 93.5 N/A 
  50.1 N/A N/A 
        
Mean 46.58 95.06 97.23 
SD 2.91 4.09 4.63 
CV % 6.252 4.307 4.767 
y = 484.78x + 121.17 
R² = 0.9995 
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2.1.5: NO2
- analysis 
To analyse plasma NO2
- concentration it was reduced to NO∙ via 5ml glacial acetic 
acid and 1ml sodium Iodide (NaI) (0.5% w/v) solution at 30°C. To quantify NO∙ (post 
reagent reduction) within the plasma samples it was carried through the reduction 
agents with nitrogen. Note the NaOH trap was not required with this reaction. The 
analysis of NO2
- was performed with an injection of 100µl of deproteinised plasma 
and performed in duplicate. For NO2
-, the acetic acid and NaI was able to reduce the 
NO2
- to NO∙ for longer (~20 injections) with consistent peaks. 
Equation 3: Plasma NO2
- reduction 
 
2I- + 2NO2
- + 4H+ → 2NO + I2 + 2H2O 
 
 
 
 
 
 
Figure 5. NOA analyser.  
Depicts the NOA analyser and equipment used to reduce the NO2
-
 to NO∙. 
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To quantify the concentrations of NO3
- and NO2
- standard curves were created daily 
using sodium NO3
- at known concentrations of 500nM to 10µM and sodium NO2
- 
from 10nM to 250nM and the luminescence was plotted via signal area in mV. At 
least 5 points were used to create each curve.  
 
 
 
 
 
 
Figure 7. Nitrite, representative standard curves. 
This figure depicts the average ± SD of 10 representative NO2
-
 standard curves.   
y = 0.5701x + 4.774 
R² = 0.9998 
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Figure 6.  NOA analyser and associated equipment.  
Shows the NOA analyser and associated equipment for nitrite reduction to NO∙. 100μl of 
deproteinised plasma was injected in the injection port. The NaI reduced the nitrite to NO∙, where 
nitrogen bubbles the NO∙ through the purge vessel, condenser and into the analyser.      
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Table 3. Nitrite plasma standards and spike recovery reproducibility.  
Table depicts the raw values, means, SD and CV for plasma standards, and two 
different spike recovery concentrations (100 and 250 nM).    
 
 
 
 
 
 
 
 
 
 
2.2: O2 uptake measurement and analysis  
For experimental chapter 3 and 4, breath-by-breath pulmonary gas exchange and 
ventilation were measured during walking (MedGraphics, CardiO2 Cardiopulmonary 
Diagnostic Systems, St. Paul, MN, USA) and cycling exercise (VmaxTM Encore, 
Yorba, Linda, CA) respectively. Before each session the O2 and CO2 analysers were 
calibrated using known concentration gases. The volume transducer was calibrated 
using a 3-litre syringe (Hans Rudolph, Kansas City, MO, USA).  
Participant’s breath-by-breath V̇O2 data were initially checked for ‘erroneous’ 
breaths. These breaths can be caused by coughing and swallowing and were 
Nitrite 
Plasma 
standard nM SR100 SR250 
  508 118 93 
  502.5 127 102 
  518.5 119 94 
  571 117 100 
  547 132 
Missing 
value 
  493 111 118 
        
Mean 523.33 120.67 101.40 
SD 28.90 6.58 4.43 
CV % 5.522 5.453 4.364 
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removed (Lamarra et al., 1987). Breaths over 4 standard deviations from the local 
mean were removed. For each individual breath-by-breath data were time aligned 
and interpolated for each transition to give second by second values (chapter 3 had 
3 transitions and chapter 4 had two). A nonlinear least squares algorithm was then 
used to fit the ensemble-averaged data, as described in the following equation. 
 
Equation 4: Nonlinear least square algorithm: 
 
 V̇O2 (t) = V̇O2 baseline + Ap(1-e
-(t-TDp)/τp) 
 
where V̇O2 (t) represents
 the absolute V̇O2 at
 a given time t; V̇O2baseline represents the 
mean V̇O2
 in the baseline period (when participants were stood still on the treadmill 
or when cycling at 0 watts); Ap, TDp, and p represent the amplitude,
 time delay, and 
time constant, respectively, describing the increase in V̇O2 above baseline when 
exercise had commenced. The end-exercise V̇O2 was defined as the mean V̇O2 
measured over the final 30 seconds of exercise. The mean response time (MRT) 
was calculated by fitting a single exponential curve to the data from the onset to the 
end of exercise.  
Equation 5 Nonlinear least square algorithm (without TD): 
 
 V̇O2 (t) = V̇O2 baseline + Ap(1-e
-(t)/τp) 
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The O2 deficit was calculated as the product of the V̇O2 response amplitude (i.e. the 
baseline to the point that a steady state was attained) and the MRT. The coefficient 
of variation for day to day variability of O2 uptake for treadmill walking using the 
MedGraphics equipment can be seen in table 4.  
Table 4. ?̇?O2 repeatability data.  
This table shows day to day ?̇?O2 repeatability. Data from 1 individual after 
interpolation and modelled as described above for 3 transitions, with the mean, SD 
and coefficient of variation calculated over 3 separate days.      
 
Time constant MRT O2 deficit Baseline Amplitude End ?̇?O2 
Day 1 42.35 47.62 0.86 296.15 1488.17 1744.62 
Day 2 42.18 48.40 0.84 306.88 1467.04 1737.20 
Day 3 41.82 48.92 0.78 327.62 1357.33 1641.72 
       Mean 42.12 48.31 0.83 310.21 1437.51 1707.85 
SD 0.22 0.54 0.03 13.06 57.35 46.86 
CV % 0.52 1.11 3.99 4.21 3.99 2.74 
 
For the experimental overview, exercise modality and transitions, please see 
individual experimental chapters.  
2.3: The apparent diffusion co-efficient of the liver, portal vein flux and velocity  
For experimental chapter 3 a 1.5 T Philips (Amsterdam, The Netherlands) magnetic 
resonance imaging (MRI) scanner was used in order to examine modifications in 
velocity and flow to the liver (portal vein) and estimate capillary diffusion in the 
posterior right lobe of the liver following NO3
- or placebo supplementation.   
The human body is comprised predominantly of water. An MRI scanner creates a 
homogenous magnetic field which allows protons within hydrogen nuclei to occupy 
one of two distinct energy states. If radiofrequency radiation is then transmitted at 
the appropriate frequency it is possible to cause transitions of protons between these 
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two energy levels. The presence of protons in the excited energy state can be 
detected via the use of appropriate detector devices and it is this mechanism that 
gives rise to the means of generating MRI images. 
2.3.1: Portal vein (flow & velocity); 
Initially, structural scans were obtained in different planes to identify the location and 
orientation of the portal vein. Subsequently, an 8mm thick imaging slice was selected 
that lay perpendicular to the long axis of the vein. Landmarks (such as the inferior 
vena cava) were used to ensure replication of slice positioning between each repeat 
measurement and for visits 1 and 2. The circumference of the portal vein was 
checked between all scans from V1 and V2. To determine flow and velocity a cardiac 
triggered velocity sensitive phase encoding imaging sequence (Gatehouse et al., 
2005) was employed which obtained image data at 20 time points throughout the 
cardiac cycle. Analysis was subsequently undertaken using a package supplied as 
part of the general philips scanner software. For each separate measurement the 
circumference of the vessel was manually drawn and recorded for each of the 20 
time points to establish a defined region of interest (ROI). Within this ROI, flow and 
velocity were automatically calculated to give profiles throughout the cardiac cycle.  
2.3.2: Apparent diffusion coefficient (ADC); 
When examined as a group of voxels, capillary flow represents a pseudo-diffusion 
process, such that fluid flow is taking place in a 3D isotropic fashion. To examine 
this, a magnetic resonance (MR) sequence sensitive to flow, via the application of 
magnetic field gradients in three orthogonal directions, was employed. From this a 
parameter known as the apparent diffusion coefficient (ADC), dependent upon 
capillary flow averaged over all directions, could be determined. To calculate ADC 
within the posterior left lobe of the liver, a ROI (typical dimensions = 2500mm3) was 
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manually drawn using the scanner software and the signal intensity within 
determined. ADC was subsequently calculated based upon the ratio of signal 
intensity from the two images generated from the MR sequence employed, one of 
which was sensitive to flow, whereas the other had a low sensitivity to flow, where:  
Equation 6: ADC: 
 
ADC= 1/(b1-b0)  Ln (S0/S1) 
S0 signal intensity in low flow sensitivity image  
S1 signal intensity in flow sensitive image  
b0 magnetic field gradient used in low flow sensitivity image=250 s/mm
2 
b1 magnetic field gradient used in flow sensitive image=750 s/mm
2 
2.3.3: ADC and portal vein repeatability  
To establish the repeatability of the portal vein velocity (see table 5 below) and ADC 
measurement (see table 6 below) 6 different, fasted individuals were assessed over 
two separate mornings. A CV was created between each of the ADC indices and 
then averaged. 
Table 5. MRI reproducibility.  
This table describes the CV for the portal vein flux and velocity for 6 fasted 
individuals on two separate mornings.  
      
 
  
Portal 
vein flux 
Portal vein 
velocity ADC 
 
 
Mean 16.64 13.61 1.15 
 
 
SD 2.28 2.18 0.12 
 
 
CV % 13.36 16.366 9.77 
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Table 6. Description of multiple ROI and its effect on reproducibility.     
This table describes the mean, SD and CV for the ADC for 6 fasted individuals on 
two separate mornings. Different numbers of regions of interests (ROI) were used to 
find the optimum number to increase repeatability.   
 
 
 
 
 
 
For study analysis the ADC and the portal vein assessment (velocity and ADC), the 
baseline scans of each day are compared with 1, 2 and 3 hours post 
supplementation. See experimental chapter 3 for a description for detailed 
description of experimental procedures.   
2.4: Standardised breakfast  
For chapter 5, (experimental chapter 3 / DiMPLe) the participants came to the MRI 
research centre at St Luke’s Campus in a fasted state. Participants were asked to 
fast from 10pm the night before however water was admissible. Approximately 1 
hour after arrival participants were provided with breakfast. Each participant was 
supplemented (breakfast) with 76g of carbohydrates which is comparable to the 
glucose dose given in an OGTT (75g(Bartoli et al., 2011b)). The carbohydrate 
supplement was in the form of 2 beetroot juice sports shots (32g), 2 slices of brown 
bread (25g), butter (~0g) and jam (19g).  
An OGTT test begins with an overnight fast and an acclimatisation period with the 
patient seated throughout the testing period. A baseline plasma glucose 
 
ADC SD CV 
6 ROI 1.09 0.33 30.32 
3 ROI 1.10 0.23 21.34 
2 ROI  1.11 0.21 15.29 
1 ROI 1.15 0.12 9.77 
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measurement is then taken. Two hours after the carbohydrate bolus another plasma 
glucose measurement is taken. In 1997 the American Diabetes Association(Gavin et 
al., 1997) lowered the fasting plasma glucose measurement cut criteria for impaired 
fasting glycaemia from 140 mg/dl (7.7) to 126 (6.99mmol/L). In 1979 the national 
diabetes data group set a distinct cut of value for impaired glucose tolerance which 
was given following the 2 hour post plasma glucose concentrations for impaired 
glucose tolerance as 140 (7.7) - 199 mg/dl (11mmol/L) (NDDG, 1979). In the present 
study (experimental chapter 3), blood glucose concentrations were measured every 
hour following the standard breakfast for 3 subsequent hours.    
2.5: General data handling and methods  
Prior to data collection for any of the experimental chapters Microsoft Access 
(Redmond, WA, USA) databases were set up with all appropriate variables encoded. 
Data was double entered by an independent researcher. When both data sets were 
entered and the study complete a macro was run between the files to check for 
anomalies. All discrepancies were checked within the clinical records folder and 
amended into one database. Patient identifiable data were entered into a separate 
database and saved on a non-networked password encrypted hard drive in the 
diabetes and vascular research centre.  
Variables were transposed into SPSS software version 21.0 (Chicago, IL, USA). All 
data were tested for normality prior to determination of statistical processing (i.e. 
parametric or non-parametric). Statistical difference was accepted when P < 0.05. 
For specific randomisation blinding and statistical tests please see experimental 
chapters.  
 
92 
 
3.0: Experimental chapters 
3.1: Experimental chapter 1(Dietary NO3
- supplementation in T2DM) 
Title: Effects of dietary nitrate supplementation on the oxygen cost of exercise and 
walking performance in individuals with type 2 diabetes: a randomised, double blind, 
placebo-controlled cross-over trial. 
3.1.1: Authors: Anthony I Shepherd1,2, Mark Gilchrist2, Paul G Winyard2, Andrew M 
Jones1,
  Ewelina Hallmann3, Renata Kazimierczak3, Ewa Rembialkowska3, Nigel 
Benjamin2, Angela C Shore2, Daryl P Wilkerson1  
3.1.2: Affiliations: College of Life and Environmental Sciences, Sport and Health 
Sciences, University of Exeter, Devon, UK, 2 University of Exeter Medical School and 
NIHR Exeter Clinical Research Facility, Royal Devon and Exeter Hospital, Exeter, 
Devon, UK, 3 Warsaw University of Life Sciences, Warsaw, Poland.  
3.1.3: Abstract  
Background: Dietary NO3
- supplementation has been shown to reduce the O2 cost of 
exercise and enhance exercise tolerance in healthy individuals. This study assessed 
whether similar effects could be observed in individuals with type 2 diabetes (T2DM). 
Methods: In a randomised, double blind, placebo-controlled cross-over study, 48 
participants with T2DM supplemented their diet for four days with either NO3
- rich 
beetroot juice (70 ml/day, 6.43 mmol NO3
-/day) or NO3
- depleted beetroot juice as 
placebo (70 ml/day, 0.07 mmol NO3
-/day).  After each intervention period, resting 
plasma NO3
- and NO2
- concentrations were measured subsequent to participants 
completing moderate-paced walking. Pulmonary gas exchange was measured to 
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assess the O2 cost of walking.  Following a rest period, participants performed the 
six-minute walk test (6MWT). 
Results: Relative to placebo, beetroot juice resulted in a significant increase in 
plasma NO3
- (placebo; 57 ± 66 vs. beetroot juice; 319 ± 110 µM; P <0.001) and 
plasma nitrite concentration (placebo; 680 ± 256 vs. beetroot juice; 1065 ± 607 nM; 
P <0.001). There were no differences between placebo juice vs. beetroot juice for 
the O2 cost of walking (placebo; 946 ± 221 vs. beetroot juice; 939 ± 223 ml
.min-1, 
respectively; P =0.59), and distance covered in the 6MWT (placebo; 550 ± 83 vs. 
beetroot juice; 554 ± 90m, respectively; P =0.17). 
Conclusion: Nitrate supplementation did not affect the O2 cost of moderate-paced 
walking or improve performance in the 6MWT. These findings indicate that dietary 
NO3
- supplementation does not modulate the response to exercise in individuals with 
T2DM.  
3.1.4: Introduction  
Individuals with type 2 diabetes mellitus (T2DM) have profound reductions in their 
tolerance to exercise compared to healthy individuals (Regensteiner et al., 1995b). 
The discomfort experienced by individuals with T2DM during exercise may impact 
upon their ability or willingness to attain their recommended level of exercise, which 
is a key aspect of disease management (NICE, 2008). Exercise intolerance in this 
population has been attributed to abnormalities at multiple points during the transport 
of O2 from the lungs to its site of utilisation in the muscles (Scognamiglio et al., 1998, 
Regensteiner et al., 1995a, Regensteiner et al., 1998). There is evidence that 
individuals with T2DM have reductions in the biosynthesis and bioavailability of the 
biological messenger nitric oxide (NO∙) (Xu et al., 2007, Meininger et al., 2000).  NO∙ 
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is known to play an important role in muscle contractility, skeletal muscle glucose 
uptake, calcium handling (Stamler and Meissner, 2001), vascular function, blood flow 
regulation (Dejam et al., 2007), and mitochondrial respiration and biogenesis 
(Cooper and Giulivi, 2007).  
There are two known pathways by which NO∙ is synthesised, the L-arginine pathway 
and the entero-salivary pathway. The L-arginine pathway involves the synthesis of 
NO∙ from L-arginine by the nitric oxide synthase (NOS) family of enzymes. The 
entero-salivary pathway involves a stepwise conversion of NO3
- to NO2
-, and 
subsequently, NO2
- to NO∙. Briefly, NO3
- from the diet (or from NO∙/ NO2
- oxidation) 
is absorbed into the circulation where it is concentrated in the salivary glands. NO3
- 
is then reduced to NO2
- via facultative anaerobic bacteria on the surface of the 
tongue (Duncan et al., 1995) and subsequently swallowed. Some of the swallowed 
NO2
- is reduced to NO∙ in the acidic environment of the stomach, with important local 
effects on gastric function and protection against enteric pathogens (Gilchrist et al., 
2010) and the remainder enters the circulation. Circulating NO2
- acts as a reservoir 
for NO∙, with its reduction to NO∙ potentiated in acidic or hypoxic areas, such as 
contracting skeletal muscle (Bryan, 2006). It has been suggested that the entero-
salivary pathway is a complementary system for NO∙ synthesis (Lundberg et al., 
2008). 
There is extensive evidence in healthy individuals that NO3
- supplementation, via 
either sodium NO3
- or NO3
- rich beetroot juice, increases plasma NO2
- concentration 
(Bailey et al., 2009, Lundberg and Govoni, 2004), lowers blood pressure (BP) (Bailey 
et al., 2010b, Larsen et al., 2006), and reduces the O2 cost of exercise (Bailey et al., 
2009, Larsen et al., 2007a, Wylie et al., 2013a). The reduction in the O2 cost of 
exercise has been proposed to be related to a reduction in the ATP cost of muscle 
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force production (Bailey et al., 2010b), an improvement in mitochondrial efficiency 
(Larsen et al., 2011), or a combination of both (Bailey et al., 2012). 
It has been reported that the bioavailability of NO∙ is reduced in individuals with 
T2DM due to increased scavenging and/or reduced synthesis. Reactive oxygen 
species (ROS) (Crabtree et al., 2011) and hyperglycaemia (Ding et al., 2004) may 
result in lower L-arginine derived NO∙. Further, there is evidence that NO∙ production 
is suppressed by NOS inhibitors such as asymmetric dimethylarginine (ADMA) 
(Abbasi et al., 2001) and caveolin-1 (Catalán et al., 2008), which are elevated in 
T2DM. Conversely, others have reported increased plasma NO3
- and NO2
- 
concentrations in individuals with T2DM (Ghasemi et al., 2010, Chien et al., 2005), 
which may indicate a quenching of NO∙ activity or upregulation of NO∙ synthesis to 
counteract resistance. It is possible that dietary NO3
- supplementation in this 
population could ameliorate the impact of T2DM on NOS dependent NO∙ synthesis 
by increasing the amount of NO∙ produced via the entero-salivary pathway 
(Lundberg et al., 2008). We recently reported no effect of dietary NO3
- 
supplementation on the 24h ambulatory BP in individuals with T2DM (Gilchrist et al., 
2013), but the impact on the O2 cost of exercise, and exercise tolerance in 
individuals with T2DM remains unknown.  
The aim of this study was, therefore, to examine the effects of dietary NO3
- 
supplementation (NO3
- rich beetroot juice) on the O2 cost of exercise and walking 
performance, and to confirm our previous finding regarding resting BP, in individuals 
with T2DM. It was hypothesised that, compared to NO3
- depleted beetroot juice, NO3
- 
rich beetroot juice would reduce the amount of O2 required per unit of time to 
perform moderate-paced walking, and increase the distance covered in the 6-minute 
walk test. 
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3.1.5: Methods 
Patients 
Forty eight patients (35 males) with T2DM (see Table 7 for characteristics) 
volunteered to participate in this randomised, double blind, placebo-controlled cross-
over study. Participants were recruited from the NIHR Exeter Clinical Research 
Facility, Exeter 10,000 cohort, a database of individuals who have consented to be 
contacted for research. Ethical approval was granted by the Cornwall and Plymouth 
NRES Committee 12/SW/0118 and the study was registered as a clinical trial on the 
ClinicalTrials.gov website, ID # NCT02206074. All participants provided written 
informed consent. Patients were recruited if they had been diagnosed with T2DM (as 
defined by the WHO) at least five years prior to enrolment in the study and were 
35−75 years of age. Patients were excluded from the study if they had significant 
renal impairment (eGFR <30), uncontrolled hypertension, a BMI <25 or >35 (kg/m2), 
a history of myocardial infarction or cerebro-vascular event, were taking regular 
organic NO3
- or nicorandil, or were smokers (or who had stopped smoking within the 
previous three months). Patients taking phosphodiesterase inhibitors were asked to 
refrain from doing so for the duration of the study. On experimental days, participants 
were asked to arrive at the laboratory in a rested and fully hydrated state, at least 3 
hours postprandial, and having avoided caffeine and alcohol for 6 and 24 hours, 
respectively. Participants were also asked to avoid exercise for 24 hours prior to 
each testing session.  Participants were asked to record their diet for 24 hours prior 
to each experimental visit. Following the crossover the participant were asked to 
replicate their previous diet and this was verbally confirmed at the second visit. 
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Table 7. Characteristics of patients included in the final analysis. Data are mean ± 
SD, or as a % of the cohort on a medication.   
 
    
 
Age (years)   63.35 ± 7.27 
 
 
Diabetes Duration (years)  
 
10.31 ± 5.26 
 
 
HbA1c (mmol/mol) 
 
60.83 ± 13.37 
 
 
Body Mass Index (kg/m2)  
 
30.17 ± 2.93 
 
 
Baseline systolic BP (mmHg)  
 
142.13 ± 12.84 
 
 
Baseline diastolic BP (mmHg)  
 
80.85 ± 7.36 
 
 
No. of 30+ minutes of exercise per week  
 
3.83 ± 3.16 
 
 
Portions of fruit and vegetables per day 
 
3.83 ± 2.00 
 
 
Metformin % 
 
83.33 
 
 
Insulin % 
 
25.00 
 
 
ARB & ACEi % 
 
47.92 
 
 
Statins %   83.33 
  
Participants attended the NIHR Exeter Clinical Research Facility where we 
completed informed consent, a medical history, anthropometric measures, and a 
resting ECG. A familiarisation session was performed for the treadmill exercise, 
allowing the determination of the walking speed for each participant that would be 
used in the experimental visits. The target speed was a pace equivalent to the 
participants’ usual walking speed that could comfortably be maintained for 6 minutes. 
Experimental Overview 
Following the pre-experimental visit, participants were assigned in a double-blind, 
randomised, crossover design to consume 70 ml/day of NO3
- rich beetroot juice 
(beetroot juice; containing 6.43 mmol of NO3
-; Beet it, James White Drinks Ltd., 
Ipswich) or NO3
- depleted beetroot juice (placebo; NO3
- depleted beetroot juice 
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containing 0.07 mmol of NO3
-; Beet it, James White Drinks Ltd., Ipswich) for four 
days. The dose of 6.43 mmol of NO3
- equated to 0.072 mmol.kg-1 per day for 3.5 
days. Similar dosing regimens (0.068 (Bailey et al., 2010b); 0.064 (Muggeridge et al., 
2013b);  0.086 (Berry et al., 2014)mmol.kg-1) to ours have been shown to be 
effective at this relative dose. Production of the placebo juice has been detailed 
previously (Lansley et al., 2010), with the final product being indistinguishable in 
taste, colour, texture, appearance and odour to the NO3
- rich beetroot juice (Gilchrist 
et al., 2014). The final 70 ml of juice was consumed ~3 hours before the 
commencement of exercise on the morning of testing. Participants were required to 
abstain from using antibacterial mouthwash and chewing gum throughout the study, 
as this has been shown to reduce the concentration of oral bacteria responsible for 
the reduction of NO3
- to NO2
- (Govoni et al., 2008).   
During the two experimental visits, resting BP was measured and venous blood 
samples were drawn into lithium-heparin tubes (Sarstedt S-Monovette, Nümbrecht, 
Germany) and prepared for NO3
- and NO2
- analysis as previously described 
(Gilchrist et al., 2013). Subsequently, participants performed 3 bouts of walking on a 
motorised treadmill (NordicTrack T14.0, Chaska, MN, USA) at the target speed that 
was determined in the pre-experimental visit. Each bout was preceded by a resting 
baseline period of three minutes, with the three bouts separated by 15 minutes of 
passive recovery. Following a further 15 minutes of seated rest, participants 
performed a 6 minute walk test (6MWT) to assess functional capacity. This test was 
conducted indoors on a straight, flat course between 2 cones which were 32.2 
meters apart, with patients instructed to cover as much distance as possible in the 
allotted time. Standardised verbal encouragement was given throughout.  Following 
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their first experimental visit, participants began a washout period (10-14 days) before 
entering the opposing arm of the study. 
Measurements  
Prior to any exercise testing during the experimental visits, resting BP of the brachial 
artery was measured using an automated sphygmomanometer (Omron M6, Kyoto, 
Japan). Five measurements were taken in total, with the mean of the final three 
measurements being recorded. 
For the determination of plasma NO2
- concentration, venous blood samples (~4 ml) 
were drawn into lithium-heparin tubes (Sarstedt S-Monovette, Nümbrecht, 
Germany), centrifuged, aliquoted and immediately frozen in liquid nitrogen and 
stored at -80ºC. Prior to analysis all samples were deproteinized using a variant of 
the protocol used by Higuchi and Motomizu (1999). Fresh reagents were created 
each day and checked for contamination. No contamination was detectable for 
water, sodium hydroxide, zinc sulphate or sodium iodide. Determination of plasma 
NO3
- and NO2
- concentrations was performed on a nitric oxide analyser via ozone 
chemiluminescence (Sievers NOA 280; Analytix Ltd, Durham, UK) using the protocol 
described by Bateman et al. (2002). 
Pulmonary gas exchange was measured breath by breath during all treadmill 
walking exercise (MedGraphics CardiO2 Cardiopulmonary Diagnostic Systems, 
St. Paul, MN, USA). The volume transducer was calibrated before each test with a 3-
liter calibration syringe (Hans Rudolph, Kansas City, MO, USA) and the O2 and CO2 
analysers were calibrated using gases of known concentration.  During treadmill 
walking exercise, heart rate (HR) was measured every 5 seconds via telemetry 
(Polar R5400sd, Kempele, Finland).  
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Data Analysis  
The breath by breath O2 uptake (V̇O2) data were initially inspected for errant breaths 
(e.g. associated with coughing and swallowing), with values lying more than four 
SDs from the local mean being removed. The breath-by-breath data were linearly 
interpolated to provide second-by-second values and, for each individual, the three 
bouts were time-aligned to the start of exercise and ensemble-averaged. A nonlinear 
least-square algorithm was used to fit the data, as described in the following 
equation: 
 
 V̇O2 (t) = V̇O2 baseline + Ap (1-e
-(t-TDp)/τp) 
 
where V̇O2 (t) represents
 the absolute V̇O2 at
 a given time t; V̇O2baseline represents the 
mean V̇O2
 in the baseline period (when participants were stood still on the treadmill); 
Ap, TDp, and p represent the amplitude,
 time delay, and time constant, respectively, 
describing the increase in V̇O2 above baseline when exercise had commenced. The 
end-exercise V̇O2 was defined as the mean V̇O2 measured over the final 30 seconds 
of exercise. The mean response time (MRT) was calculated by fitting a single 
exponential curve to the data with no time delay from the onset to the end of 
exercise. The O2 deficit was calculated as the product of the V̇O2 response amplitude 
(i.e. the baseline to the point that a steady state was attained) and the MRT.  For a 
schematic representation of the V̇O2 kinetics parameters, see Figure 1. 
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Figure 1. Schematic showing the parameters of the O2 uptake kinetics on a representative 
participant’s data. 
Juice analysis  
It has previously been suggested that the antioxidant content of beetroot juice may 
have beneficial effects (Lansley et al., 2011a). In order to establish whether the 
concentrations of known antioxidants in beetroot juice (polyphenols and betacyanins) 
were different in the active and placebo juice, both were analysed using the high-
performance liquid chromatography technique according to our previously described 
methods (Kazimierczak et al., 2014). 
Sample size and randomisation 
An a priori sample size calculation was performed by a statistician from the 
University of Exeter Medical School. A pilot study (n=6) in individuals who have 
T2DM revealed a mean difference between beetroot juice and placebo juice of 45 
ml.min-1 for end exercise V̇O2 (1SD) during cycling exercise. For 90% power and an 
α-level set at P = 0.05 (two tailed), to detect a 0.5 SD difference 44 patients were 
102 
 
required. In order to account for dropout, we anticipated that 48 patients would begin 
the study. Each participant was randomised by a research nurse, who also supplied 
them with the appropriate juice.   
Data and statistical analysis 
All data were tested for normality and are presented as means ± standard deviation 
(SD) unless otherwise stated.  Differences in plasma NO3
- and NO2
- concentrations, 
BP, V̇O2, and distance covered in the 6-minute walk test between the conditions 
were analysed using two-tailed, paired-samples t-tests. Where normality of data was 
not met, differences between the aforementioned data were tested using a non-
parametric test (Wilcoxon rank-sum test). When the sample was split for patients 
taking different classes of medications, independent samples t-tests were performed. 
Pearson product–moment correlation coefficients were used to assess the 
relationships between variables. Statistical analyses were performed on SPSS 
software version 21.0 (Chicago, IL, USA), with statistical difference accepted when P 
< 0.05.   
3.1.6: Results 
48 subjects completed the study.  For detailed information regarding participant 
recruitment and withdrawal, see Figure 8.  Participants’ self-reported adherence to 
beetroot juice and avoidance of mouth wash was 100% for both arms of the study. 
All participants reported similar physical activity and dietary patterns for both 
supplementation periods. The ingestion of both juices was well tolerated with no 
adverse side effects. As in previous studies using beetroot juice supplementation, 
participants reported beeturia (red urine) and red stools (Bailey et al., 2009).  
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Figure 8. Flow diagram of trial 
Plasma NO3
- and NO2
- concentrations: Relative to placebo, beetroot juice resulted in 
a significant increase in plasma NO3
- concentration (placebo: 57 ± 66 vs. beetroot 
juice 319 ± 90µM, P < 0.001, 95% CI -220, 302; Figure 9A). Plasma NO2
- 
concentration also increased for beetroot juice in comparison to placebo (placebo: 
680 ± 256 vs. beetroot juice 1065 ± 607 nM, P < 0.001, 95% CI -220, 548; Figure 
9B). There were no differences in baseline (placebo) plasma NO2
- when subjects 
were split into groups based on drug classes; ACEi and ARB (n= 25; difference vs. 
those not on these drugs -68 ± 75 nM, P = 0.37, 95% CI -218, 83), metformin (n = 
40; difference -18 ± 105 nM, P = 0.87, 95% CI -231, 196), insulin (n= 12; difference 3 
± 86 nM, P = 0.97, 95% CI -171, 177) statins (n = 40; difference 164 ± 97 nM, P = 
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0.09, 95% CI -31, 360) and sulphonylurea (n = 15; difference 35 ± 134 nM, P = 0.79, 
95% CI -237, 306). Other classifications of drugs were prescribed, however the 
sample size was too small to make inferences; gliptins (n = 2), exenatide (n = 2), 
sulfazalazine (n = 1), alpha blocker (n = 3), beta blocker (n = 1), calcium channel 
blocker (n = 6), loop diuretic (n = 1), thiazide (n = 2) P > 0.05).  
 
Figure 9. Plasma NO3
-
 and NO2
-
 concentration in individuals with T2DM.  
A depicts plasma NO3
-
 and B shows plasma NO2
-
 group mean concentrations analysed via 
chemiluminescence. Values are means ± SD. *significantly different from the placebo P < 0.001. 
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Treadmill walking, V̇O2 kinetics, and heart rate: Relative to placebo, beetroot juice 
supplementation had no effect on baseline (placebo: 282 ± 50 vs. beetroot juice: 281 
± 46 ml.min-1; P = 0.82, 95% CI -12.9, 10.21) or end-exercise V̇O2 (placebo: 939 ± 
223 vs. beetroot juice: 946 ± 221 ml.min-1; P = 0.60, 95% CI -20, 34.3; Figure 10). 
The time constant and MRT of V̇O2 response, and the O2 deficit were also not 
different between conditions (see Table 8). End-exercise heart rate was not different 
between conditions (placebo: 96 ± 12 vs. beetroot juice: 94 ± 11 BPM, P = 0.36, 95% 
CI -4.7, 1. 7). No significant correlation was observed between the change in plasma 
NO2
- concentration and end-exercise V̇O2 (r = 0.04, P = 0.77). 
 
Figure 10. Pulmonary O2 uptake response to beetroot juice in individuals with T2DM.  
The group mean pulmonary O2 uptake response for placebo (A) and NO3
- 
rich beetroot (B). The 
vertical line represents the initiation of walking exercise from the standing baseline. Group mean 
responses are shown with error bars every 30s.  
A 
B 
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Table 8. O2 uptake kinetics during walking exercise with placebo and beetroot juice 
supplementation.  
Six minute walk test: No difference was found between placebo and beetroot juice 
for distance covered during the six minute walk test (placebo: 554 ± 90 vs. beetroot 
juice: 550 ± 83 m, P = 0.17, 95% CI -11, 2.04). No difference was observed for 
distance covered during the six minute walk test when the group was split for ACEi 
and ARB compared with individuals not on this classification of drug (change -7.6 ± 
44.6 m, P = 0.25, 95% CI -20.6, 5.4).  
Blood pressure: Comparisons between placebo and beetroot juice revealed no 
statistically significant effect on systolic BP (placebo: 134 ± 10 vs. beetroot juice: 132 
± 12 mmHg, P = 0.17, 95% CI -4.09, 1.17) or diastolic BP (placebo: 77 ± 7 vs. 
beetroot juice: 76 ± 11 mmHg, P = 0.27, 95% CI -4.04, 0.74; Figure 11 A and B).  
                                                             Placebo                     
              
Beetroot juice      
Baseline (ml.min-1)                                282 ± 50                  281 ± 46  
Primary amplitude (ml.min-1)  656 ± 205 665 ± 199 
End-exercise (ml.min-1) 938 ± 223 946 ± 221 
O2 deficit (L) 0.48 ± 0.17 0.50 ± 0.19 
Mean response time (s) 45 ± 10 45 ± 10 
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Figure 11. Systolic and diastolic blood pressure response to beetroot juice in individuals with T2DM. 
Effects of NO3
-
 on blood pressure, A: Groups means for systolic blood pressure and B depicts the 
group mean for diastolic blood pressure. Values are means ± SD.  
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Antioxidants in beetroot juice: Antioxidant concentrations in placebo and active 
beetroot juice are displayed in Table 9. Betacyanins and polyphenol compounds in 
beetroot juice.  
The content of total betacyanins and polyphenol compounds in two different beetroot 
juices. Table A, depicts all identified compounds and figure B shows the compound 
groups. Mean value ± standard deviation (in mg/100 ml of fresh juice). 
 
 
Identified compound Beetroot juice Placebo 
Betanin-3-O-glucoside 452.71 ± 19.56  519.31 ± 11.43  
Betanidine 6.03 ± 0.40  3.61 ± 0.19  
Gallic acid 1.80 ± 0.12  1.43 ± 0.14  
Chlorogenic acid 3.03 ± 0.55  2.10 ± 0.22  
Caffeic acid 0.90 ± 0.20  0.58 ± 0.11  
Ferulic acid 0.56 ± 0.00  0.53 ± 0.01  
Rutinoside-3-O-quercetin 1.97 ± 0.08  1.81 ± 0.04  
Glucoside-3-O-quercetin 0.89 ± 0.04  0.83 ± 0.02  
Myrycetin 0.44 ± 0.01  0.47 ± 0.02  
Luteolin 0.23 ± 0.01  0.16 ± 0.01  
Quercetin 0.25 ± 0.01  0.19 ± 0.00  
Kaempferol 0.22 ± 0.01  0.17 ± 0.00  
 
 
Group of compounds Beetroot juice Placebo 
Total betacyanins 458.73 ±1 9.73 522.92 ± 11.43 
Total polyphenols 10.29 ± 0.72 8.30 ± 0.34 
Total phenolic acids 6.30 ± 0.67 4.65 ± 0.34 
Total flavonoids 3.99 ± 0.10 3.65 ± 0.05 
A 
B 
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3.1.7 :Discussion  
This is the first study to investigate the effects of dietary NO3
- supplementation on 
the exercise responses of individuals with T2DM. The principal findings of this 
investigation were that short-term dietary NO3
- supplementation did not reduce the 
O2 cost of walking, or increase the distance covered in the six minute walk test in this 
population. We also confirmed our previous finding that NO3
- supplementation had 
no effect on resting blood pressure in individuals with T2DM. These findings may be 
considered surprising given the compelling effects of dietary NO3
- supplementation 
reported in other populations. Possible explanations for the lack of effects in the 
present study relate to an elevated baseline plasma NO2
- concentration in the control 
condition, and/or reductions in the bioavailability of NO∙ in individuals with T2DM. 
Nitrate supplementation and plasma NO3
- and plasma NO2
- concentration.  
Plasma NO3
- and NO2
- concentrations were significantly elevated following NO3
-
supplementation, which is consistent with previous studies examining young (Bailey 
et al., 2009, Lundberg and Govoni, 2004) and older  healthy participants (Kelly et al., 
2013a), and individuals with peripheral arterial disease (Kenjale et al., 2011). The 
post placebo plasma NO2
- concentration was approximately two to six-times higher 
in the present study than those reported in the aforementioned studies. The elevated 
plasma NO2
- concentration in individuals with T2DM in the placebo condition may be 
associated with the habitual up-regulation of iNOS which is endemic in this 
population (Krause et al., 2012). It is possible that the elevated baseline (placebo) 
plasma NO2
- concentration is indicative of disease pathology and mitigates the 
attainment of the benefits of dietary NO3
- supplementation that have been reported in 
other populations. 
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The plasma NO2
- concentration was 680 ± 256 nM in the placebo arm in the present 
study.  In the only other study which could be directly comparable, the  plasma NO2
- 
concentration was 232 nmol/L (200, 265), median (IQR) in the placebo arm (Gilchrist 
et al., 2013). The control plasma from Gilchrist et al. (2013) was re-measured during 
the current study to establish agreement between the NO2
- values measured in the 
two studies.  It is therefore unlikely that analytical error is the reason for our elevated 
‘baseline’ plasma NO2
- concentrations. There are notable differences between the 
two studies with respect to the timing of beetroot juice doses and plasma sampling.  
In the present work, studies were conducted at midday, with subjects having had 
breakfast including the beetroot juice and their usual morning hypoglycaemic and 
antihypertensive medications 3 hours previously. In our previous study in subjects 
with T2DM (Gilchrist et al., 2013), plasma sampling occurred after an overnight fast, 
with subjects having omitted their usual morning hypoglycaemic and 
antihypertensive medications, 16 hours after their last beetroot juice.   
Multiple agents within these broad classes of medication have been shown to up-
regulate eNOS activity (Davis et al., 2006, Ceconi et al., 2007, Andrade et al., 2013). 
When the current cohort was split for drug classifications, no differences in baseline 
plasma NO2
- were detectable. It is therefore unlikely that drug classification affected 
plasma NO2
- concentrations, though the study was not powered to detect any such 
difference. Furthermore, there are data to suggest circadian variation in eNOS 
activity, with the lowest levels in the morning, rising through the day before falling 
again at night (Elherik et al., 2002). This could further influence the difference 
between plasma NO2
- concentrations in the two groups. With a growing number of 
studies in patient groups, understanding the effect of concomitant medication on 
plasma NO2
- and NO3
- concentrations is becoming increasingly important. 
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Accordingly, sufficiently powered research is required to examine the 
pharmacokinetics and dynamics of medications and NOx concentrations in order to 
elucidate the possibility of NO3
- related therapeutic effects on exercise performance. 
Nitrate supplementation and pulmonary O2 uptake  
There was no difference between active and placebo juice in the V̇O2 responses to 
low intensity walking exercise in the present study. A reduction in the baseline 
(Lansley et al., 2010) and steady state (Bailey et al., 2009, Vanhatalo et al., 2010, 
Lansley et al., 2010) O2 cost of low intensity exercise has previously been reported 
in young healthy individuals following similar NO3
- dosage regimens to that which 
was implemented in the present study. No change in the O2 cost of exercise was 
reported in healthy older individuals following NO3
- supplementation (Kelly et al., 
2013a). However, these authors reported a significant speeding of the V̇O2 kinetics, 
something that was not observed in the present study.  It is therefore unlikely that 
aging per se explains the lack of effect on the V̇O2 kinetics in the present study. 
Other studies have reported no significant difference in the V̇O2 response to exercise 
subsequent to NO3
- supplementation in healthy, well-trained athletes (Wilkerson et 
al., 2012, Bescos et al., 2011). This lack of effect has also been reported in 
individuals with COPD (Shepherd et al., 2015, Berry et al., 2014, Kerley et al., 2015). 
These studies all had relatively small sample sizes (n = 8 (Wilkerson et al., 2012), 11 
(Bescos et al., 2011, Kerley et al., 2015), 13 (Shepherd et al., 2015), and 15 (Berry 
et al., 2014)). 
One possible explanation for the lack of effect on the O2 cost of exercise may relate 
to the elevated plasma NO2
- concentration in the placebo condition (baseline) of this 
study which might reduce the scope for the further increases in plasma NO2
- 
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concentration that have been realised via NO3
- supplementation in other populations. 
Thus the lack of effect of dietary NO3
- supplementation on the O2 cost of exercise 
noted in the present study may indicate the existence of an upper limit for the 
baseline plasma NO2
- concentration, beyond which the scope for positive effects 
from further increasing plasma NO2
- concentration is reduced.  In support of this 
suggestion, a significant negative correlation has been reported between the 
changes in plasma NO2
- concentration with beetroot juice vs. placebo juice and the 
change in performance during cycling exercise (i.e. participants whose plasma NO2
- 
increased more following NO3
- supplementation experienced a greater improvement 
in exercise performance, and vice versa) (Wilkerson et al., 2012). However, in the 
current study there was no correlation between either placebo plasma NO2
- 
concentration, or change in plasma NO2
- concentration with NO3
- rich vs. placebo 
juice, and the O2 cost of exercise.   
An alternative suggestion for the lack of effect of NO3
- supplementation on the O2 
cost of exercise may be related to the reduction in the bioavailability of NO∙ which 
has been reported in individuals with T2DM (Calver et al., 1992, Cockcroft et al., 
2000, Cohen, 1993). This reduced bioavailability has been linked with the 
concentration of plasma ADMA (an analogue of L-arginine), which is elevated in 
individuals with T2DM (Devangelio et al., 2007). ADMA is known to inhibit all three 
NOS isoforms, particularly eNOS (Siasos et al., 2007), leading to eNOS uncoupling 
and the generation of superoxide radicals (Tousoulis et al., 2007), ultimately 
resulting in increased oxidative stress. When NO∙ and superoxide react, peroxynitrite 
is generated. This is known to result in a quenching of NO∙ activity and thus a 
reduction in its bioavailability, which may serve to diminish any positive impact of 
NO3
- supplementation (Beckman and Koppenol, 1996, Coppey et al., 2001). 
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Furthermore, sustained exposure to oxidative and nitrative stress could result in 
damage to mitochondrial membranes (Kowaltowski and Vercesi, 1999) and thus 
reduce the P/O ratio (i.e more O2 would be required to produce a given amount of 
ATP). It is possible that damaged mitochondria associated with T2DM (Kowaltowski 
and Vercesi, 1999) means that this population are less likely to benefit from the 
improved mitochondrial function subsequent to NO3
- supplementation, which may 
underpin, in part, the reduced O2 cost of exercise in healthy individuals (Cooper and 
Giulivi, 2007).  
A further possible explanation for the lack of effect of NO3
- supplementation on the 
exercise response in individuals with T2DM may relate to pathological consumption 
of NO2
- during exercise. Post-exercise plasma NO2
- concentration has been shown 
to fall markedly in individuals with cardiovascular risk factors (Rassaf et al., 2010) 
compared with the typical rise in plasma NO2
- reported in healthy individuals 
(Cuzzolin et al., 2000). This may suggest that either the production of NO∙ cannot 
keep up with metabolic demand, or the NO∙ produced is scavenged more rapidly in 
individuals with cardiovascular risk factors compared with healthy individuals.  It is 
plausible that a similar effect is seen in individuals with T2DM, with a marked net 
consumption of plasma NO2
- during exercise. It should be noted, however, that this 
would not explain the lack of effect of NO3
- supplementation on BP in our study as 
these measurements were conducted at rest. 
It should be noted that although we have postulated a pro-oxidant state as an 
explanation for the lack of effect of NO3
- supplementation in individuals with T2DM, 
beneficial effects of NO3
- have been seen in other patient groups who are likely to be 
in a pro-oxidant state. Zamani et al. (2015) reported an improvement in exercise 
capacity (but no reduction in the O2 cost of exercise) following beetroot juice 
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supplementation in individuals with heart failure. Similar findings have been reported 
in individuals with peripheral artery disease (Kenjale et al., 2011) and chronic 
obstructive pulmonary disease (Shepherd et al. (2015), Berry et al., 2014, Kerley et 
al., 2015). It should be noted, however, that to date no study has shown a reduction 
in the O2 cost of exercise in a patient group, despite reporting improvements in 
exercise tolerance. It is feasible that the improvement in exercise tolerance in the 
aforementioned studies is associated with elevated muscle blood flow consequent to 
an elevated plasma NO2
- concentration (Cosby et al., 2003), although this requires 
further investigation to confirm. 
Nitrate supplementation and functional Capacity. 
There was no difference between the active and placebo juice conditions for the 
distance covered in the 6MWT.  This is consistent with the only other study to have 
investigated the impact of NO3
- supplementation on exercise performance using the 
6MWT (in healthy older individuals) (Kelly et al., 2013a). Since any improvement in 
walking performance could reasonably be assumed to be underpinned by alterations 
in the V̇O2 response to exercise, and considering that this was not modulated by 
NO3
- supplementation, it is perhaps not surprising that functional capacity was also 
not different between conditions. It is likely that the explanation for the lack of effect 
of NO3
- supplementation on walking performance is synonymous with the potential 
explanations for the lack of effect on the O2 cost of exercise (see previous section).  
Walking performance has been shown to be enhanced in individuals who are taking 
ACEi (Ahimastos et al., 2013). Our cohort included 48% of individuals on ACEi 
and/or ARBs, thus any potential improvements in walking performance subsequent 
to NO3
- supplementation may have been masked. When we separated the group into 
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those prescribed ACEi or ARBs compared to the remaining individuals, no difference 
was seen between groups for walking performance. The groups were split 48% (n = 
23) with prescribed ACEi or ARBs and 52% (n = 25) not taking ACEi/ARB.  One 
possible explanation for the finding is that the 6MWT was the last of the experimental 
procedures to be conducted and followed 18 minutes of treadmill walking. The prior 
exercise (and time since last NO3
- supplementation) may have meant that some of 
the additional NO2
- which was available following NO3
- supplementation had been 
utilised, especially given our cohort’s elevated cardiovascular risk (Rassaf et al., 
2010). 
Nitrate supplementation and resting blood pressure. 
In agreement with our previous study examining the effect of dietary NO3
- 
supplementation on blood pressure in individuals with T2DM (Gilchrist et al., 2013), 
we found no difference in BP between conditions.  NO3
- doses similar to that which 
was administered in the present study (6.43 mmol per day) have elicited reductions 
systolic BP in healthy young (Bailey et al., 2009, Bailey et al., 2010b, Lansley et al., 
2010) and old (Kelly et al., 2013a) individuals and reduced diastolic BP in healthy 
young individuals (Bailey et al., 2009) and those with peripheral arterial disease 
(Kenjale et al., 2011).  
There are a number of possible explanations for the lack of effect of NO3
- 
supplementation on the resting BP of individuals with T2DM. A reduced NO∙ 
responsiveness has been linked to vascular stiffening in older individuals (Lyons et 
al., 1997). However, aging per se is unlikely to explain the lack of effect in the 
present study as BP was significantly reduced subsequent to NO3
- supplementation 
in healthy older adults (on no medication) (Kelly et al., 2013a). Secondly, the 
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elevated oxidative stress prevalent in individuals with T2DM would be expected to 
result in an increase in the scavenging of NO∙, potentially diminishing any 
hypotensive effects from NO3
- supplementation. 
Antioxidants in beetroot juice  
It has been demonstrated that the beneficial effects of beetroot juice are largely 
explained by its NO3
- content (Lansley et al., 2010).  However, it has also been 
suggested that an antioxidant effect may also be occurring, such as is observed 
under in vitro experiments with polyphenols (Kanner et al., 2001). Though there are 
small differences in antioxidants between the two juices used (placebo and active), 
the magnitude of this difference is unlikely to be physiologically relevant. Typical total 
daily polyphenol intake across multiple populations has been estimated to be in the 
region of 1g daily (Bohn, 2014); the effective dose from either juice in the current 
study therefore represents less than 1% of average total intake. Betacyanins were 
present in much higher quantities. The bioavailability of these compounds is however 
uncertain, but it appears to be very low with typical estimates from <1% to 4% of an 
oral dose, with some individuals having far greater absorption (Watts et al., 1993, 
Tesoriere et al., 2004). Furthermore, the removal of betanin from plasma is rapid, 
with a t1/2 of 0.94±0.07 hours. These factors suggest the betacyanin content of 
beetroot juice is unlikely to have a clinically meaningful effect.  
Strengths and limitations.  
To date this is the largest trial, implementing robust methods, to examine the effect 
of inorganic NO3
- or pharmacological NO3
- supplementation on the O2 cost of 
exercise.  The a priori sample size calculation was designed to enable the study to 
detect an 8% reduction in the O2 cost of low intensity exercise with a 0.05 alpha level 
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and an 80% power. From the 95% CI it is likely that the actual difference for the O2 
cost of low intensity exercise following NO3
- supplementation in individuals with 
T2DM was between -2.1% and 3.6%. Therefore the minimum detectable reduction in 
the O2 cost of exercise in our study is 2.1%. This is very similar to the day to day 
variability of V̇O2 measurement, thus it is unlikely that a larger sample size would 
elucidate a clinically significant difference in the O2 cost of walking exercise in this 
patient group. A potential limitation of the present study is that the 6MWT was 
completed up to 4 hours subsequent to the consumption of the final beverage, and 
after 18 minutes of walking when the increments in NO2
- from supplementation may 
have been utilised already. As plasma NO2
- concentration was not determined prior 
to the 6MWT, we cannot be certain that this remained elevated following NO3
- 
supplementation compared to the placebo condition. However, this does mean that 
the study provides knowledge of the level of improvement (or lack of it) that a patient 
with type 2 diabetes could expect in the early afternoon of normal daily living. 
3.1.8: Conclusion         
In contrast to much of the literature in young healthy individuals and despite a 
statistically significant and physiologically meaningful increase in plasma NO2
- 
concentration, four days of beetroot juice supplementation with 6.43 mmol of NO3
- 
did not reduce the O2 cost of walking, improve functional capacity as determined by 
the 6MWT, or reduce resting BP in individuals with T2DM. The lack of effects of 
dietary NO3
- supplementation in individuals with T2DM may be explained by 
increased oxidative stress and its impact on the bioavailability of NO∙, or an elevated 
‘baseline’ plasma NO2
- concentration which reduces the scope for the beneficial 
effects reported in other populations.  
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3.2: Experimental chapter 2 (Dietary nitrate supplementation in COPD) 
Title: The effect of dietary nitrate supplementation on the oxygen cost of cycling, walking 
performance and resting blood pressure in individuals with chronic obstructive pulmonary 
disease: A double blind placebo controlled, randomised control trial. 
3.2.1: Authors: Anthony I Shepherd1,2, Daryl P Wilkerson1, Lee Dobson3 James Kelly1, 
Paul G Winyard2, Andrew M Jones1, Nigel Benjamin2,3, Angela C Shore2, Mark Gilchrist2 
3.2.2: Affiliation: 1College of Life and Environmental Sciences, Sport and Health 
Sciences, University of Exeter, Devon, UK, 2 University of Exeter Medical School and 
NIHR Exeter Clinical Research Facility, Royal Devon and Exeter Hospital, Exeter, Devon, 
UK 3 Torbay Hospital, Heart and Lung Unit, Torquay, Devon, UK.   
3.2.3: Abstract  
Background 
Chronic obstructive pulmonary disease (COPD) results in exercise intolerance. 
Dietary NO3
- supplementation has been shown to lower blood pressure (BP), reduce 
the O2 cost of exercise, and enhance exercise tolerance in healthy volunteers. This 
study assessed the effects of dietary NO3
- on the O2 cost of cycling, walking 
performance and BP in individuals with mild-moderate COPD.  
Methods 
Thirteen patients with mild-moderate COPD were recruited. Participants consumed 
70 ml of either NO3
- rich (6.77 mmol NO3
-; beetroot juice) or NO3
- depleted beetroot 
juice (0.002 mmol NO3
-; placebo) twice a day for 2.5 days, with the final supplement 
~3 hours before testing. BP was measured before completing two bouts of 
moderate-intensity cycling, where pulmonary gas exchange was measured 
throughout. The six-minute walk test (6MWT) was completed 30 minutes subsequent 
to the second cycling bout.  
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Results 
Plasma NO3
- concentration was significantly elevated following beetroot juice vs. 
placebo (placebo; 48 ± 86 vs. beetroot juice; 215 ± 84 µM, P=0.002). No significant 
differences were observed between placebo vs. beetroot juice for O2 cost of exercise 
(933 ± 323 vs. 939 ± 302 ml: min-1; P=0.88), distance covered in the 6MWT (456 ± 
86 vs.  449 ± 79 m; P=0.37), systolic BP (123 ± 14 vs.  123 ± 14 mmHg; P=0.91), or 
diastolic BP (77 ± 9 vs. 79 ± 9 mmHg; P=0.27).  
Conclusion 
Despite a large rise in plasma NO3
- concentration, two days of NO3
- supplementation 
did not reduce the O2 cost of moderate intensity cycling, increase distance covered 
in the 6MWT, or lower BP. 
3.2.4: Introduction 
Exercise in individuals with COPD is limited by multiple factors which can result in 
hypoxemia. These include loss of normal lung architecture, impaired cardiac function 
(Jardin et al., 1984), abnormal pulmonary blood flow distribution (Marshall et al., 
1994) and peripheral muscle de-conditioning (Maltais et al., 2014). O2 uptake in the 
lungs and delivery of O2 to working muscle is impaired by increases in pulmonary 
blood flow which increase shunting through blood vessels resulting in incomplete gas 
exchange (Cooper, 2009) and cor pulmonale later in the disease course. These 
abnormalities result in feelings of breathlessness and fatigue (Nici et al., 2006), with 
individuals often finding that activities of daily living are physically challenging.  
The beneficial effects of a diet rich in vegetables upon cardiovascular health 
(Gilchrist et al., 2010),  risk of morbidity and mortality (Joshipura et al., 2001), and 
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COPD development (Hirayama et al., 2009, Watson et al., 2002) have been well 
described. These positive effects have, in part, been attributed to inorganic NO3
- 
(NO3
-) which is found in particularly high quantities in leafy green vegetables and 
some root vegetables such as beetroot (Bryan and Hord, 2010). Nitrate 
supplementation in the form of sodium NO3
- or NO3
- rich beetroot juice has been 
shown to have remarkable effects in healthy young individuals and athletes, 
including reductions in the O2 cost of exercise (Bailey et al., 2009), enhanced 
exercise tolerance/performance and reduced blood pressure (BP) (Bailey et al., 
2009, Bailey et al., 2010b). Some of these effects have subsequently been observed 
in individuals with peripheral artery disease following dietary NO3
- supplementation 
(Kenjale et al., 2011). These findings have been attributed to an increase in the 
bioavailability of nitric oxide (NO∙). 
NO∙ is a signalling molecule with multiple functions including regulation of vascular 
tone, mitochondrial respiration and skeletal muscle function (Cosby et al., 2003, 
Merry et al., 2010, Larsen et al., 2011). These factors are important in the 
physiological response to exercise. NO∙ is produced in two distinct ways in man. The 
best known is the classical L-arginine nitric oxide synthase (NOS) pathway which is 
O2 dependent (Alderton et al., 2001). The second is the entero-salivary pathway and 
is O2 independent. Briefly, NO3
- from the diet is rapidly and extensively absorbed in 
the stomach and proximal small intestine with bioavailability approaching 100% 
(Florin et al., 1990). Nitrate is then concentrated in the salivary glands, with 
concentrations 10 fold greater in saliva than in plasma. NO3
- secreted in saliva is 
reduced to NO2
- by facultative anaerobic bacteria on the dorsum of the tongue 
(Duncan et al., 1995). On swallowing, the acidic environment of the stomach results 
in NO∙ formation with important local effects on gastric function and host defence 
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(Gilchrist et al., 2010, Benjamin et al., 1994). Some NO2
- is absorbed into the 
circulation where it acts as a storage pool for subsequent NO∙ production (Cosby et 
al., 2003). The conversion of NO2
- to NO∙ is expedited in conditions of acidosis 
(Modin et al., 2001) or hypoxemia (Cosby et al., 2003) which often occur in the 
exercising muscle of individuals with COPD (Fiaccadori et al., 1987).  
In many individuals with COPD, functional capacity is reduced to a level where 
activities of daily living may impose a challenge due to an energy requirement 
representing a high fraction of their maximal O2 uptake. While a number of 
cardiovascular and physiological benefits have been shown as a result of dietary 
NO3
- supplementation in healthy populations, little is known about possible effects in 
clinical populations. We aimed to determine whether dietary NO3
- supplementation 
has a beneficial impact upon the O2 cost of sub-maximal cycling exercise, walking 
performance and BP in individuals with COPD.  
Purpose 
The aim of this study was to assess the effects of 2.5 days of dietary NO3
- 
supplementation on the O2 cost of sub-maximal cycling, walking performance, and 
resting BP in individuals with mild-moderate COPD.  
3.2.5: Methods 
Patients 
Fourteen individuals with mild-moderate COPD (see table 10 for patient 
characteristics) gave written informed consent to participate in this double-blind, 
placebo-controlled, cross-over design study between April 2013 and January 2014.  
The study was registered as a clinical trial at ClinicalTrials.gov (NCT01712386). The 
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Exeter NRES Committee gave ethical approval (12//SW//0327). Patients were 
recruited if lung function was between 30-80% of predicted FEV1 values, aged 40-75 
years old and able to give informed consent. Participants were excluded if they had 
chronic kidney disease (estimated glomerular filtration rate <30 ml/min/1.73 m2), 
uncontrolled hypertension (systolic BP> 160 mmHg or diastolic >100 mmHg), were 
smokers (smoked within past 3 months), consumed regular organic NO3
- or 
nicorandil. Patients taking phosphodiesterase inhibitors were asked to refrain from 
doing so for the duration of the study.  
 
Table 9. Characteristics of patients included in the final analyses.  
Data are mean ± SD or as % of the cohort on a medication.  
Age (years) 64.7 ± 7.7 
FEV1 (%)  57 ± 9 
FVC (l) 3.6 ± 0.9 
FEV1/FVC 41 ± 16 
Body Mass Index (kg/m2)  29 ± 8 
Baseline SBP (mmHg)  132 ± 15 
Baseline DBP (mmHg)  85 ± 10 
No. of 30+ minutes of exercise per week  4.7 ± 3.6  
ARB /ACEi (%)  23 
Calcium channel blocker (%) 15 
Short-acting β2-agonists (%) 77 
Long-acting β2-agonists (%) 77 
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Pre-experimental tests 
Participants arrived at the Heart and Lung unit at Torbay hospital where informed 
consent, medical history, anthropometric measures, BP, lung function and an ECG 
were performed. Participants completed a ramp incremental cycle ergometer test (10 
W∙min-1) to determine their gas exchange threshold (GET). Breath-by-breath 
pulmonary gas exchange was measured throughout and the GET was determined 
using the V-slope method as described previously (Beaver et al., 1986).  
Experimental Overview 
Participants consumed 70 ml of NO3
- rich beetroot juice (beetroot juice; 6.77 mmol 
NO3
-; Beet it, James White Drinks Ltd., Ashbocking, UK) or NO3
- depleted beetroot 
juice as a placebo (placebo; 0.002 mmol NO3
-; Beet it, James White Drinks Ltd., 
Ashbocking, UK), with one beverage in the morning and one in the evening for two 
days preceding testing. On study days, participants consumed a final 70 ml beetroot 
juice drink ~3 hours prior to exercising. Participants self-reported concordance with 
the supplementation regime which was confirmed by measurement of plasma NO3
- 
concentration. After exercise testing the participants began a washout period (7 
days) before entering the opposing arm of the study. The placebo was 
indistinguishable from the NO3
- rich juice in taste, colour, texture, appearance and 
odour as described previously (Gilchrist et al., 2014).  
Participants arrived at the laboratory in a fully hydrated state, having avoided 
consumption of caffeine, alcohol, cruciferous vegetables, leafy greens, beetroot, and 
completion of strenuous exercise 24 hours prior to testing. Participants were asked 
to record their food intake for 24 hours prior to testing and to replicate this after the 
crossover and this was verbally confirmed on the second exercise visit. Participants 
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avoided antibacterial mouthwash for 7 days prior to testing. Participants arrived 45 
minutes before the initiation of exercise following ingestion of the randomised juice 
with their morning meal. Brachial artery BP was taken, after a 10 minute resting 
period whilst supine, with an automated sphygmomanometer (Omron M6, Kyoto, 
Japan). Five measurements were performed and the mean of the last three was 
recorded. Venous blood was drawn and processed for plasma NO3
- concentration as 
per our previously described chemiluminescence technique (Gilchrist et al., 2013). 
Participants completed two bouts of cycling at 80% of their GET on a cycle 
ergometer (Ergoselect 100, Bitz, Germany) with 30 minutes recovery between bouts. 
Following 30 minutes rest, participants performed a six-minute walk test to assess 
functional capacity. Participants walked around a clear rectangular corridor (14 x 
12m) for a total of 52m per lap, covering as much distance as possible. Standardised 
verbal encouragement was given throughout.  
Measurements  
Pulmonary gas exchange and ventilation were measured during the cycling exercise 
(VmaxTM Encore, Yorba, Linda, CA). Before each session the analysers were 
calibrated using gases of known concentration.  The volume transducer was 
calibrated using a 3-litre syringe (Hans Rudolph, Kansas City, MO, USA).  
Outcome measures 
Primary outcome measure: does 2.5 days of NO3
- supplementation reduce the O2 
cost of moderate intensity cycling? Secondary outcome measure (i): does 2.5 days 
of NO3
- supplementation improve functional capacity as measured via the six-minute 
walk test?  Secondary outcome measure (ii): does 2.5 days of NO3
- supplementation 
reduce resting BP?  
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Sample size and randomisation 
An a priori sample size calculation was performed. Previous literature in healthy 
young volunteers has shown a mean change between beetroot juice and control of 
69 ml for end exercise pulmonary O2 uptake (V̇O2) (1SD) and 121 ml for V̇O2 
amplitude (2SD) (Bailey et al., 2009). For 90% power and an α-level set at P=0.05 
(two tailed), to detect a 1 SD difference 13 patients were required. The reproducibility 
of these measures in patients with COPD are similar to healthy controls (Covey et 
al., 1999). An unrestricted computer generated sequence was used by a research 
nurse to assign each participant a randomisation number and supply them with the 
requisite juice.  
Data and statistical analysis 
Participant’s breath by breath V̇O2 data were initially checked for erroneous breaths 
(caused by coughing and swallowing). Breaths > 4 SDs away from the local mean 
were removed prior to interpolation. Breath by breath data for each cycling bout were 
time aligned and interpolated to provide second by second values. A nonlinear least 
squares algorithm was then used to fit the ensemble-averaged data.  The overall 
V̇O2 kinetics were described using the mean response time (MRT), which was 
calculated by fitting a single exponential curve to the data with no time delay from the 
onset to the end of exercise. The O2 deficit was calculated as the product of the V̇O2 
response amplitude (i.e. the baseline to the point that a steady state was attained) 
and the MRT.  For a schematic representation of the kinetics parameters, please see 
figure 12.  
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Figure 12. Parameters of O2 uptake kinetics.  
 
All data were tested for normality. Statistical differences were assessed using paired 
t-tests for normally distributed data and Wilcoxon rank-sum test for non-normally 
distributed data. All data are presented as means ± standard deviation (SD). 
Statistical analysis was performed on SPSS software version 21.0 (Chicago, IL, 
USA). Statistical difference was accepted when P < 0.05.  
3.2.6: Results  
14 individuals with COPD provided written informed consent. Following screening, 
one individual was withdrawn due to FEV1 < 30%. 13 participants were randomised 
to start in either the beetroot juice or placebo condition of the study. All participants 
reported 100% adherence to the supplementation regime. Participants reported 
similar dietary patterns and physical activity during both study arms. Dietary NO3
- 
supplementation was well tolerated with no adverse events apart from red stools and 
beeturia, as in previous studies (Bailey et al., 2009).  
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Plasma NO3
- concentration: Relative to placebo, beetroot juice significantly 
increased plasma NO3
- concentration (placebo; 48 ± 85 vs. beetroot juice; 215 ± 
84µM, P = 0.002, 95% CI 75, 260; Figure 13).  
Figure 13. Plasma NO3
- 
concentration in individuals with COPD.  
Plasma NO3
-
 concentration following placebo and beetroot juice supplementation. The open bar 
represents placebo and the closed bar, beetroot juice. *Significantly different from placebo P < 0.01. 
Effects on the O2 cost of cycling exercise: The group mean pulmonary V̇O2 response 
to exercise for both placebo and beetroot juice conditions can be seen in figure 14, 
with the V̇O2 kinetics resulting from the model fits displayed in Table 11. Relative to 
placebo, beetroot juice supplementation had no effect on baseline V̇O2 (placebo; 634 
± 233 vs. beetroot juice; 622 ± 253 ml∙min-1, P = 0.56, 95% CI -57, 32) or end 
exercise V̇O2 (placebo; 933 ± 323 vs. beetroot juice; 939 ± 302 ml∙min
-1, P = 0.88, 
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95% CI -68, 78). There were no differences between conditions for the MRT (P = 
0.90, CI -25, 28) or the O2 deficit (P = 0.71, CI -.2, .3).  
Table 10. Pulmonary gas exchange during moderate intensity cycling following 
placebo and beetroot juice supplementation.  
 
 
 Placebo Beetroot juice 
   Baseline V̇O2 (ml/min) 634 ± 233 622 ± 253 
V̇O2 Amplitude (ml/min)  292 ± 80 308 ± 85 
End-exercise V̇O2 (ml/min) 933 ± 323 939 ± 302 
O2 deficit (L) 0.39 ± 0.19 0.43 ± 0.29 
MRT (s)   80 ± 19 81 ± 35 
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Figure 14. Pulmonary O2 uptake response to beetroot juice in individuals with COPD.  
The pulmonary O2 uptake response during the transition from unloaded cycling to cycling at 80% of 
the GET for 6 minutes following placebo (A) and beetroot juice supplementation (B). The vertical line 
denotes the transition from baseline to moderate intensity cycling.  
Effects on functional capacity: There was no difference between conditions for 
distance covered during the six-minute walk test (placebo; 456 ± 86 vs. beetroot 
juice; 449 ± 79 m, P = 0.17, 95% CI -22, 9). 
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Effects on resting blood pressure: Compared to the placebo juice, beetroot juice did 
not significantly reduce systolic BP (placebo; 123 ± 14 vs. beetroot juice; 123 ± 14 
mmHg, P = 0.91, 95% CI -5, 4) or diastolic BP (placebo; 78 ± 9 vs.  beetroot juice; 79 
± 9 mmHg, P = 0.25, 95% CI -2, 5; Figure 15).  
 
Figure 15. Systolic (SBP) and diastolic (DBP) blood pressure following placebo and beetroot juice 
supplementation.  
The open bar represents placebo and the closed box, beetroot juice.  
3.2.7: Discussion  
Beetroot juice supplementation, (NO3
-; 6.77 mmol) twice daily, for 2.5 days did not 
reduce the O2 cost of cycle ergometer exercise, improve functional capacity or 
reduce resting BP in individuals with COPD. There was no difference between 
conditions for these variables despite a statistically significant and physiologically 
meaningful rise in plasma NO3
- concentration following NO3
- supplementation. 
A 
B 
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Possible explanations for the lack of effect in this study include NO3
- dosage, efficacy 
of NO3
- reduction to NO2
-, oxidative stress, and the age of the participants.  
Nitrate supplementation and effects on plasma NO3
- concentration. 
Plasma NO3
- concentration was 48µM post placebo and 215µM following NO3
- rich 
beetroot juice, which is consistent with much of the literature in healthy young 
individuals (Larsen et al., 2010, Bescos et al., 2011) and individuals with type 2 
diabetes (Gilchrist et al., 2014). Similar changes in plasma NO3
- concentrations have 
been shown to elicit reductions in the O2 cost of exercise, improved exercise 
tolerance/performance and reductions in BP (Larsen et al., 2007a, Muggeridge et al., 
2013b, Wylie et al., 2013a). Due to logistical constraints, plasma NO2
- concentration 
was not assessed in this study. In all previous studies involving dietary NO3
- 
supplementation where plasma NO2
- concentration has been determined, a rise in 
plasma NO3
- concentration similar to the magnitude observed in the present study 
has been accompanied by a physiologically meaningful and statistically significant 
rise in plasma NO2
- concentration (Muggeridge et al., 2013b, Larsen et al., 2007a, 
Larsen et al., 2011). However, we cannot exclude the possibility that there is an 
impaired capacity for reduction of NO3
- to NO2
- in individuals with COPD. Such an 
impairment could potentially be related to differences between individuals with 
COPD and healthy individuals in oral microflora due to oral steroids and repeated 
exposure to courses of antibiotics (Mobbs et al., 1999). 
Nitrate supplementation and effects on the O2 cost of cycling exercise. 
We found no reduction in the O2 cost of cycling exercise at baseline or end-exercise 
in individuals with COPD following NO3
- rich beetroot juice supplementation 
compared to placebo. Nitrate supplementation in healthy young individuals has 
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previously resulted in reductions in the O2 cost of exercise (Bailey et al., 2009). 
However, we recently reported that the O2 cost of exercise was not altered by dietary 
NO3
- supplementation in a group of healthy older adults (Kelly et al., 2013a). The 
current study is the first to examine the effects of NO3
- supplementation on the O2 
cost of exercise in any clinical population. The supplementation regime used in this 
study, consisting of 6.77 mmol  twice a day for 2.5 days,  has previously been shown 
to increase plasma NO2
- concentrations (Bailey et al., 2009, Vanhatalo et al., 2010, 
Lansley et al., 2010) and elicit reductions in the O2 cost of exercise (Muggeridge et 
al., 2013b). It is therefore unlikely that the dosage and the timing of NO3
- 
supplementation explain why no effect on the O2 cost of exercise was observed.  
One possible explanation for the reduction in O2 cost following dietary NO3
- 
supplementation in other populations is an increase in the P/O ratio (i.e. less O2 
being consumed to produce a given amount of ATP). Larsen et al (Larsen et al., 
2011) reported an increase in the P/O ratio of harvested mitochondria following three 
days NO3
- supplementation. However, we did not observe a reduction in the O2 cost 
of exercise, which may be related to the impact of oxidative stress, which is reported 
to damage mitochondrial membranes (Kowaltowski and Vercesi, 1999), potentially 
resulting in a reduction in the P/O ratio. COPD is associated with increased oxidative 
stress, with reactive oxygen species (ROS) being produced within the inflammatory 
cells and epithelial cells of the airways in conjunction with increased systemic 
generation of ROS (Ciencewicki et al., 2008). Oxidative stress leads to uncoupling of 
the NO∙ synthase enzymes (Li and Forstermann, 2013), thus reducing NO∙ 
bioavailability and creating a negative feedback loop of diminishing NO∙ production 
and elevated NO∙ scavenging. This may be a substantial barrier to NO∙ based 
therapeutics in COPD.   
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Nitrate supplementation and effects on functional capacity. 
No statistical difference in distance covered for the six-minute walk test was 
observed between conditions. Considering that the O2 cost of exercise and rate of 
adaptation of V̇O2 were not altered following NO3
- supplementation, it is perhaps not 
surprising that functional capacity was also not different between conditions.  It is 
likely that these lack of effects share a common explanation, which may be related to 
the impact of oxidative stress on the bioavailability of NO∙ (Li and Forstermann, 
2013) (see previous section).  
The only other studies that have examined the impact of dietary NO3
- 
supplementation on walking performance have reported both positive and neutral 
effects. Kenjale et al. (2011) reported an increased walking time to exhaustion (17%) 
in a cohort of peripheral artery disease patients. However, dietary NO3
- 
supplementation had no effect on the distance covered in a six-minute walk test in 
healthy older individuals (Kelly et al., 2013a). Since plasma NO3
- (and NO2
- in 
Kenjale et al. 2011 and Kelly et al. 2013) concentrations were similar for the present 
study and two previous studies, the differences in walking performance post NO3
- 
supplementation are likely related to methodological differences. Kenjale et al. 
(2011) assessed walking performance via an incremental test to exhaustion on a 
treadmill, whereas in the present study and that of Kelly et al. (2013a) walking 
performance was assessed via completion of a (submaximal) six-minute walk test. It 
is likely that the higher exercise intensity encountered by the participants in Kenjale 
et al. (2011) resulted in the development of a hypoxic and acidic cellular environment 
that is known to be conducive for the reduction of NO3
- to NO2
- (Modin et al., 2001). 
Such an environment would have been less likely to occur during the lower exercise 
intensity in the present and Kelly et al’s (2013a) study. Finally, Kenjale et al. (2011) 
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did not use a placebo that was indistinguishable from their active juice, thus a 
‘placebo effect’ cannot be ruled out.  
Nitrate supplementation and effect on resting BP. 
There was no difference in systolic or diastolic resting BP following NO3
- rich beetroot 
juice compared to placebo. This may be related to a factor specific to COPD such as 
the elevated oxidative stress (Ciencewicki et al., 2008) in this population would be 
expected to increase the scavenging of NO∙, thus reducing its effectiveness. 
Alternatively there are multiple other factors which may modify the BP effect. Studies 
investigating the effects of dietary NO3
- supplementation in older subjects with and 
without pathology have reported inconsistent BP effects. Gilchrist et al (2013) 
examined the impact of dietary NO3
- supplementation in individuals with type 2 
diabetes, and found no statistical difference in mean 24h ambulatory BP. In subjects 
with peripheral artery disease Kenjale et al. (2011) reported a statistically significant 
reduction in diastolic BP (7 mmHg) but no change in systolic BP. It is possible that 
ageing per se may attenuate NO∙ mediated BP reduction, however in Kelly et al. 
(2013a) study of healthy older adults dietary NO3
- supplementation resulted in 
reductions in systolic and diastolic BP of 5 and 3 mmHg, respectively. In contrast, 
more recently, a larger study by Bondonno et al. (2014a) used a vegetable based, 
NO3
- rich diet for 7 days. Ten hour ambulatory BP along with home and office based 
measurements were used to assess BP. They found no reductions in BP or arterial 
stiffness. There are key differences around the supplementation protocol and timing 
and method of blood pressure measurement. In Kelly et al’s study the office based 
blood pressure measurement was timed to coincide with the plasma NO2
- peak post 
NO3
- ingestion. In the Bondonno et al study measurements took place outside this 
window.  
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It is also worth noting the differing BMI’s in these studies and our present 
manuscript. Kelly et al’s cohort of older adults are the only group in the normal range 
(24±3 kg/m2). Our present cohort had a mean BMI of 29 ± 8kg/m2, Bondonno et al’s 
cohort were overweight 27±4 kg/m2, and in our previous study of subjects with type 2 
diabetes the group mean BMI was 30.8±3.2 kg/m2. This raises the possibility that 
adiposity may attenuate the response to inorganic NO3
- by an as yet unknown 
mechanism.    
One factor which may have had an impact is that subjects in the present study were 
taking multiple classes of drugs including antihypertensives. It is possible that the 
scope for reductions in BP subsequent to NO3
- supplementation is significantly 
reduced when individuals are already taking antihypertensive medication. It is 
noteworthy that in studies where subjects were taking antihypertensives (current 
study - 38% prescribed antihypertensives; Gilchrist et al. (2013) - 98% prescribed 
antihypertensives), no reductions in BP have been reported (see table 1 for drug 
classifications). Alternatively, the  healthy older adults, on no medications, studied by 
Kelly et al. (2013a) showed a significant reduction in BP following NO3
- 
supplementation. It is possible that antihypertensive agents mitigate the NO∙ 
mediated reduction in BP.   
There is conflicting evidence to suggest that ACEi/ARBs can alter the bioavailability 
of NOx with some studies showing reduction (Cacciatore et al., 2011) and others 
proposing increases (Ceconi et al., 2007, Jacoby and Rader, 2003). Therefore the 
direction in which ACEi/ARBs may alter the bioavailability of NO∙ remains unclear. 
ß2-adrenergic receptor agonists are known to increase endothelial NO∙ production 
and are at least, in part, responsible for their vasodilatory effects (Yong-Xiang et al., 
1993). ß2-agonists are the most common treatment for individuals with COPD and 
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thus we could not reasonably exclude individuals who were prescribed this 
medication. We cannot exclude the possibility that prescribed medications which 
modulate NO∙ bioavailability may attenuate a beneficial effect from dietary NO3
- 
supplementation. This study is a crossover design and therefore both treatment arms 
will be equally affected. Further study is required to better understand the possible 
interaction of different medications and inorganic NO3
- and NO2
-. 
Berry et al. (2014) recently examined the effect of NO3
- rich beetroot juice vs. prune 
juice (as a placebo) in individuals with COPD. Plasma NO2
- concentration was 
significantly higher post beetroot juice compared to post prune juice, which indicates 
that the entero-salivary pathway is operational in people with COPD. The authors 
reported reductions in resting systolic BP, iso-time (defined as: last 60s of the 
shortest exercise time during either active or placebo visits compared with the same 
time point from the longer exercise time) BP, end exercise diastolic BP and an 
improvement in exercise tolerance (i.e. lengthened time to exhaustion during 
submaximal constant rate). Whilst the increase in exercise time is of interest, there 
are significant limitations in this study. Firstly, the design utilises prune juice as the 
placebo, which is likely to  have a substantially different antioxidant content which 
could alter NO∙ bioavailability (Bondonno et al., 2012). Secondly, and related to the 
lack of a ‘true’ placebo where the participant did not know whether active or placebo 
juice was being taken (as used in the present study), the widely reported (in the 
national press as well as in scientific literature) beneficial effects of beetroot juice on 
exercise performance/tolerance may have given rise to a placebo effect in informed 
volunteers. The authors do not show a reduction in the O2 cost of exercise which is 
consistent with the present study. However, with no reduction in the O2 cost of 
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exercise, it is not immediately clear what mechanism  underpins the improved time to 
exhaustion reported by Berry et al. (2014).  
This is the first double blind,  randomised, placebo, controlled, crossover design  
study to examine the effects of NO3
- supplementation on the O2 cost of exercise, 
walking performance and BP in individuals with COPD. The study had a robust 
experimental design (double-blind, placebo-controlled, randomised, cross-over 
study). A limitation is that we were not able to ascertain whether or not the increase 
in plasma NO3
- concentration lead to an increase in plasma NO2
- concentration, as 
we were not able to measure the latter due to logistical constraints. However, a 
recent study examining NO2
- levels in individuals with COPD did show elevated 
plasma NO2
- concentrations (Berry et al., 2014) which suggests the entero-salivary 
pathway is operational.    
3.2.8: Conclusion        
 In contrast to findings in healthy young individuals, and despite a statistically 
significant and physiologically meaningful rise in plasma NO3
- concentration, 2.5 
days of beetroot supplementation with 6.77 mmol of NO3
- twice daily did not reduce 
the O2 cost of cycling exercise, improve functional capacity or reduce resting blood 
pressure. Potential explanations for the lack of effect include a reduced P/O ratio due 
to systemic ROS generation associated with oxidative stress, or a reduced 
conversion of NO3
- to NO2
- in this population.  
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3.3: Experimental chapter 3 (Nitrate supplementation, hepatic diffusion and glucose 
homeostasis) 
Title: Nitrate supplementation, hepatic diffusion and glucose homeostasis: A double-blind, 
placebo controlled, randomised control trial. 
3.3.1: Authors: Anthony I Shepherd1,2, Daryl P Wilkerson1, Jon Fulford2, Paul G Winyard2, 
Nigel Benjamin2,3, Angela C Shore2, Mark Gilchrist2 
3.3.2: Affiliation: 1College of Life and Environmental Sciences, Sport and Health 
Sciences, University of Exeter, Devon, UK, 2 University of Exeter Medical School and 
NIHR Exeter Clinical Research Facility, Royal Devon and Exeter Hospital, Exeter, Devon, 
UK 3 Torbay Hospital, Heart and Lung Unit, Torquay, Devon, UK.   
3.3.3: Abstract  
Background:  
Type 2 diabetes mellitus is a growing burden on the NHS budget predominantly due 
to an increased cardiovascular and diabetes risk factors. Nitrates derivatives (nitrite 
and nitric oxide) have been shown to alter gastric blood flow, improve vascular 
function and mediate glucose uptake within the intestines and skeletal muscle. 
Dietary NO3
- appears to be a potential low cost therapy that may help maintain 
glucose homeostasis.      
Methods:  
In a randomised, double blind, placebo-controlled cross-over study, 31 participants 
(16 young adults and 15 healthy older adults) arrived fasted overnight and had a 
standardised breakfast, supplemented with either NO3
- rich beetroot juice (11.91 
mmol NO3
-) or NO3
- depleted beetroot juice as placebo (0.01 mmol NO3
-). A 
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minimum 7 day washout period was employed. Magnetic resonance imaging was 
used to assess apparent diffusion coefficient (ADC), portal vein flux and velocity. 
Plasma glucose concentrations and blood pressure were also assessed. On each 
visit outcome variables were measured at baseline and again every hour for 3 
subsequent hours. Repeated measures ANOVA were used to assess the interaction 
effect of time and supplement.  
Results:  
Compared with a placebo, beetroot juice resulted in a physiologically meaningful and 
significant elevation in plasma NO3
- and plasma nitrite concentration in both cohorts. 
No differences were seen between placebo and beetroot juice for ADC (young 
adults: F(3, 45) = 0.25, P = 0.74; older adults; F(3, 42) = 1.3, P = 0.28) , portal vein flux 
(young adults: F(3, 45) = 0.339, P = 0.79; older adults; F(3, 42) = 1.65, P = 0.19), 
however, there was an interaction effect in the young adults: (F(3, 45) = 2.9, P = 0.04) 
but not in the older adults; F(3, 42) = 1.8, P = 0.16) between visits for portal vein 
velocity. Nitrate supplementation did not reduce plasma glucose concentrations 
(young adults: F(3, 45) = 0.96, P = 0.42; older adults; F(3, 42) = 0.04, P = 0.99). Nitrate 
supplementation did not reduce systolic blood pressure (young adults: F(3, 45) = 0.20, 
P = 0.89; older adults; F(3, 42) = 1.7, P = 0.18) or diastolic blood pressure (young 
adults: F(3, 45) = 0.25, P = 0.86; older adults; F(3, 42) = 0.45, P = 0.72).     
Conclusion:  
This was the first study to examine the hepatic blood flow response to NO3
-
supplementation. Despite a large and physiologically meaningful elevation in plasma 
NO2
- concentration following an acute dose of 11.91 mmol of NO3
-, there was no 
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effect on hepatic blood flow, plasma glucose concentrations or systolic blood 
pressure.  
3.3.4: Introduction   
The total cost of direct and indirect care of individuals with T2DM is in the UK is 
£20.5 billion and equates to 8% of the annual NHS budget (Hex et al., 2012). It is 
anticipated that by 2030, 439 million individuals will have type 2 diabetes (T2DM) 
worldwide (Shaw et al., 2010). This represents a serious challenge to global 
healthcare systems (Wild et al., 2004). T2DM is a disease of progressive 
hyperglycemia. Hyperglycemia is strongly associated with cardiovascular disease 
and microvascular complications such as retinopathy, neuropathy, nephropathy 
(Stratton et al., 2000). Reductions in glycated hemoglobin (HbA1c) have been 
associated with reduced risk of both micro and macrovascular complications 
(Stratton et al., 2000) and events (Patel et al., 2008).  
Diets rich in vegetables have been shown to have beneficial effects on 
cardiovascular health (Gilchrist et al., 2010), morbidity and mortality (Joshipura et al., 
2001) and reduces the risk of developing T2DM (Carter et al., 2010). These diets are 
rich in inorganic NO3
-. There is growing evidence to suggest NO3
- is at least in part 
responsible for these beneficial effects (Bryan and Hord, 2010). Recent reports have 
shown NO3
- supplementation reduces systolic and diastolic blood pressure in healthy 
older adults (Jajja et al., 2014, Kapil et al., 2015, Kelly et al., 2013a) and in clinical 
cohorts with elevated cardiovascular risk factors (Berry et al., 2014, Kerley et al., 
2015, Kenjale et al., 2011). This may in part be due to its effects on vascular tone 
and prevention of vasospasm (Cosby et al., 2003, Pluta et al., 2005).  
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One of NO3
- derivatives, nitric oxide (NO) has been shown to mediate glucose 
uptake from the intestines (Guan et al., 2003) and facilitate its disposal into skeletal 
muscle in animal models (Merry et al., 2010) and in individuals with T2DM (Kingwell 
et al., 2002). Whilst another derivative of NO3
-, nitrite (NO2
-) when supplemented in 
eNOS deficient mice for 10 weeks has shown to reduce glycated hemoglobin 
concentrations, lower baseline and postprandial glucose concentrations (Carlström 
et al., 2010). An vivo study in young adults has shown a  reduction in plasma 
glucose concentrations following nitrate supplementation following exercise (Wylie et 
al., 2013b). Recently, another study has described reduction in baseline plasma 
glucose concentrations 2.5h after supplementation with pharmacological sodium 
NO3
- in individuals with T2DM whilst there was no effect on post prandial glucose 
concentrations following an oral glucose tolerance test (Cermak et al., 2015). 
Incretins are a group of gastrointestinal hormones which stimulate NO∙ production 
(Hattori et al., 2010, Ding et al., 2004). Upon ingestion of food, plasma incretin 
concentrations rise following release from the small intestines (Holst, 2007) and 
concurrently, NO∙ increases gastric blood flow (Björne et al., 2004, Petersson et al., 
2007). Incretins are intrinsically linked with insulin and are a key component in 
glucose homeostasis via their insulinotropic effect. Incretins mediate the uptake of 
glucose in the intestines in a NO∙ dependent fashion (Guan et al., 2003). Incretins 
have also been shown to expedite the production of NO∙ within the portal vein (Ding 
et al., 2004).  
NO∙ is produced within the body via two independent pathways. The first pathway in 
which NO∙ is produced is via the amino acid L-arginine combining with an enzyme, 
nitric oxide synthase (NOS) and is O2 dependent (Alderton et al., 2001). The second 
pathway, known as the entero-salivary pathway is O2 independent. Nitrate from the 
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diet is ingested, absorbed through the stomach wall and proximal small intestine 
(Bartholomew and Hill, 1984, Florin et al., 1990) into the circulation where it is 
concentrated in the salivary glands. A reduction of NO3
- to NO2
- via facultative 
anaerobic bacteria occurs within the mouth (Duncan et al., 1995). Nitrite is then 
swallowed where some NO2
- is converted to NO∙ in the acidic environment of the 
stomach (Benjamin et al., 1994) whilst some of the NO2
- is absorbed into the 
circulation and acts as a storage pool for subsequently conversion to NO∙ (Lundberg 
et al., 2008). Another possible mechanism exists for the conversion of NO3
- to NO2
-, 
whereby hepatic xanthine oxidoreductase reduces NO3
- to NO2
- (Jansson et al., 
2008). This mechanism in conjunction with the uptake of NO2
- into the portal 
circulation may explain why one of the highest concentrations of nitrite in any organ 
are found within the liver (Totzeck et al., 2012, Bryan et al., 2005). Subsequent 
increases in the bioavailability of NO∙ within the liver may be expedited by a number 
of nitrite reductases which are in relatively high concentrations such as; xanthine 
oxidoreductase (Li et al., 2008b, Martin et al., 2004), aldehyde oxidase (Li et al., 
2008a, Kundu et al., 2012), neuroglobin (Fordel et al., 2007, Tiso et al., 2011), 
cytoglobin (Burmester et al., 2002, Fordel et al., 2007, Li et al., 2012), 
deoxyhaemoglobin (Cosby et al., 2003) and myoglobin (Cossins et al., 2009). The 
potential increase of NO∙ within the hepatic vasculature may lead to vasodilation of 
the parenchyma and lead to greater surface area for glucose uptake to occur. 
Increases in the bioavailability of NO∙ has also bene shown to stimulate insulin 
secretion (Nystrom et al., 2012) and increase GLUT4 translocation (Li et al., 2004).  
Purpose / hypothesis  
By reducing post-prandial hyperglycaemia it may be possible to reduce the 
associated micro and macrovascular complications (Stratton et al., 2000). A 
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reduction in hyperglycaemic exertions is a long term goal in the treatment of T2DM in 
order to protect against cardiovascular events and microvascular damage (Shamoon 
et al., 1993, Del Prato et al., 2005) and even the risk of morbidity and mortality. 
Therefore, dietary NO3
- may offer a simple, low cost means of modifying diabetes 
and cardiovascular risk factors.   
The aim of this study was to assess if inorganic NO3
- modulates portal vein flux and 
velocity and hepatic microvascular diffusion and secondly; does NO3
- lower post-
prandial plasma glucose concentrations and blood pressure in healthy young and 
older adults. We hypothesised that supplementation of the diet with dietary NO3
- 
would increase blood flow to the liver and vasodilate the microvasculature causing 
improved postprandial glucose uptake. We also hypothesise that dietary nitrate 
supplementation would reduce blood pressure.  
3.3.5: Methods 
Volunteers    
37 individuals (17 healthy young individuals and 20 healthy older adults) provided 
written informed consent to participate in this double-blind, placebo-controlled, cross-
over design study (see table 12 for subject characteristic). The healthy young 
individuals were recruited via word of mouth. The older adults were recruited via the 
NIHR Exeter Clinical Research Facility, Exeter 10,000 cohort. This is a database of 
individuals who have been pre-screened and consented to be contacted as research 
volunteers. The trial commenced in July 2014 and ended in April 2015. Ethical 
approval was obtained from the Exeter NRES Committee (14/SW/0092). This trial 
was registered on the ClinicalTrials.gov website (NCT02195856). Healthy young 
individuals were recruited if they were aged between 18 and 35. Older adults were 
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recruited if they were aged between 50 and 75. Exclusion criteria were incapacity to 
consent, on any regular vasoactive medications, uncontrolled hypertension, antibiotic 
therapy within the preceding two weeks, on regular organic NO3
-, thiazolidinidiones 
or nicorandil, severe claustrophobia, were smokers (smoked within past 3 months), 
presence of chronic kidney disease (estimated glomerular filtration rate (eGFR) <30 
ml/min/1.73 m2), myocardial infarction or cerebro-vascular event within the preceding 
3 months, previous brain surgery, cardiac pacemaker, metal fragments in the eye or 
larger metal objects that would interfere with data collection or analysis. Volunteers, 
who had medical interventions where metal implants (including some plates, clips, 
staples or sutures) were inserted, were thoroughly assessed to determine safety in 
the scanner. 
Table 11. Participant characteristics included in the final analysis.      
  
Young adults 
 
Older adults 
n 
 
16 
 
15 
Age (years) 
 
26.6 
 
59.2 
Male (%) 
 
68.8 
 
53.3 
Height (m) 
 
1.75 
 
1.69 
Weight (kg) 
 
76.2 
 
75.3 
BMI (kg/m2) 
 
24.6 
 
26.3 
Baseline SBP (mmHg) 
 
121.0 
 
130.0 
Baseline DBP (mmHg) 
 
70.0 
 
79.0 
 
    Experimental Overview  
Screening and consent took place at the Diabetes and Vascular Research Centre at 
the NIHR Exeter Clinical Research Facility. Following arrival, volunteers completed 
informed consent followed by a medical history, anthropometric measures and a 
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resting ECG were taken. Venous blood samples were taken and checked for 
markers of undiagnosed liver disease, lipid profile, eGFR and glycated haemoglobin. 
Following the screening checks the volunteers were randomly assigned to a double-
blind crossover experimental design to consume 140 ml of NO3
- rich beetroot juice 
(beetroot juice; containing 11.91 mmol of NO3
-; Beet it, James White Drinks Ltd., 
Ipswich) or NO3
- depleted beetroot juice (placebo; NO3
- depleted beetroot juice 
containing 0.01 mmol of NO3
-; Beet it, James White Drinks Ltd., Ipswich). The 
placebo production has been detailed previously (Gilchrist et al., 2014); the final 
product is identical in appearance, odour taste, colour and texture.     
Volunteers were asked to fast overnight (from 10pm) although water consumption 
was allowed to ensure they arrived in a hydrated state. Volunteers were asked to 
refrain from antibacterial mouthwash throughout the study and for at least 7 days 
prior to the experimental visits. Antibacterial mouthwash has been demonstrated to 
reduce the concentration of oral bacterial anaerobes responsible for the reduction of 
NO3
- in the entero-salivary pathway (Govoni et al., 2008). Volunteers were also 
asked to avoid caffeine for 12 hours, alcohol and strenuous activity for 24 hours and 
NO3
- rich foods on the day prior to their visits..        
Volunteers arrived at the Peninsula Magnetic Resonance Research Centre at the 
University of Exeter. A 30 minute acclimatisation period was implemented prior to the 
magnetic resonance imaging (MRI) scans. During this acclimatisation period a 
cannula was inserted in order to take baseline plasma concentrations for glucose 
(fluoride & EDTA tubes; Sarstedt, S-Monovette, Nümbrecht, Germany). Plasma NO3
- 
and NO2
- were collected (lithium heparin tubes; Sarstedt, S-Monovette, Nümbrecht, 
Germany) and analysis was performed as previously described (Gilchrist et al., 
2013). Immediately prior to the baseline MRI scan, 5 resting blood pressure (BP) 
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measurements were taken (Schiller Medical, Wissembourg, France) and an average 
of the final 3 recorded.  
Following the baseline MRI scans the volunteers were provided with either the NO3
- 
rich beetroot juice or the placebo with two slices of toast, butter and jam. The 
combined quantity of carbohydrate equated to 76 grams and is equivalent to that that 
would be consumed during an oral glucose tolerance test (Bartoli et al., 2011a). 
Every hour, for three subsequent hours, from the consumption of the beetroot juice 
another set of scans were performed. Immediately prior to each scan brachial artery 
blood pressure and venous blood samples were taken and processed as previously 
described. A minimum 7 day washout period between the crossover was employed.     
MRI scans      
A 1.5 T (Philips, Amsterdam, The Netherlands) magnetic resonance imaging (MRI) 
scanner was used in order to examine changes in velocity and flux in the portal vein 
and microvascular diffusion in the posterior right lobe of the liver.  
Initial structural images were obtained to orientate the portal vein and an 8mm slice 
was selected perpendicular to the long axis of the vein. To determine flux and 
velocity a cardiac triggered velocity sensitive phase encoding imaging sequence 
(Gatehouse et al., 2005) was employed which obtained image data at 20 time points 
throughout the cardiac cycle. Analysis of the portal vein was subsequently 
undertaken using a package supplied as part of the general scanner software. For 
each separate measurement the circumference of the vessel was manually drawn 
and recorded for each of the 20 time points to establish a defined region of interest 
(ROI). Within this ROI, flow and velocity were automatically calculated to give 
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profiles throughout the cardiac cycle. A mean across the cardiac cycle for flux and 
velocity was created.   
To examine the microvascular diffusion in the posterior right lobe of the liver, a 
magnetic resonance sequence sensitive to flow was employed via the application of 
magnetic field gradients in three orthogonal directions. Microvascular diffusion was 
averaged over all directions within the region of interest and is known as the 
apparent diffusion coefficient (ADC). Day to day repeatability was assessed in 6 
individuals for ADC (1 ROI: ADC = 1.15 ± 0.12, CV = 9.77) and with multiple ROI. 
One ROI away from any major vessels had greater repeatability that 2, 3 and 6 sites 
(2 ROI: ADC = 1.11 ± 0.21, CV = 15.29; 3 ROI: ADC = 1.10 ± 0.23, CV = 21.34; 6 
ROI : ADC = 1.09 ± 0.33, CV = 30.32). To calculate ADC within the posterior left lobe 
of the liver, a ROI (typically 2500mm3) was manually drawn using the scanner 
software and the signal intensity within determined. ADC was subsequently 
calculated based upon the ratio of signal intensity from the two images generated 
from the MR sequence employed, one of which was sensitive to flow, whereas the 
other had a low sensitivity to flow, where:  
ADC= -1/(b1-b0)  Ln (S0/S1) 
S0 signal intensity in low flow sensitivity image  
S1 signal intensity in flow sensitive image  
b0 magnetic field gradient used in low flow sensitivity image=250 s/mm
2 
b1 magnetic field gradient used in flow sensitive image=750 s/mm
2. 
Sample size and randomisation 
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For 90% power with an α-level set at P = 0.05 (two tailed), to detect a 1 SD 
difference, 13 volunteers were required to compare between placebo and active 
conditions. A computer program was used to generate a randomisation schedule for 
both groups.    
Data and statistical analysis 
All data were tested for normality. Data are presented as means ± standard deviation 
(SD). Statistical analyses were performed on SPSS software version 21.0 (Chicago, 
IL, USA). Statistical difference was accepted when P < 0.05. Statistical differences 
were assessed using paired samples t-tests.    
3.3.6: Results  
37 individuals (17 healthy young individuals and 20 healthy older adults) gave written 
informed consent to participate. Post screening and consent 6 individuals were 
excluded from the trial. 1 individual had abnormal liver function, 1 had a metal pin (in 
an area which would interfere with data collection) and 4 had previously 
undiagnosed claustrophobia. 31 individuals (16 healthy young individuals and 15 
healthy older adults) were randomised to start in either the NO3
- rich beetroot arm or 
the placebo arm. No differences between dietary intake or exercise patterns were 
recorded prior to both study visits. The beetroot juice was well tolerated and no 
adverse events were reported.  
Plasma NO3
- concentration:  
Repeated measures ANOVA revealed a significant main effect for time, 
supplementation and an interaction for plasma NO3
- concentration in the young 
adults and the older adults; P < 0.001. Post hoc analysis revealed no significant 
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differences at baseline (prior to any supplementation) for plasma NO3
- concentration 
(young adults: mean difference; 2 ± 4.4 µM, P = 0.64, 95% CI -7.4, 11.5; older 
adults: mean difference; 1.5 ± 4.1 µM, P = 0.72, 95% CI -10.4, 7.4)  Post hoc 
analysis revealed  a significant increase when beetroot juice was compared with 
placebo at 1 hour post supplementation (young adult: mean difference; 543 ± 37 µM, 
P < 0.001, 95% CI 463, 624; older adult: mean difference; 505 ± 39 µM, P < 0.001, 
95% CI 420, 590), 2 hours post (young adult: mean difference; 645 ± 29 µM, P < 
0.001, 95% CI 581, 707; older adult: mean difference; 632 ± 35 µM, P < 0.001, 95% 
CI 556, 710) and 3 hours post (young adult: mean difference; 598 ± 31 µM, P < 
0.001, 95% CI 530, 665; older adult: mean difference; 616 ± 26 µM, P < 0.001, 95% 
CI 559, 673). 
 
 
 
 
 
 
 
 
Figure 16. Plasma NO3
-
 concentration in a young adult cohort. 
This figure shows plasma NO3
-
 concentration for the young adult cohort with changes across time for 
beetroot and placebo juice. The open circles are placebo and the closed circles beetroot juice. The * 
represents a significant difference when beetroot juice is compared with placebo < 0.001.    
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Figure 17. Plasma NO3
-
 concentration in a older adult cohort. 
This figure shows plasma NO3
-
 concentration for the older adult cohort with changes across time for 
beetroot and placebo juice. The open circles are placebo and the closed circles beetroot juice. The * 
represents a significant difference when beetroot juice is compared with placebo < 0.001.    
 
Plasma NO2
- concentration:  
Repeated measures ANOVA revealed a significant main effect for time, 
supplementation and an interaction for plasma NO2
- concentration in the young 
adults and the older adults; P < 0.001. Post hoc analysis revealed no significant 
differences at baseline (prior to any supplementation) for plasma NO2
- concentration 
(young adults: mean difference; -3.3 ± 74 nM, P = 0.86, 95% CI -43, 36; older adults: 
mean difference; 26.5 ± 78 nM, P = 0.21, 95% CI -17, 69)  Post hoc analysis 
revealed  a significant increase when beetroot juice was compared with placebo at 1 
hour post supplementation (young adults: mean difference; 283 ± 201 nM, P < 0.001, 
95% CI 176, 391: older adults: mean difference; 471 ± 381 nM, P < 0.001, 95% CI 
260, 682), 2 hours post (young adults: mean difference; 497 ± 259 nM, P < 0.001, 
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95% CI 353, 640: older adults: mean difference; 545 ± 325 nM, P < 0.001, 95% CI 
364, 325) and 3 hours post (young adults: mean difference; 559 ± 201 nM, P < 
0.001, 95% CI 442, 675: older adults: mean difference; 797 ± 525 nM, P < 0.001, 
95% CI 493, 1100). There was also a significant increase at peak plasma nitrite 
concentration (hour 3), compared with hour 2 (mean difference; 201 ± 344 nM, P = 
0.039, 95% CI 11, 392). 
  
 
 
 
 
 
 
 
 
Figure 18. Plasma NO2
-
 concentration in a young adult cohort. 
This figure depicts plasma NO2
-
 concentration for the young adult cohort with changes across time for 
beetroot and placebo juice. The open circles are placebo and the closed circles beetroot juice. The * 
represents a significant difference when beetroot juice is compared with placebo < 0.001.    
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Figure 19. Plasma NO2
-
 concentration in a older adult cohort. 
This figure depicts plasma NO2
-
 concentration for the older adult cohort with changes across time for 
beetroot and placebo juice. The open circles are placebo and the closed circles beetroot juice. The * 
represents a significant difference when beetroot juice is compared with placebo < 0.001.  The # 
shows a significant difference in the beetroot condition when hour 2 is compared to hour 3.  
ADC:  
Repeated measures ANOVA revealed no significant main effect for time (young 
adults: F(3, 45) = 0.96, P = 0.42; older adults; F(3, 42) = 0.27, P = 0.85), supplementation 
(young adults: F(1, 15) = .314, P = 0.58; older adults; F(1, 14) = 1.65, P = 0.22) or an 
interaction (young adults: F(3, 45) = 0.25, P = 0.74; older adults; F(3, 42) = 1.3, P = 0.28) 
between visits for ADC index.   
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Figure 20. ADC in a young adult cohort across time for beetroot and placebo juice. 
The figure shows ADC (microvascular diffusion) for the young adult cohort with changes across time 
for beetroot and placebo juice. The open circles are placebo and the closed circles beetroot juice.  
 
 
 
 
 
 
 
 
 
Figure 21. ADC in a older adult cohort across time for beetroot and placebo juice. 
This table shows ADC (microvascular diffusion) for the older adult cohort with changes across time for 
beetroot and placebo juice. The open circles are placebo and the closed circles beetroot.  
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Portal Vein Flux 
 
 
 
 
 
 
 
Figure 22. Portal vein flux in a young adult cohort across time for beetroot and placebo juice. 
This figure shows portal vein flux for the young adult cohort with changes across time for beetroot and 
placebo juice. The open circles are placebo and the closed circles beetroot.  
 
Repeated measures ANOVA revealed a significant main effect for time (young 
adults: F(3, 45) = 14.07, P < 0.001; older adults; F(3, 42) = 32.84, P < 0.001), however, 
no significant effect for supplementation (young adults: F(1, 15) = 1.00, P = 0.33; older 
adults; F(1, 14) = 3.04, P = 0.10) or interaction (young adults: F(3, 45) = 0.339, P = 0.79; 
older adults; F(3, 42) = 1.65, P = 0.19) between visits for portal vein flux.  However, 
there was a baseline difference for older adults (older adults: placebo; 14.6 ± 4.3 vs. 
beetroot juice; 11.7 ± 2.9 ml/s, P = 0.04, 95% CI -5.67, -0.13). 
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Figure 23. Portal vein flux in an older adult cohort across time for beetroot and placebo juice. 
This table shows portal vein flux for the older adult cohort with changes across time for beetroot and 
placebo juice. The open circles are placebo and the closed circles beetroot.  The * represents a 
statistically different baseline portal vein flux between conditions. 
Portal Vein Velocity  
 
 
 
 
 
 
Figure 24. Portal vein velocity in a young adult cohort across time for beetroot and placebo juice. 
This figure shows portal vein velocity for the young adult cohort with changes across time for beetroot 
and placebo juice. The open circles are placebo and the closed circles beetroot.  The * represents a 
statistically different baseline portal vein velocity between conditions.  
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Repeated measures ANOVA revealed a significant main effect for time (young 
adults: F(3, 45) = 10.7, P < 0.001; older adults; F(3, 42) = 17.7, P < 0.001), however, no 
significant effect for supplementation (young adults: F(1, 15) = 0.1, P = 0.75; older 
adults; F(1, 14) = 2.3, P = 0.15) however, there was an interaction effect in the young 
adults: (F(3, 45) = 2.9, P = 0.04) but not in the older adults; F(3, 42) = 1.8, P = 0.16) 
between visits for portal vein velocity. Post hoc analysis of the interaction revealed 
no statistical differences. However, there was a baseline difference for older adults 
(older adults: placebo; 13 ± 3.4 vs. beetroot; 11.1 ± 3 cm/s, P = 0.04, 95% CI -3.7, -
1.1). 
 
 
 
 
 
 
 
 
 
 
Figure 25. Portal vein velocity in a older adult cohort across time for beetroot and placebo juice. 
This figure shows portal vein velocity for the older adult cohort with changes across time for beetroot 
and placebo juice. The open circles are placebo and the closed circles beetroot.  The * represents a 
statistically different baseline portal vein velocity between conditions. 
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Plasma glucose concentration:  
Repeated measures ANOVA revealed a significant main effect for time (young 
adults: F(3, 45) = 7.3, P < 0.001; older adults; F(3, 42) = 17.7, P < 0.001), however, no 
significant main effect on supplementation (young adults: F(1, 15) = 0.96, P = 0.35; 
older adults; F(1, 14) = 1.4, P = 0.26) or an interaction (young adults: F(3, 45) = 0.96, P = 
0.42; older adults; F(3, 42) = 0.04, P = 0.99) between visits for plasma glucose 
concentration.  
 
 
 
 
 
 
 
 
 
Figure 26. Plasma glucose concentrations in a young adult cohort across time for beetroot and 
placebo juice. 
Figure shows plasma glucose concentration for the young adult cohort with changes across time for 
beetroot and placebo juice. The open circles are placebo and the closed circles beetroot.  
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Figure 27. Plasma glucose concentrations in a older adult cohort across time for beetroot and placebo 
juice. 
This figure shows plasma glucose concentration for the older adult cohort with changes across time 
for beetroot and placebo juice. The open circles are placebo and the closed circles beetroot. The * 
represents a statistically different baseline glucose concentration between conditions.  
 
Effects on resting blood pressure:  
Repeated measures ANOVA revealed a significant main effect for time (young 
adults: F(3, 45) = 4.5, P = 0.008; older adults; F(3, 42) = 13.3, P < 0.001), however, no 
significant main effect on supplementation (young adults: F(1, 15) = 1.2, P = 0.28; 
older adults; F(1, 14) = 1.7, P = 0.20) or an interaction (young adults: F(3, 45) = 0.20, P = 
0.89; older adults; F(3, 42) = 1.7, P = 0.18) between visits for systolic blood pressure.  
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Figure 28. Systolic blood pressure in a young adult cohort across time for beetroot and placebo juice. 
Depicts systolic blood pressure for the young adult cohort with changes across time for beetroot and 
placebo juice. The open circles are placebo and the closed circles beetroot.  
 
 
 
 
 
 
 
 
Figure 29. Systolic blood pressure in a older adult cohort across time for beetroot and placebo juice. 
Depicts systolic blood pressure for the older adult cohort with changes across time for beetroot and 
placebo juice.  
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Repeated measures ANOVA revealed a non-significant main effect on diastolic 
blood pressure for time in young adults (F(3, 45) = 2.4, P = 0.08) and a significant main 
effect of time in older adults (F(3, 42) = 18.8, P < 0.001), however, no significant main 
effect on supplementation in young adults (F(1, 15) = 2.6, P = 0.13). There was 
however, a trend for a reduction as a main effect of supplementation in older adults 
(F(1, 14) = 4.0, P = 0.06). No effect on interaction (young adults: F(3, 45) = 0.25, P = 
0.86; older adults; F(3, 42) = 0.45, P = 0.72) was found between visits for diastolic 
blood pressure.  
 
Figure 30. Diastolic blood pressure in a young adult cohort across time for beetroot and placebo juice. 
Depicts diastolic blood pressure for the young adult cohort with changes across time for beetroot and 
placebo juice. The open circles are placebo and the closed circles beetroot.  
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Figure 31. Diastolic blood pressure in a older adult cohort across time for beetroot and placebo juice. 
Depicts diastolic blood pressure for the older adult cohort with changes across time for beetroot and 
placebo juice. The open circles are placebo and the closed circles beetroot.  
 
3.3.7: Discussion  
This is the first study to investigate the effects of dietary NO3
- supplementation on 
hepatic blood flow and glucose homeostasis in a healthy older adult population. The 
primary outcomes were to assess changes in microvascular diffusion (ADC), portal 
vein flux and velocity. Nitrate supplementation did not alter portal vein flux, velocity 
or affect ADC. Secondary outcomes were to assess plasma glucose concentration 
and blood pressure changes. Nitrate supplementation did not alter plasma glucose 
concentration. Nitrate supplementation did not lower systolic or diastolic blood 
pressure.    
Nitrate supplementation and plasma NO3
- and plasma NO2
- concentration.  
Plasma NO3
- concentration peaked post NO3
- rich beetroot juice compared with 
placebo for both the young (30.9 vs. 664.3 µM) and older adult (32.1 vs. 633.8 µM) 
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groups at 2 hours by ~2000%. Similarly, plasma NO2
- concentration rose following 
NO3
- rich beetroot juice compared to the placebo and peaked at 2 hours for the 
young group (218.3 vs. 715.5 nM) and 3 hours for the older adult group (171 vs. 
967.9 nM) representing a ~230 and 460% increase, respectively. The 
pharmacokinetic response for both plasma NO3
- and NO2
- concentrations of both 
cohorts are similar to a previously reported does response study in young healthy 
individuals (Wylie et al., 2013a). However, the pharmacokinetic response of plasma 
NO3
- and NO2
- concentrations have not previously been reported in a group of 
healthy older adults. Kelly et al. (2013a) recently reported a rise in plasma NO2
- 
concentration of a similar magnitude by 418% (248 to 1037 nM) in a group of healthy 
older adults. The pharmacokinetic response in the healthy older adult group shows a 
peak at 3 hours. This is much higher than at hour 2 (757 nM) and therefore may still 
have been rising at 3 hours.  
The lengthened time to peak plasma NO2
- concentration in the older adult cohort 
may be associated with the commensal oral bacteria which play a fundamental role 
in the entero-salivary pathway. Serum antibodies to these oral bacteria decrease in 
concentration as we age (Percival et al., 1996, Challacombe et al., 1995, Percival et 
al., 1997). These reductions can lead to increased risk of infection and disease from 
pathogens (Marsh and Percival, 2006). However, this increase in oral microflora may 
lead to a greater increase in the conversion of NO3
- to NO2
-, potentially changing the 
bacteria’s’ contribution as a rate limiting factor which may explain why plasma NO2
- 
concentrations were still rising 3 hours after NO3
- supplementation. Resting salivary 
flow rates are not different between young and older healthy adults. Therefore 
salivation is unlikely to be a contributory factor leading to the delayed peak in plasma 
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NO2
- concentration (Ship and Fischer, 1997). This suggests that more NO3
- will be 
converted to NO2
-, however, due to the flow rate of saliva the peak is delayed.   
Nitrate supplementation and hepatic blood flow  
Despite a statistically significant and physiologically meaningful rise in plasma NO2
- 
concentration, this did not lead to an increase in portal vein flux, velocity or 
microvascular diffusion (ADC). The portal vein supplies 75% of inflow, with the 
remainder supplied by the hepatic artery (Rappaport, 1979) and even though the 
blood it supplies is partially deoxygenated, the portal vein  supplies ~50% of the O2 
delivery (See Hwang., 2011 and Vollmar and Menger., 2009 for reviews). A higher 
proportion of deoxyhaemoglobin may lead to a faster conversion of NO2
- to NO∙ 
(Cosby et al., 2003) in the portal vein. It is therefore likely that the highest 
concentrations of NO∙ and plasma glucose concentrations would be found in the 
liver.  
The hepatic artery has the capacity to dilate in response to changes in portal vein 
flux however, the portal vein cannot dilate in response to changes in hepatic arterial 
flow (Vollmar and Menger, 2009, Legare and Lautt, 1987). Thus if the portal vein flow 
decreases the hepatic artery will dilate to increase, flow and if the portal vein 
increases flow the hepatic artery will constrict to reduce flow (Lautt et al., 1990). This 
is known as the known as the ‘hepatic arterial buffer response’ (Hwang, 2011). This 
buffering response is limited and may be able to compensate for 25 - 60% of change 
in flow from the portal vein (Lautt, 1980, Lautt, 1977). The underlying reason behind 
this is to enable a steady perfusion rate in order to manage changes in blood flow 
from splanchnic organs and the associated hormones and nutrients (Lautt, 1980, 
Lautt, 1977). This could, in part explain the lack of effect of an increased plasma 
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NO2
- concentration on portal vein blood flow. As expected, there was an increase in 
portal vein flux and velocity from baseline to the liver regardless of condition.  
There was, however, a statistical difference in baseline portal vein flux (placebo: 14.6 
and active 11.7 cm/s; mean difference of 2.9 cm/s) and velocity (placebo: 13 and 
active 11.1 cm/s; mean difference of 1.9 ml/s) on the two visits. The day to day 
coefficient of variation for portal vein flux and velocity was 13% and 16% 
respectively. The mean differences are outside our repeatability and are likely to be 
genuine differences between visits. This suggests that portal vein flux and velocity 
were faster on the placebo visit at baseline. This may cloud any differences between 
the active condition and placebo later in the time course. Participants were fasted 
overnight, having avoided caffeine, strenuous exercise and were in a hydrated state. 
Therefore it is unclear why there is a baseline difference. It may be due to a type 2 
error.         
Nitrate supplementation and plasma glucose concentrations  
There was no significant difference between active or placebo juice for plasma 
glucose concentration. It should be noted that in the older adult cohort there was 
statistically significant baseline difference in plasma glucose concentration (mean 
difference = -0.2 mmol/l or 3.8%). On the active testing days plasma glucose 
concentration was already ~4% lower than placebo. Mechanisms for the uptake of 
glucose have been partially elucidated. NO∙ is known to mediate glucose uptake 
from the intestines and skeletal muscle (Merry et al., 2010, Guan et al., 2003, 
Kingwell et al., 2002). Potentially via elevated NO∙ bioavailability which has been 
shown to stimulate insulin secretion (Nystrom et al., 2012) and increase GLUT4 
translocation (Li et al., 2004). The potential to modifying this diabetes risk factor via 
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reductions in plasma glucose concentrations would likely reduce micro and 
macrovascular complications which are a severe cause of reduced quality of life, 
morbidity and mortality (Sprafka et al., 1991, Jaffe et al., 1984). Larger samples 
sizes that are appropriately powered are required to assess the effect of nitrate 
supplementation on plasma glucose concentrations.          
Nitrate supplementation and resting blood pressure. 
There was no significant difference in systolic or diastolic BP following NO3
- rich 
beetroot juice supplementation (at peak plasma NO2
- concentration) compared to 
placebo in the healthy young adult cohort. This is similar to some acute NO3
- 
supplementation studies (Wilkerson et al., 2012, Coles and Clifton, 2012, Sandbakk 
et al., 2014). However, most studies have shown hypotensive effects with acute 
supplementation regimens (Webb et al., 2008a, Vanhatalo et al., 2010, Vanhatalo et 
al., 2011, Lansley et al., 2010, Lansley et al., 2011a). Larger sufficiently powered 
trials are required to determine the effect of NO3
- as a hypotensive agent in young 
individuals. There was no significant reduction in systolic BP following NO3
- rich 
beetroot juice compared to placebo in the healthy older adult cohort. We report a non 
significant 5 mm Hg drop in systolic BP. Kelly et al. (2013a) report a statistically 
significant 5 mmHg drop in systolic BP, whilst another groups reported larger 
reductions (Jajja et al., 2014). Another study in healthy older adults reported no 
effect of nitrate supplementation on systolic BP (Bondonno et al., 2014b). Kelly et al. 
reported diastolic BP reductions of 3 mmHg. Whereas we report a non-significant 
change in diastolic BP of2 mmHg. A detailed pharmacokinetic study in healthy older 
adults over a prolonged period may elucidate at what time peak plasma NO2
- 
concentrations occur. If the pharmacokinetic response of plasma NO2
- 
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concentrations in the healthy older adult group continued to rise past 3 hours, a 
greater hypotensive effect than measured here may have occurred.  
Strengths and limitations.  
This is the first study to examine the effect of NO3
- supplementation on hepatic blood 
flow. This study has a robust experimental design as a double-blind, placebo 
controlled, crossover trial. A limitation to this study is that we did not measure 
plasma NO2
- concentration beyond 3 hours supplementation. Future research should 
aim to elucidate if plasma NO2
- concentration rises beyond 3 hours in healthy older 
adults.  
3.3.7: Conclusion 
This was the first study to examine the hepatic blood flow response to NO3
-
supplementation. Despite a large and physiologically meaningful elevation in plasma 
NO2
- concentration following an acute dose of 11.91 mmol of NO3
-, there was no 
effect on hepatic blood flow, plasma glucose concentrations or systolic blood 
pressure. .    
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4.0: General discussion  
This body of work has made a number of novel contributions in this area of research; 
it was the first study to investigate the effects of dietary NO3
- supplementation on the 
exercise responses of individuals with T2DM. Dietary NO3
- supplementation did not 
reduce the O2 cost of walking in individuals with T2DM or increase the distance 
covered in the six minute walk test. In addition this work confirms previous findings 
that NO3
- supplementation has no effect on resting blood pressure in individuals with 
T2DM.  
This was the third peer reviewed article to assess the effects on individuals with 
COPD (all published in Nitric Oxide within 6 weeks of each other). Dietary NO3
- 
supplementation did not reduce the O2 cost of cycling in individuals with COPD, or 
increase the distance covered in the six minute walk test. In contrast to the other 
reports in individuals with COPD, no hypotensive effect was found.  
This is the first study to examine the liver diffusion or delivery. The data shows no 
increase in liver diffusion or delivery. The data shows no effect of nitrate in blood 
glucose concentrations or blood pressure.   
Dietary NO3
- supplementation in the form of beetroot juice (in an older adult 
population) is unlikely to reduce the O2 cost of exercise, improve walking 
performance or reduce BP in individuals with T2DM and COPD. Moreover, it does 
not alter glucose homeostasis or affect blood pressure in healthy adults.   
I will begin the discussion with an update of the studies published since the 
beginning of this body of work. Table 13 describes each trial published and each of 
the key outcome measures assessed. I will then describe and critically appraise my 
findings in the context of recent literature.     
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Table 12: A, B and C. Publications on NO3
- supplementation from 2012 – April 2015 (split via age and disease status).    
A, Healthy young individuals 
B, Healthy older individuals  
C, Clinical populations  
Studies in table 13, B and C (that are not abstracts), will be critically reviewed in the discussion below. Please see marked with a *.  
 
Table A: Nitrate supplementation studies in healthy young individuals  
Author Participants & Protocol  NO3
- supplement Plasma NO3
- & 
NO2
- 
concentration (BR 
vs. PL 
respectively)   
BP 
changes 
Exercise efficiency 
or performance 
and/or clinical 
relevance 
Primary 
outcome 
successful? 
Wilkerson et 
al. (2012) 
8 well-trained male cyclists. A 
minimum of a 7 day washout 
was given. 4BP 
measurements were taken on 
each visit. Exercise involved a 
50 mile TT. 
 
500ml of BR juice (NO3
- 
=6.2mmol) or PL (NO3
- 
=0.005mmol) 2.5 hours 
prior to exercise.   
NO2
- = 379 ± 94 
and 472 ± 96 nM 
 
↔SBP, 
DBP or 
MAP 
↔ TT performance 
 
No 
Masschelein 
et al. (2012) 
15 healthy volunteers. With a 
14 day washout period. 
Exercise included cycling in 
normoxia and hypoxia.  
 
 
 
500ml of BR (0.07 Kg-1 
day-1 of body weight) for 
6 days or PL (apple and 
blackcurrant).  
NO2
- = 3.8 ± 0.1 
and 5.3 ± 0.3 μM 
NO3
- =  41 ± 3 and 
147 ± 7 μM 
N/A BR negates some 
negative effects of 
hypoxia.  
↑Arterial and muscle 
oxygenation.  
 
Mixed 
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Engan et al. 
(2012) 
12 healthy subjects. Tests; 
vital capacity, apnoeic 
duration and arterial O2 
saturation. Washout period 
not stated.  
 
70ml of BR juice (NO3
- 
=5mmol) or PL (NO3
- 
=0.003mmol) 2.5h prior 
to each test.  
Figures not given. ↓MAP ↓SaO2 
↑ Max apnoeic 
duration by 11% 
Yes 
Hobbs et al. 
(2012).  
14 subjects (sex and disease 
status unknown). 24h 
ambulatory BP was 
measured.  
Subjects consumed BR 
juice (0, 100, 250 or 
500g) or water (PL) and 
bread (PL) or BR bread 
(white and red beets).  
Abstract only, 
figures not 
presented. 
N/A ↓BP in a ~ dose 
dependant manor. 
↔ BP for white BR 
bread  
Yes 
Bond et al. 
(2012). 
(Abstract 
only) 
14 well-trained junior male 
rowers. A 7 day washout 
period was employed. 
Exercise included 6 maximal 
500m ergometer reps. 
 
500ml of BR or PL daily 
for 6 days.  
 
 
Abstract only, 
figures not 
presented. 
N/A ↑ average repetition 
time  
Yes 
Coles and 
Clifton 
(2012) 
30 healthy subjects (15 
males). 14 day washout was 
employed. 24h ambulatory 
blood pressure was taken    
500ml of BR juice (NO3
- 
=15 mmol) or PL (apple 
juice matched for colour 
and sweetness)  
 
Figures not given.  Trend for 
↓SBP 
 
↓SBP in males at 6h 
post supplement  
 
Yes 
Krajka-
Kuzniak et 
al. (2012).  
24 male 6 week old rats. Split 
into 4 independent groups. 
DNA damage and liver injury 
induced by 
hepatocarcinogenic 
N-nitrosodiethylamine 
(NDEA). 
 
 
 
Two groups fed beetroot 
juice and one of two 
different enzymes. 
Groups ¾ had PL and 
water. 
Figures not 
published. 
N/A Protects against 
oxidative stress 
Protects against liver 
damage 
Yes 
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Klewicka et 
al. (2012) 
Caco-2 cell line (Rat 
cells/colons acquired from 32 
rats, 4 groups of 8).  
Group 1 had a basal diet. 
Group 2 was fed a basal 
diet and BR juice for 30 
days. Group 3 was fed 
BR and a carcinogen. 
Group 4 had BR and a 
different carcinogen.  
 
 
N/A N/A Protect against 
precancerous aberrant 
crypt formation.  
↓Oxidative stress 
Yes 
Ferguson et 
al. (2013) 
Rats were fed BR or PL (H2O) 
for 5 days. Microvascular PO2 
was measured during 180s of 
electorally induced muscle 
contractions.   
BR (NO3
- = ~0.8 
mmol/kg/day) or PL 
(H2O) 
↑ NO2
- 
↑ NO3
- 
 
Values not provided 
N/A ↔ in steady-state 
Microvascular or PO2, 
however, it did slow 
the decline.  
BR ↑ O2 driving 
pressure during the 
resting phase  
 
Mixed 
Christensen 
et al. (2013) 
10 highly trained male 
cyclists. An approximate 14 
day washout was given. The 
exercise involved a 120 min 
preload followed by a 400-
kcal TT.     
500ml/day of BR juice 
(~0.5g of NO3
-) per day 
for 6 days. PL was a 
blackcurrant cordial. Day 
6 was consumed 3h prior 
to exercise.  
NOx = 159 ± 103 
and 40 ± 7 μM 
 
N/A ↔V̇O2 kinetics 
↔ TT performance  
 
No 
Fulford et al. 
(2013) 
8 healthy male subjects. A 
minimum of a 14 day 
washout. Exercise involved 
two tasks. Repeated MVC 
and short bouts of continuous 
exercise.  
500ml of BR juice (NO3
- 
=10.2 mmol) or PL (NO3
- 
=0.17 mmol) per day for 
15 days. Participants 
arrived 2.5h, 5 and 15 
days post 
supplementation.  
NO2
- = 408 ± 131 
and 232 ± 49 nM 
 
N/A ↔ Force output 
↔Peak contraction 
↔ Mean or End force 
↔Time effect 
Trend for↓ Pcr cost as 
an average (0.06) and 
a ↓ Pcr cost for end 
exercise  
 
Mixed 
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Wylie et al. 
(2013b) 
14 healthy male subjects. A 
minimum 72h washout period 
was used. Exercise involved a 
Yo-Yo IR1.  
BR juice (NO3
- =4.1 
mmol) or PL (NO3
- =0.04 
mmol). Participants 
consumed two shots in 
the morning and two in 
the evening the day 
before testing. On the 
day two shots were 
consumed 2.5h and 1 
shot 1.5h prior to 
exercise.  
NO2
- = 584 ± 343 
and 118 ± 44 nM 
NO3
- =  768 ± 180 
and 25 ± 9 μM. 
 
NO2
- values 
declined by 20% in 
PL and 54% in BR. 
NO3
- rose by 17% 
in PL and 10% in 
BR.  
N/A ↑ Yo-Yo performance 
(4.2%) 
↑ Plasma potassium 
↓Blood glucose levels  
Yes 
Wylie et al. 
(2013a) 
10 healthy male subjects. A 
minimum of 3 days washout 
was given. Exercise involved 
a 2 MI and 1 SI bout on each 
of 6 visits (1 visit per 
condition).    
Participants consumed 
70ml, 140ml and 280ml 
BR juice (NO3
- = 4.2 
mmol) or PL ((NO3
- =0.04 
mmol) per shot).  
NO2
- = 425 ± 225 
and 150 ± 73 nM 
NO3
- = 580 ± 89 
and 130 ± 17 μM. 
↑ in a dose 
dependant manor. 
↓SBP 
(peak at 
4h) 
↓DBP 
(peak at 
4h) 
↓MAP 
(peak at 
1h) 
140 & 280 ↓ steady 
state O2 and time to 
task failure. 
 
 
Yes 
Kelly et al. 
(2013b) 
9 healthy active males. 
Exercise involved 4 SI bouts 
at different % of peak power 
to exhaustion.  
500ml of BR juice (NO3
- 
=8.2 mmol) or PL (NO3
- 
=0.006 mmol) 
NO2
- = 297 ± 98 nM 
and  98 ± 41 nM 
 
N/A ↑ at 60%, 70% and 
80% peak power but 
not 100%. 
↔CP or W’ 
Yes 
Breese et al. 
(2013) 
9 (4 males) healthy subjects. 
A 7 day washout period was 
utilised. NIRS, muscle 
oxygenation and V̇O2 kinetics 
were assessed.  
 
 
 
Participants consumed 
70ml, BR juice (NO3
- = 4 
mmol) or PL ((NO3
- 
=0.002 mmol) per shot) 
in the morning and the 
evening for 6 days. 
 
NO2
- = 348 ± 170 
nM and 65 ± 32 nM 
 
N/A ↑ speed of V̇O2 kinetics 
↑ deoxyhaemoglobin 
kinetics (derived from 
NIRS) 
↑time to task failure  
Yes 
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Hoon et al. 
(2013) 
10 highly trained male rowers. 
Exercise involved a 2000m 
TT.  
Participants consumed 
70ml, BR juice (NO3
- = 
4.2 mmol or 8.4 mmol ) 
or PL (NO3
- = 0 mmol).  
 
Abstract only, 
figures not 
presented. 
N/A ↔ in rowing 
performance 
No 
Muggeridge 
et al. 
(2013a) 
8 healthy male kayakers. 
Exercise included 15m 
paddling at 60% max WR and 
5x10s all out sprints and a 
1km TT.  
Participants consumed 
70ml, BR juice or PL.  
NO2
- = 687.9 ± 20 
and 519.8 ± 25.8  
nM 
NO3
- = 152 ± 3.5 
and 33.8 ± 1.9 μM. 
 
N/A ↔ TT performance 
↔ Peak power 
↓ steady state V̇O2 
 
 
No 
Muggeridge 
et al. 
(2013b) 
9 male trained cyclists.  
Exercise included a 15 ride at 
60% max WR and a 16.1 km 
TT at 2500m simulated 
altitude. 
Participants consumed 
70ml, BR juice or PL 3h 
prior to exercise.  
NO2
- = 678.1 ± 
103.5 and 289.8 ± 
27.9  nM 
NO3
- = 150.5 ± 9.3 
and 39.1 ± 3.5 μM. 
N/A ↓ steady state V̇O2 
↑TT performance  
Yes 
Velmurugan 
et al. (2013) 
24 healthy subjects (12 
males). With a 1-4 week 
washout period.  In vivo and 
in vitro methods were used. 
250ml BR juice or K NO3
- 
(NO3
- = 8 mmol)  vs. PL.  
Figures not 
published. 
N/A ↓Platelet reactivity in 
males but not in 
females. Males have a 
greater dependence 
on the NO- sGC 
pathway.  
Yes 
Lane et al. 
(2013) 
24, Trained cyclists 
completed 4 experimental 
conditions. BR, caffeine, BR & 
caffeine and control. 
Ergometer TT.   
Caffeine  = 3 Kg-1 day-1 of 
body weight and BR (8.4 
mmol) supplementation 
2h prior to testing.  
Abstract only, 
figures not 
presented.  
N/A ↔ in TT performance 
following BR vs. PL. 
No 
Bond Jr et 
al. (2013) 
(Abstract 
only) 
 
12 healthy young african 
americans. Protocol, rest and 
40, 60 and 80% peak V̇O2.  
BR and orange juice as 
placebo.  
Abstract only, 
figures not 
presented. 
↓SBP 
↔DBP 
 
↓ V̇O2 ↔ in RQ, minute 
ventilation and HR 
 
Yes 
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Schiffer et 
al. (2013) 
15 healthy young males. 
Indirect calorimetry.  
Three days (NO3
- = 
0.1mmol Kg-1 day-1) or 
PL (NaCl) 
Published abstract, 
not data presented.  
N/A ↓ metabolic rate 
Plasma NO2
- 
correlates (r 0.7) with 
BMR.  
Yes 
Murphy et 
al. (2014) 
(Abstract 
only) 
13 recreationally active 
males. 10 day washout. 
Protocol, 10 x 6s repeated 
sprints with 30s recovery.  
BR (5 mmol) 
supplementation vs. PL 
2.5h prior to exercise.  
Abstract only, 
figures not 
presented. 
N/A ↔ V̇O2 or fatigue No 
Hoon et al. 
(2014)  
26 well-trained cyclists. 2 x 
4min TT, separated by 75 
mins. 6 day washout.  
70ml BR 75 or 150 mins 
prior to exercise with 
35ml top up following first 
bout.  
Figures not 
published, but 
peaked at 75 mins.  
N/A ↔ in TT performance 
following BR vs. PL. 
Potential negative 
effects.  
No 
Boorsma et 
al. (2014) 
8 elite male 1500m runners. 
7+ day washout. Protocol 
incudes a submaximal run 
and 1500 m TT run. 
 
210ml BR juice for 8 
days 
(NO3
- = 19.5 mmol)  vs. 
PL. 
NO3
- = 870 ± 259 
and 37 ± 15 μM. 
 
N/A ↔ V̇O2 or 
improvement in TT 
performance. 
No 
Peeling et 
al. (2014) 
Study A: 6 male national level 
kayakers completed a 7 x 4 
min lab based step test TT.  
 
Study B: 5 Females national 
level kayakers completed a 
500 m ‘on water’ TT.  
 
Study A: 70 ml BR (4.8 
mmol) or PL (not a true 
PL) 2.5h prior to 
exercise.  
 
Study B: 140 ml BR (9.6 
mmol) or PL (not a true 
PL). 2 h prior to exercise. 
 
Abstract only, 
figures not 
presented. 
N/A ↓ V̇O2 (mod)  
↔ in TT performance 
in the laboratory but  
↑ TT in the field.  
Primary 
outcome not 
stated.  
Richards et 
al. (2014) 
 
7 young adults performed 
hand grip strength at 5, 15 
and 25% of MVC. Doppler 
ultrasound was used to 
assess changes in blood flow.   
 
12.6 mmol BR post 
baseline. Exercise 2 
hours post ingestion.  
Abstract only, 
figures not 
presented. 
N/A ↑ forearm blood flow 
and sig more as % 
MVC went up and also 
in hypoxia 
 
Yes 
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Thompson 
et al. (2014) 
16 recreationally active 
males. 20 min stages at 50%, 
70% V̇O2 peak and exercise to 
volitional exhaustion at 90% 
V̇O2 peak. 7 day washout. 
450ml BR (5 mmol) or 
blackcurrant PL. 
NO2
- = 222 ± 61 
and 124 ± 10 nM 
 
↓ SBP 
↔ DBP 
 
↑ exercise tolerance at 
90% V̇O2peak. 
↔ in RPE, energy 
levels or cognitive 
function.  
Yes 
Martin et al. 
(2014) 
16 recreationally active male 
(9) and females (7). Repeated 
8s sprints with 30s recovery 
until volitional exhaustion.  
70 ml (0.3 g of NO3
-) or 
PL 2h prior to exercise.  
NOx not measured.  N/A ↔ repeated sprint 
performance.  
↓ total work 
No 
Sandbakk et 
al. (2014) 
9 elite male cross-country 
skiers. Sub maximal running 
economy and 5km TT.  
A; L-arginine (6g) & NO3
- 
(614 mg). B; NO3
- (614 
mg) & PL. C; L-arginine 
and PL. 
 
NO2
- = 328 ± 107 
nM and 149 ± 64 
nM 
 
↔ MAP - L-arginine did not 
increase NO2
- 
concentration.  
↔ economy or TT.  
No 
Bond et al. 
(2014) 
13 female African Americans. 
Washout not specified. 
Measures were taken at 
baseline, 40 & 80% V̇O2 peak. 
HR variability measured via 
SD of RR intervals of an 
ECG. Collofello et al. (2014) 
 
500 ml BR (750 mg), PL 
= orange juice. 2h 20min 
prior to exercise.  
NO = 21.1 ± 4.9 
and 4.4 ± 1 nM 
↓ SBP 
 
↑ Heart rate variability 
during exercise.  
 
Yes 
Collofello et 
al. (2014) 
12 healthy females. 20s 
submaximal static apnoea 
with 90s rest followed by a 
max effort apnoea.  
70ml BR juice for 8 days 
(NO3
- = 5 mmol)  vs. PL 
(NO3
- = 0.003 mmol). 2.5 
post ingestion the 
measurement begun.  
NOx not measured 
/ reported.  
↓ SBP 
↔ DBP 
↔ MAP 
↔ maximal static 
apnoea  
No 
Pinna et al. 
(2014) 
14 moderately trained male 
masters swimmers performed 
two incremental swimming 
tests.  
 
500ml BR juice for 6 
days (NO3
- = 5.5 mmol) 
vs. no supplementation.   
NOx not measured 
/ reported. 
N/A ↓ V̇O2 during 
swimming.  
↑ anaerobic threshold 
Yes 
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Bentley et 
al. (2014) 
9 healthy males. fMRI was 
performed at 15% & 25% 
MVC.  
700 ml BR 2.5 h prior to 
exercise scan vs. no 
juice.  
NOx not measured 
/ reported. 
N/A ↓ tissue oxygenation 
maximal change (more 
effective at lower 
intensities) 
↔ recovery rate 
Yes 
Puype et al. 
(2014) 
22 healthy males in 
independent groups (n=11). 6 
week training program. 5 x 
30mins a week sustaining a 
BLa of 4-6 mmol.  
NO3
- = 0.07 mmol Kg-1 
day-1 or PL (apple-
blackcurrant juice) 2.5 h 
prior to each training 
session.   
NO3
- 
concentrations not 
given. Estimate 
from figure = 165 
and 35 μM. 
 
N/A 16% ↑ PO & TT.  
↔ activated AMP, 
glycogen breakdown 
or mRNA variables.  
Yes 
Ferguson et 
al. (2014) 
20 rats were split into 
independent groups. 
Microvascular PO2 was 
measured during 180s of 
electorally induced twitches    
BR juice (NO3
- = 0.08 
mmol Kg-1 day-1) or water 
day-1) 
NO3
- & NO2
- 
concentrations but 
given. Estimate 
from figure =  
NO3
- = 140 and 22 
μM. 
NO2
- = 640 and 200 
nM 
N/A ↔ Microvascular PO2 
↓ O2 driving pressure 
No 
Ashmore et 
al. (2014) 
40 male wister rats. Exposed 
to chronic hypoxia (13%).  
0.7 mmol l−1 NaCl (as 
control) 
or 0.7 mmol l−1 NaNO3,  
Elevated plasma 
NO3
- levels by 80%.  
Figures not given 
but graphical 
representation is.  
N/A Nitrate maintains 
redox state (compared 
to hypoxia) 
↑ ETC protein levels 
↓ Respiration rate,  
↑ ATP 
↑ L-arginine  
Yes 
Muggeridge 
et al. (2014) 
9 trained cyclists. 10 mins sub 
max followed by a 10 mile TT. 
4 conditions, NO3
- GEL and 
UV-A , UV-A and PL, NO3
- 
GEL and sham light and PL 
and sham light  
2 gels (=16.2 mmol), 2.5 
h prior to exercise 
Plasma NO2
- was 
higher for GEL + 
SHAM 332; and 
NIT + UV-A 456 
nM; PL + SHAM 
215. PL 282 nM  
↓ SBP 
↔ DBP 
↓ MAP 
UV-A light and NO3
- 
alters response to 
exercise. UV-A does 
not improve exercise 
performance alone.   
No  
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Kim et al. 
(2014) 
abstract only 
12 young healthy adults. 3h 
post supplementation, 
brachial artery diameter, flow, 
and blood velocity were 
measured (Doppler 
ultrasound) at rest and during 
6 exercise intensities.  
 
140 ml of BR (= 12.9 
mmol) or PL.  
NO3
- 
supplementation 
raised plasma NO3
-  
(19.5-fold) and 
NO2
- (1.6-fold) 
concentrations. 
Values not given. 
 
N/A ↓ PWV.  
↔ brachial artery 
diameter.  
↔ brachial artery flow 
↔ brachial artery 
sheer stress 
Yes 
Carpentier 
et al. (2014) 
13 recreationally active 
males. 20 min at 85% V̇O2 
max 
450 mg potassium NO3
- 
or PL for 7 days.  
Not measured.  N/A ↔ kidney function No 
Porcelli et al. 
(2014) 
21 young male individuals 
(28.2 to 81.7 ml. kg-1. min-1). 
Sub max running and a 
incremental running test. + 3k 
TT 
5.5 mmol of NO3
- per day 
for 6 days.  
NO2
- = 462.3 ± 
249.5 and 265.7 ± 
163.7  nM 
NO3
- = 181 ± 32.7 
and 21.3 ± 3.4 μM. 
N/A A strong negative 
correlation (-0.8) 
between reduction of 
O2 cost of submaximal 
exercise and individual 
aerobic fitness level 
was observed. Strong 
positive correlation 
(0.75) for aerobic 
fitness and increase in 
NO2
- concentration.  
Yes 
Keen et al. 
(2014) 
6 healthy adults. Microdialysis 
fibers on ventral forearm. L-
NAME inhibitor. Laser-
Doppler 
 
70 ml (5 mmol) one a 
day for 3 days  
Not measured. ↓ MAP 
↓ DBP 
↑ NOS independent 
vasodilation to local 
heating 
Yes 
Casey et al. 
(2015) 
13 young and 12 older adults. 
20% MVC during normoxia 
and hypoxia. Forearm 
vascular conductance was 
measured   
140 ml BR or PL (topped 
up with water to 500ml). 
NO3
- content not 
assessed.  
Precise figures not 
given. State that it 
increased 
significantly P < 
0.0001.  
N/A ↑ compensatory 
vasodilatory response 
to hypoxia in older but 
not young adults 
Yes 
177 
 
Levitt et al. 
(2015) 
7 healthy males. Microdialysis 
fibers on ventral forearm. L-
NAME inhibitor. Whole body 
heating  
70 ml (5 mmol) one a 
day for 3 days 
Not measured. ↓ MAP  
↓ SBP 
↔ DBP 
(during 
heat 
stress) 
↔ skin blood flow 
↑ vasodilation in the 
skin 
No 
Rocha et al. 
(2015) 
2 healthy adults and male 
Wister rats (n not specified). 
Gastric head space was 
sampled for ethyl NO2
- and 
smooth muscle relaxation in 
the rats 
50g of lettice and wine or 
whiskey 
NO particles per 
billion. Figures not 
given but in 
graphical 
representation.       
N/A Nitrosation of ethanol 
produced ethyl NO2
- in 
the stomach after wine 
and whiskey when 
consumed with NO3
- 
rich foods.  
Yes 
Kocoloski 
and 
Crecelius 
(2015) 
6 young, moderate active 
males. Performed a ramp test 
and 45 min moderate 
exercise (38% max).  
70 ml 0.4g NO3
- 2 hours 
prior to exercise. Placebo 
was created via the use 
of mouthwash.   
 
Abstract only, 
figures not 
presented. 
↓ MAP ↔ O2 cost 
 
No 
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Table 13, B. Nitrate supplementation studies in healthy older adults.  
Author Participants & Protocol  NO3
- supplement Plasma NO3
- & 
NO2
- 
concentration (BR 
vs. PL 
respectively)   
BP changes Exercise 
efficiency or 
performance 
and/or clinical 
relevance 
Primary 
outcome 
successful? 
Treichler et 
al. (2015) 
abstract 
only 
13 young and 12 older 
normotensive adults. Aortic 
BP and wave reflection were 
assessed.  
Data not available. Looks 
like the same cohort as 
Casey et al., 2015.  
Precise figures not 
given. State that it 
increased 
significantly P < 
0.0001 
↓ SBP 
↓ DBP 
 
↓ central aortic 
pressure 
Yes 
Jajja et al. 
(2014)* 
21 older healthy participants 
had BP measured over a 4 
week period with 3 different 
measures. Resting clinic BP, 
24 hour ambulatory BP and 
home monitoring.  
70 ml (300 mg of NO3
-) 
or PL (blackcurrant juice) 
2h prior to exercise. 
NO3
- 
concentrations not 
given. Estimate 
from salivary figure 
= 6 mmol/l and 1.2 
mmol/l. 
↔ Resting 
clinic BP, 24 
hour 
ambulatory 
BP. 
↓ Home SBP 
 Yes 
Kelly et al. 
(2013a)* 
12 healthy older adults (64 ± 
4 years). Minimum of a 72h 
washout. Exercise involved a 
6MWT, cognitive function 
tests and a symptom limited 
ramp test.  
 
70ml BR juice (NO3
- =4.8 
mmol) or PL (NO3
- =0.01 
mmol) twice a day for 2.5 
days.  
NO2
- = 1,037 ± 627 
and 248 ± 182 nM 
 
↓SBP 
↓DBP 
↓MAP 
 
↔ O2 cost of 
exercise 
↔Cognitive 
function 
↔ 6MWT 
↔Brain 
metabolite 
concentrations  
↑V̇O2 kinetics 
No 
Miller et al. 
(2012). 
(Abstract 
only) 
13 older (72.5 ± 4.7 years) 
healthy adults (8 males & 5 
females). BP and NO3
- & NO2
- 
were measured before each 
meal and hourly for 3h post.  
Supplementation 
involved 3 days of LNF 
and BR juice, HNF and 
HNF & BR juice.  
↑ NO3
- & NO2
- with 
foods and 
supplement 
↓SBP All treatment arms 
↓SBP in older 
adults.  
Yes 
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Bondonno 
et al. 
(2014b)* 
38 (60.6 ± 7 years) healthy 
older adults. Ambulatory, 
home and office BP 
measured. Arterial stiffness  
 
Dietary intervention. Low 
and high NO3
- diets. High 
diets = > 300mg/day. 
Low diet < 100 mg/day.  
NO2
- = 2 ± 1.5 and 
8 ± 6.5 μmol/L.  
 
↔ SBP  
↔ DBP 
Ambulatory BP ↔ 
Home BP ↔ 
office BP ↔ 
No 
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Table 13, C. Nitrate supplementation studies in clinical populations.  
Author Participants & Protocol  NO3
- supplement Plasma NO3
- & 
NO2
- 
concentration (BR 
vs. PL 
respectively)   
BP 
changes 
Exercise 
efficiency or 
performance 
and/or clinical 
relevance 
Primary 
outcome 
successful? 
Kapil et al. 
(2015)* 
68 hypertensive adults. 2 
week washout. BP measured 
at clinic, ambulatory and 
home (34 in independent 
groups, BR and PL).  
250ml BR or PL. 6.4 
mmol. Once per day for 4 
weeks.  
Figures not given.  ↓SBP 24h 
ambulatory 
and home.  
 
Improved 
endothelial 
function. 
Measured via 
FMD. PWV not 
altered.  
 
 
Yes 
Gilchrist et al. 
(2014)* 
27 individuals with T2DM. 
Protocol includes a battery of 
5 cognitive function tests. 
250 ml (7.5 mmol) vs. PL 
(0.002 mmol) daily for 2 
weeks.  
NO2
- = (IQR) 390 
and 232 nM 
NO3
- = 150 and 
31μM. 
 
 
N/A ↓ simple reaction 
time 
 
No 
Zamani et al. 
(2015)* 
17 individuals with heart 
failure. Supine V̇O2 max with 
measures of cardiac output 
and skeletal muscle 
oxygenation.(5 day washout 
period) 
A single dose of NO3
- 3 
hours prior to exercise 
(12.9 mmol). 
Data not given.  N/A ↑ ejection 
fractions  
↔ O2 cost of 
exercise 
↓ arterial wave 
reflections 
Tendency to 
improve 
mitochondrial 
efficiency.  
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Gilchrist et al. 
(2013)* 
27 (18 males). T2DM 
subjects. A four week 
washout period was utilised. 
24h ambulatory BP was 
taken. Macro & Microvascular 
endothelial fiction measures 
were assed 
250ml of BR juice (NO3
- 
=7.5 mmol) or PL (NO3
- 
=0.002 mmol) a day for 
14 days.  
BR & PL were consumed 
with their evening meal 
to prevent 
hyperglycaemic events.  
NO2
- = 537 and  
390  nM  
NO3
- = 150 and 31 
μM. 
 
 
↔SBP 
↔DBP 
↔MAP 
 
↔ Micro or 
Macro vascular 
function.  
No 
Shepherd et 
al. (2015)* 
Experimental 
chapter 2. 
13 individuals with COPD. 
80% GET. BP and 6MWT 
70 ml of 6.77 mmol twice 
daily for 2 days. Plus 70 
ml ~3h prior to exercise.  
 
NO3
-  
215 and 48 μM 
↔ SBP  
↔ DBP 
↔ O2 cost 
↔ 6MWT 
No 
Berry et al. 
(2014)* 
15 individuals with COPD. 
Sub-maximal 75% max work 
rate.  
140ml BR juice  
(NO3
- = 7.58 mmol)  vs. 
PL (prune juice) 2.5h 
prior to exercise.  
NO2
- increased by 
379% accurate 
values not 
presented. 375nM 
and 175 nM 
(estimates from fig) 
↓ SBP 
↔ DBP 
 
↑ exercise iso-
time 
↔ sub-max V̇O2 
↔ dyspnoea  
↔ dynamic 
hyperinflation 
Yes 
Kerley et al. 
(2015)* 
11 individuals with COPD. 
Incremental shuttle walk test 
and BP 
140 ml (12.9 mmol) 3h 
prior to test plus 
blackcurrant juice. Vs PL 
= water and blackcurrant 
juice 
 
NO2
- = 751 and 139 
nM 
NO3
- = 508 and 56 
μM. 
↓ SBP 
↓ DBP 
↓ MAP 
↑ Incremental 
shuttle walk test 
Yes 
. 
 
 
↑ = statistical significant increase; ↔ = no statistical reduction; ↓ = statistical significant reduction; V̇O2 = oxygen uptake; V̇O2peak = peak oxygen uptake; WR = work rate; GE = 
gross efficiency; DE = delta efficiency; SBP = systolic blood pressure, DBP = diastolic blood pressure; MAP = mean arterial blood pressure; IR = ischemic reperfusion, FMD =  
flow-mediated dilation; PWV = pulse wave velocity; MI = moderate intensity; RPE = rating of perceived exertion ; SI = severe intensity; LI = low intensity; HI = high intensity; PCr 
= phosphocreatine; Pi = inorganic phosphate; ADP = adenosine diphosphate; ATP = adenosine triphosphate; GET = gas exchange threshold; PAD = peripheral arterial 
disease; cGMP = cyclic guanosine monophosphate; SaO2 = arterial O2 saturation; Tlim = limit of tolerance; P/O ratio = phosphorylation efficiency; PO = power output; TT = time 
trial;  TTE = time to exhaustion; LNF = low nitrate food; HNF = high nitrate food; PO2 = partial pressure of oxygen; DMBA = dimethoxybenzaldehyde (a powerful organ-specific 
laboratory carcinogen); NIRS = near infrared spectrometry and sGC = Soluble guanylate cyclase; RQ = respiratory quotation; MVC = maximal voluntary contraction; ETC = 
electron transport chain. Where NO3
-
 & NO2
- 
values are given it is from the final supplementation period if multiple doses given. 
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General issues in the NO3
- literature  
A major limitation of the majority of the inorganic NO3
- supplementation literature (n= 
53) regardless of the outcome measure is that they have small sample sizes (mean 
of 14.2 ± 9.4, with a range of 7 - 68 as of 01/12/14). Moreover, Kapil et al. (2015) 
who had the largest n (68) used a parallel group design. The largest crossover 
design (apart from experimental chapter 1; n = 48) examined blood pressure 
changes following NO3
- in older adults. The cohort size was 38 (Bondonno et al., 
2014b). Reporting of power calculations and confidence intervals are rare. This 
makes determination of effect sizes difficult. The lack of power in assessing BP 
changes following NO3
- supplementation has been somewhat explored by meta-
analysis by Siervo et al. (2013). His findings showed an association for a significant 
reduction in systolic blood pressure of 4.4 mmHg. However, larger sample sizes 
would elucidate more definitive conclusions.  
Assay variation is still an issue within the NO3
- research community. Kapil et al., 
(2011) was the first study to report plasma NO2
- concentration in the μM range in an 
unsupplemented or placebo condition. Since the beginning of this body of work two 
further studies have reported plasma NO2
- concentration in the μM range (Bondonno 
et al., 2014b, Masschelein et al., 2012). The values reported in these studies 
(Bondonno et al., 2014b, Masschelein et al., 2012, Bescos et al., 2011) are unlikely 
to be accurate given that dietary intake accounts for ~1 - 2 mmol of NO3
- per day 
(ECETOC., 1988). Moreover, these studies gave a much lower dose of NO3
- than 
Webb et al. (2008a)  Wylie et al. (2013b) Kapil et al. (2011) who gave the largest 
doses of NO3
- (~20 mmol) to date and did not reach the μM range post NO3
- rich 
beetroot juice supplementation.     
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Nitrate supplementation and effects on plasma NO2
- concentration  
Baseline plasma NO2
- concentration varied markedly between cohorts in this body of 
work. The healthy young individuals had a mean baseline plasma NO2
- concentration 
of 218 nM while the healthy older adults had a mean of 171 nM. These 
concentrations rose following NO3
- rich beetroot juice to 715 and 968 nM, 
respectively. These concentrations are within the expected range given the peer 
reviewed literature (Kelly et al., 2013a, Sandbakk et al., 2014, Muggeridge et al., 
2013b). Moreover, the pharmacokinetic responses and peak plasma NO2
- 
concentration were similar to a profile from a cohort of young healthy individuals 
previously published (Wylie et al., 2013a). Interestingly, the baseline plasma NO2
- 
concentrations of individuals with T2DM were significantly elevated (see figure 32). A 
detailed discussion of the possible ramifications and explanations of an elevated 
baseline are explored in the discussion of experimental chapter 1. However, 
previous reports reviewed by Vanhoutte (2009) suggest that NO∙ concentration is 
reduced in individuals with T2DM. This is brought about via a reduced production of 
NO∙ via eNOS (Vanhoutte, 2009). The reduction in eNOS activity is likely due to 
endopenetration by macrophages, cellular growth and atherosclerosis (Voetsch et 
al., 2004, Li et al., 2002). If eNOS activity is reduced, explanations for the high 
concentrations of plasma NO2
- found in experimental chapter 1 consist of; an 
habitual up-regulation of iNOS activity in this population (Krause et al., 2012), the 
elevated oxidative stress prevalent in individuals with T2DM (Stadler, 2013) which 
would be expected to result in an increase in the scavenging of NO∙, leading to 
higher NO2
- concentrations or medications which increase NOS activity (Davis et al., 
2006, Ceconi et al., 2007, Andrade et al., 2013).   
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Figure 32. Baseline plasma NO2
-
 concentration for young adults, older adults and individuals with 
T2DM.  
Shows the baseline plasma NO2
-
 concentration for all samples collected from this body of work for 
young adults (green triangles), older adults (red squares) and individuals with T2DM (blue diamonds).   
 
NO3
- supplementation and its effect on exercise in individuals with T2DM.  
The O2 requirement of exercise is a key determinant of an individual’s ability to 
tolerate exercise (Whipp et al., 1981). By reducing the O2 cost of exercise the 
individual will be further away from the maximal O2 uptake and thus, will feel less 
physiological stress and will fatigue slower (Regensteiner et al., 1998, Regensteiner 
et al., 1995a). The aetiology of fatigue in individuals with T2DM is predominantly due 
to deficiencies in O2 delivery (Regensteiner et al., 1998, Regensteiner et al., 1995b, 
Scognamiglio et al., 1998). These deficiencies in delivery of O2 include; 
transportation from the lungs (Scognamiglio et al., 1998), reduced stroke volume 
(Gusso et al., 2008), cardiac autonomic function (Gerritsen et al., 2001) and reduced 
O2 extraction in the mitochondria (Baldi et al., 2002; MÅrin et al., 1994; O. Mathieu-
Costello et al., 2005; Padilla et al., 2007; J. Regensteiner, G et al., 1998; J. 
Regensteiner, G et al., 1995).  
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Reducing the O2 cost of exercise or improving the kinetics of O2 uptake in any 
clinical population would likely have important implications. By reducing the O2 cost 
of exercise it may be possible to improve the quality of life in these patients.  An 
individual’s V̇O2 kinetics and the O2 deficit are key determinants to the individual’s 
ability to tolerate exercise (Jones and Poole, 2005). For example, by speeding the 
uptake of O2 so the individual attains a steady state V̇O2, the greater the contribution 
of a oxidative metabolism compared to an anaerobic contribution (Jones and Poole, 
2005). By using oxidative metabolism compared to an anaerobic metabolism the 
speed that lactic acid concentrations build up is slowed (Bruton et al., 1998, Pate et 
al., 1995, Westerblad et al., 1997, Wiseman et al., 1996).  
We reported no difference between the active and placebo conditions for the V̇O2 
responses (kinetics, O2 deficit or the O2 cost of exercise) to moderate intensity 
walking exercise in experimental chapter 1. This is in contrast to much of the 
literature which has described a reduction in steady state O2 cost of moderate 
intensity exercise (Bailey et al., 2009, Vanhatalo et al., 2010, Lansley et al., 2010). 
No reduction in the O2 cost of exercise has been reported in any clinical population 
to date (Berry et al., 2014, Zamani et al., 2015) (including experimental chapters 1 
and 2) whilst other studies examining the effect of NO3
- supplementation in clinical 
populations have not looked at the O2 cost of exercise and have focused on exercise 
capacity in terms of walking performance (Kenjale et al., 2011, Kerley et al., 2015). 
Nitrate supplementation has also been shown to improve cardiac output and stroke 
volume in heart failure patients (Zamani et al., 2015) but not reduce the O2 cost of 
exercise. 
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There was no difference between the active and placebo juice conditions for the 
distance covered in the 6MWT. Walking performance, however, has been improved 
following NO3
- supplementation in other clinical populations such as peripheral artery 
disease and COPD (Kenjale et al., 2011, Kerley et al., 2015, Berry et al., 2014). 
Potential reasons for the lack of effect in individuals with T2DM include: an elevated 
baseline plasma NO2
- concentrations, reduced NO∙ bioavailability due to higher 
levels of oxidative stress or pathological consumption of NO2
- during exercise and 
medications.   
This cohort was split for drug classification (ACEi/ARB, metformin, insulin and 
statins; other drug sample sizes too small), no effect on plasma NO2
- concentration, 
walking performance, O2 cost of exercise or blood pressure were found. It is 
therefore unlikely that medication is having an effect on these outcomes (note: we 
were not powered to find these effects). Unfortunately, in experimental chapter 1, 
plasma samples were only taken prior to exercise. A detailed pharmacokinetic study 
of NO2
- concentration levels during exercise (Rassaf et al., 2010) may elucidate the 
speed of change plasma NO2
- in this cohort. Diminished NO∙ bioavailability due to 
oxidative stress maybe the reason for the lack of effects following NO3
- 
supplementation in individuals with T2DM. Restoring balance to the redox state in 
individuals with T2DM (prior to nitrate supplementation) may prolong the half-life and 
thus, bioavailability of NO∙.   
Nitrate supplementation in individuals with COPD and A critical appraisal of the 
literature.  
Recently Berry et al. (2014) and Kerley et al. (2015) examined the effect of NO3
- rich 
beetroot juice supplementation vs. prune juice or water (respectively: as a placebo) 
in individuals with COPD. In experimental chapter 2 (NO3
- and COPD) logistical 
187 
 
restraints prevented the measurement of plasma NO2
- concentration. Berry et al. 
(2014) and Kerley et al. (2015) reported significantly elevated plasma NO3
- and NO2
- 
concentrations compared with placebo. This indicates that the entero-salivary 
pathway is operational in people with COPD. 
Berry et al., reported reductions in resting systolic BP, iso-time BP, end exercise 
diastolic BP. Whilst Kerley et al., report reductions in systolic, diastolic blood 
pressure and MAP following NO3
- supplementation compared to placebo. Following 
placebo (water) Kerley et al., showed a statistically significant increase in systolic (3 
mmHg) diastolic (9 mmHg) blood pressure and MAP (7 mmHg). Berry et al., reported 
an improvement in exercise tolerance (i.e. lengthened time to exhaustion during 
submaximal constant rate).  
Kerley et al., report improved distance covered in an incremental shuttle walk test 
following NO3
- rich beetroot juice compared to placebo. The placebo condition 
significantly decreased walking performance by 7.6% from baseline. The significant 
change in outcome measures (blood pressure and exercise performance) following 
placebo in the Kerley et al cohort is difficult to explain given the ‘double-blind’ nature 
of the trial. The O2 cost of exercise was not assessed in this study.  Berry et al., do 
not show a reduction in the O2 cost of exercise which is consistent with experimental 
chapter 2. However, with no reduction in the O2 cost of exercise, it is not clear what 
mechanism underpins the improved time to exhaustion reported by Berry et al. 
(2014) and Kerley et al. (2015). 
A potential reason for the improvement seen in walking performance that does not 
reflect a reduction in the O2 cost of exercise maybe an increase in the delivery of O2 
to the working muscle (Ferguson et al., 2014, Ferguson et al., 2013). This would 
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mask any reduction in the O2 cost of exercise and help to improve exercise 
performance. However, given the lack of evidence in the experimental chapters 1 
and 2, we were either underpowered to detect this or this is not the mechanism for 
the improvement in walking performance.       
Although these studies in the literature highlight the potential for NO3
- 
supplementation to be beneficial to individuals with COPD in terms of blood pressure 
reduction and improved walking performance these studies have major limitations. 
Of paramount importance with both studies is a lack of a true placebo as used in 
experimental chapter 2. Given the substantial media attention given in the scientific 
literature, written press and on the television in recent years describing the beneficial 
effects of beetroot juice for exercise performance/economy and blood pressure it is 
impossible to rule out a placebo effect for knowledgeable and enthused volunteers. 
In informal discussions with the cohort of volunteers in the present trials, many of the 
participants in this body of work were aware of the putative beneficial effects of 
beetroot prior to receiving the participant information sheets. An example published 
on the 29/06/2010 in the daily mail online (DailyMail, 2013) had a headline which 
read: beetroot juice ‘could save your life’. Secondly, the antioxidant content of prune 
juice and water are likely to be significantly different to beetroot juice (Donovan et al., 
1998). This change in antioxidant content may affect NO∙ bioavailability (Bondonno 
et al., 2012) due to reduced scavenging of NO∙. This may increase the half-life on 
NO∙ in diseased populations. Berry et al., matched the calorie content of the different 
juice supplementation to control for the performance benefits of carbohydrate 
availability. Kerley et al., did not match this and had a 120 kcal difference between 
the conditions. However, this is unlikely to be the reason for the improvement given 
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evidence from Vermeeren et al. (2001) who demonstrated a 250 kcal supplement did 
not improve submaximal cycling performance in individuals with COPD.  
Berry et al., used an iso-time to established the O2 cost of exercise. This method 
takes an average of the last minute of O2 consumption of the shorter exercise period 
and compares to the longer exercise period. These averages were then compared. A 
methodological weakness exists in Berry et al’s assessment of the O2 cost of 
exercise. Using one minute of data is not a robust measure of the O2 cost of 
exercise. Towards the end of an exercise session coughing and spluttering as you 
fatigue is common (Lamarra et al., 1987). Typically, 6 minutes of steady state V̇O2 is 
used with multiple transitions to improve repeatability of the measure. This cohort of 
individuals have severe respiratory dysfunction as described in the introduction. This 
will increase the variability of data and given the short period of assessment this will 
magnify the variability. Given this, it is unlikely that this method of assessment of iso-
time assessment of O2 uptake is appropriate in this cohort of participants.  
While the findings from Berry and Kerley were of interest, they were not replicated in 
a truly double blind trial and, in part, do not utilise the most robust measurement for 
O2 uptake dynamics.   
Although many mechanisms were explored for the lack of effect on the O2 cost of 
exercise in the discussion of experimental chapter 2, a further possible explanation 
exists. In individuals with COPD, increasing the bioavailability of NO∙ (NO∙ gas in this 
study) may increase venous return and caused elevated pulmonary artery pressure 
in heart failure patients (Ichinose et al., 2004). By elevating pulmonary artery 
pressure, gas exchange may be slowed which may prevent the reduction in the O2 
cost of exercise that was hypothesised. However, the inorganic molecule GTN (in 
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dogs), has been shown to reduce pulmonary artery hypertension (Kim et al., 2010). 
More research is needed in this area to establish whether increasing NO∙ 
bioavailability increases or decreases pulmonary artery hypertension. Conversely, it 
may be due to the differing effects of the pharmacokinetic and dynamic responses of 
inorganic vs. organic NO3
-/ NO2
- and not the bioavailability of NO∙ (Omar et al., 
2012).       
Nitrate supplementation and blood pressure in other clinical populations.  
The gold standard measurement of blood pressure is 24h ambulatory blood pressure 
monitoring. For ease of measurement repeated rested brachial artery BP was used 
for all experimental chapters. This method can be susceptible to the white coat 
syndrome (Pickering, 1996). Given the timing of blood pressure measurement 
(described in the experimental chapters) it coincided with peak plasma NO2
- (Wylie 
et al., 2013a) which would give the optimal chance for observing any blood pressure 
reductions.  
Recently, the results from a 24h ambulatory blood pressure monitoring protocol 
following NO3
- supplementation or placebo were reported in a group of individuals 
with T2DM. The authors reported no reductions in blood pressure (Gilchrist et al., 
2013). The mean change in systolic blood pressure was 0.5 mmHg. This is similar to 
the effect shown in systolic blood pressure in experimental chapter 1 (-2 mmHg). A 
recently reported phase II trial in hypertensive adults following NO3
- supplementation 
was published. The trial by Kapil et al. (2015) is the largest NO3
- supplementation 
study, in any population to date (apart from experimental chapter 1). Clinic BP, home 
BP and 24h ambulatory blood pressure monitoring was employed. They showed in a 
phase 2, randomised, parallel group design that 4 weeks of NO3
- supplementation 
causes a reduction in diastolic (2.4 – 3.8 mmHg depending on method) and systolic 
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blood pressure (7.7 – 8.1 mmHg depending on method). Following withdrawal of 
NO3
-, BP returned to baseline levels. One study has looked at the effect of NO3
- 
supplementation in 8 individuals with peripheral artery disease. Kenjale et al. (2011) 
reported reductions in diastolic blood pressure at rest and during exercise. No 
reductions in systolic blood pressure or MAP were present.  
Nitrate supplementation and blood pressure in healthy individuals.  
Varying reports of the blood pressure lowering effects of NO3
- supplementation have 
been reported in young healthy individuals. In experimental chapter 3 we report no 
reductions in systolic or diastolic blood pressure following acute supplementation of 
NO3
- rich beetroot juice in young healthy individuals. This is similar to some of the 
studies (Wilkerson et al., 2012, Coles and Clifton, 2012, Sandbakk et al., 2014) 
whilst most have reported reductions (Webb et al., 2008a, Vanhatalo et al., 2010, 
Vanhatalo et al., 2011, Lansley et al., 2010, Lansley et al., 2011a, Engan et al., 
2012, Wylie et al., 2013b, Thompson et al., 2014, Muggeridge et al., 2014, Keen et 
al., 2014, Levitt et al., 2015, Treichler et al., 2015, Kocoloski and Crecelius, 2015, 
Bond Jr et al., 2013, Bond et al., 2014). There does not appear to be obvious 
differences in age, BMI, disease status, ethnicity or physical activity level between 
the studies who found a reduction and those that did not.   
In experimental chapter 3 systolic and diastolic blood pressure were assessed as a 
secondary outcome measure. These data confirms the findings described by 
Bondonno et al. (2014b) who found no effect of NO3
- supplementation on systolic 
blood pressure. Kelly et al. (2013a),  Jajja et al. (2014)  and two other studies have 
shown reductions in systolic blood pressure in an healthy older adult population 
however, only abstracts are available online (Miller et al., 2012, Treichler et al., 
2015). However, these studies are the only other studies to examine the effects of 
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NO3
- in an older adult cohort. Kelly et al., and the data from experimental chapter 3 
report a 5 mmHg drop whilst Jajja et al. (2014) report a 7 mmHg drop in systolic 
blood pressure compared to baseline. It should be noted that Jajja et al., did not use 
a true placebo and did not find reduction using 24 hour blood pressure monitoring or 
clinical blood pressure assessment. Bondonno et al., cohort had a mean age of ~60 
but there range was from 38-70 years old. Moreover some participants were on 
antihypertensives. A discussion on drug therapy and its effects on NO3
- 
supplementation (and study outcomes) can be found in the discussion sections of 
experimental chapters 1 and 2. Bondonno et al.,  also used (predominantly) green 
leafy vegetables to increase the NO3
- dose in each individual’s diet. Although it is 
relatively easy to estimate the NO3
- content of foods, it is much harder to standardise 
the dose. NO3
- content of different crops could have different concentrations 
depending on growth rate (Rodgers and Barneix, 1988) although this is not always 
the case (Mattsson et al., 1991). Kelly et al., report a statistically significant 3 mmHg 
drop in diastolic blood pressure whilst we report a non-significant 2 mmHg drop. Jajja 
et al. (2014) report no change in diastolic blood pressure. A larger trial examining the 
effect in older adults is required to examine the efficacy of NO3
- supplementation in 
normotensive older adults. If NO3
- lowers blood pressure it may prevent/delay the 
onset of hypertension.  
Nitrate supplementation, portal vein flux, velocity and hepatic diffusion and glucose 
concentration  
Camilleri et al. (1985) described the uptake of solids and liquid foods from the 
stomach (see figure 33). At 1 hour the food has started to be absorbed with ~ 60% of 
the fluids taken up and 20% of the solids. At 2 hours 65% of the solids have been 
taken up and 90% of the fluids. At 3 hours both the fluids and solids have been 
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absorbed. Thus it is likely that hepatic blood flow and importantly, peak glucose 
concentration would occur at 2 hours.  
 
 
 
 
 
 
 
 
 
 
Figure 33. Uptake of liquids and solids from the stomach.  
This figure is from Camilleri et al. (1985) with the appropriate rights from the publishers.  
 
As glucose and other micro nutrients are absorbed through the stomach and 
proximal small intestine, nitrite is simultaneously absorbed. Peak plasma nitrite 
concentrations occur at 2 – 2.5 hours (Wylie et al., 2013a, Webb et al., 2008a). The 
nitrite along with the nutrients will meet within the portal vein from tributaries of the 
stomach, proximal small intestine and the spleen. Blood from the portal vein, having 
already been through vascular beds will be deoxygenated. Deoxyhaemoglobin is a 
nitrite reductase (Cosby et al., 2003). Therefore, NO∙ bioavailability would be 
expected to increase and thus vasodilate the portal vein leading to an increase in 
flux.  
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The liver has many nitrite reductases. Neuroglobin and cytoglobin are in small 
concentrations and therefore may not have a meaningful effect (Reeder, 2010, Omar 
and Webb, 2014). However, xanthine oxide and aldehyde oxidase are in much 
higher concentrations (Martin et al., 2004, Li et al., 2008b). Increase in the 
bioavailability of NO∙ has the potential to have significant biological effects within the 
liver. NO∙ has previously been shown to mediate the uptake of glucose into skeletal 
muscle (Merry et al., 2010) and mediate its uptake from the intestines via incretins 
(Guan et al., 2003) into the circulation. Moreover, a study by Carlstrom et al., 
showed that in eNOS deficient mice that 10 weeks of nitrite supplementation in their 
drinking water, redcued HbA1c, baseline glucose concentrations and post prandial 
glucose concentrations (Carlström et al., 2010). In healthy humans and in individuals 
with T2DM, a NOS inhibitor has shown a reduction in the uptake of glcusoe within 
the exercising skeletal muscle (Kingwell et al., 2002). It is therefore possible or even 
probable (given the elevated NO∙ and glucose concentrations) that it will help 
mediate the uptake of glucose in to hepatic tissue along with skeletal muscle. In vitro 
work on liver cells may help to elucidate this mechanism. GLP-1 and incretins in 
general appear to be interlinked in many biological processes such as increasing 
glucose utilisation (in an NO∙ dependant mechanism) (Chai et al., 2012) and 
production of NO∙ in the portal vein (Ding, Zhong, Xu, & Isales, 2004). By elevating 
the NO∙ bioavailability we may increase GLP-1 and vice versa (Post et al., 2010) and 
thus facilitate uptake of glucose (Bhashyam et al., 2010) into cells leading to lower 
blood glucose concentrations.   
Experimental chapter 3 shows that dietary NO3
- supplementation did not alter portal 
vein flux, velocity or hepatic diffusion. The hepatic arterial buffer response described 
by Hwang (2011) suggests that the hepatic artery can vasodilate in response to the 
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portal vein. Therefore if the portal vein changes in flow the hepatic artery responds 
with constriction of relaxation (Hwang, 2011, Lautt et al., 1990). The buffer response 
can only compensate for 25-60% of alterations in blood flow from the portal vein 
(Lautt, 1980, Lautt, 1977). The primary reason behind this mechanism is to maintain 
a constant perfusion rate from organs such as the stomach, spleen and intestines 
(Lautt, 1980, Lautt, 1977). Therefore dietary NO3
- has the capacity to affect up to 
75% of flow to the liver. This may be a potential reason why we saw no effect in this 
study.  
Methodological issues / limitations with experimental chapters.  
The link between NO∙, glucose uptake, insulin and incretin release has been 
discussed in depth with in experimental chapter 3 and the general discussion. 
Samples for incretin and insulin quantification for experimental chapter 3 have been 
stored. Unfortunately, we did not secure the funding to analyse these samples and 
this should be recognised as a limitation of the study and thesis in general.   
Hepatic ADC analysis 
From repeatability analysis involving multiple regions of interest it appears that to 
gain an accurate and repeatable ADC, the region of interest needs to be away from 
large vessels such as the right branch of the hepatic vein and the anteroinferior 
branch of the portal vein. The closer the ROI to the vessel the more unpredictable 
the ADC becomes. Potentially due to a higher variability of flow in larger blood 
vessels compared with a constant flow in the liver parenchyma.  
The area in red and its close surrounding allow for reproducibility. The closer you get 
to the black box the more variable the data becomes.  
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Figure 34. Depicts a slice of a liver from a representative participant. The highlighted 
boxes shows the regions of interest with the best and worst repeatability.  
Future work 
The results from this body of work have helped to answer many questions and has 
raised others. Notably, the pharmacokinetic response of older adults, the potential 
for blood pressure reductions in older adults, antioxidants in individuals with T2DM 
and critically the effect of dietary NO3
- on plasma glucose concentration.  
Antioxidants in clinical populations.   
Previously it has been demonstrated that the beneficial effects of beetroot juice can 
be predominantly explained by its large NO3
- content (Lansley et al., 2010). It has 
been suggested that polyphenols (in vitro) may have a beneficial antioxidant effects 
(Kanner et al., 2001). Given the pro-oxidant state of many clinical populations a 
supplement that could help to re-balance the redox state could help to prolong the 
NO∙ half-life. If this is possible then the hypothesis in experimental chapter one with 
improved efficiency in individuals with T2DM could be revisited. Thus enabling 
individuals with T2DM to gain from the mitochondrial adaptations that healthy young 
adults appear to benefit from.       
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Pharmacokinetic response in older adults and a phase II trial.  
In experimental chapter 3 the data show that plasma NO2
- concentrations are 
continuing to rise after 2 hours and peak at 3. This suggests that plasma NO2
- 
concentration may rise beyond 3 hours which has only been shown once before 
(Kapil et al., 2011) with a peak at 6 hours. Future work should try to elucidate the 
precise pharmacokinetic response to dietary NO3
-. In experimental chapter 3, 
systolic blood pressure was reduced. This coincided with peak plasma NO2
- 
concentration. If the conversion of NO3
- to NO2
- continues past 3 hours this 
hypotensive effect may continue.  
Three small studies to date have consistently shown a reduction in blood pressure of 
normotensive, drug naive older adults. A larger phase II trial in normotensive adults 
would help to characterise the blood pressure reductions shown in this work and by 
Kelly et al. (2013a) and Jajja et al. (2014). Dietary NO3
- supplementation could slow 
the onset of hypertension in healthy older adults. The potential to save the NHS 
money on treatment of hypertension and the associated diseases caused via 
hypertension is vast. A health economist should also be used to assess any potential 
savings.       
Plasma glucose concentration 
The potential to reduce the plasma glucose concentration following a NO3
- rich meal 
compared to baseline has been shown in experimental chapter 3. Nitrate-rich 
beetroot juice reduced plasma glucose concentration levels where placebo did not. 
However, this experiment did not show a reduction at two hours post 
supplementation and a standardised meal between conditions. Although the data are 
not unequivocal it does raise the possibility of a reduction in postprandial glucose 
concentrations and should be assessed again in larger numbers of healthy older 
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adults. This could help to prevent delay the onset of insulin resistance and even 
T2DM. If the findings are replicated then a trial in individuals with T2DM would be of 
interest. The potential to reduce plasma glucose concentrations in this cohort could 
help to manage the disease and has the potential to save the NHS vast amounts of 
money in treatment costs. Although this would require a significant increase in the 
nationwide uptake of NO3
- supplementation. A phase II trial would be the next step in 
this process. This may be easier to achieve via pharmacological means i.e. sodium 
or potassium NO3
- than NO3
- rich beetroot juice or increasing the intake of NO3
- rich 
vegetables.  
Summary and conclusion of findings in this body of work  
This is the first body of work to assess the effect of dietary NO3
- supplementation on 
the O2 cost of exercise in individuals with T2DM and COPD with a true placebo. 
Supplementation of the diet with dietary NO3
- does not reduce the O2 cost of walking 
(in individuals with T2DM) or cycling (in individuals with COPD), improve distance 
covered in the 6MWT or reduce BP in individuals with T2DM or COPD. This body of 
work is the first to assess the effect NO3
- rich beetroot juice on hepatic blood flow. 
Dietary NO3
- does not affect liver diffusion, portal vein flux or velocity, reduce 
systolic, diastolic BP or plasma glucose concentrations in healthy adults. By 
modifying an individual’s diet with NO3
- supplementation it is unlikely to reduce the 
O2 cost of exercise, improve walking performance or reduce BP. Potential reasons 
for this are; an elevated baseline plasma NO2
- concentration in the placebo 
condition, and/or reductions in the bioavailability of NO∙ in individuals with T2DM. In 
individuals with COPD likely reasons for the lack of effect include; NO3
- dosage, 
oxidative stress, ageing and efficacy of NO3
- reduction to NO2
-. A hypothesis for the 
lack of effect in microvascular diffusion is the hepatic arterial buffer response.  
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Modifying an individual diet with supplementary NO3
- does not appear to reduce the 
O2 cost of exercise, improve walking performance or reduce BP in individuals with 
T2DM or COPD. Nitrate supplementation does not affect systolic, diastolic blood 
pressure or plasma glucose concentrations in healthy young and older adults.   
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